[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4446
6. Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R: Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One; 2017;12(10):e0186043
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
  • METHODS: Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer.
  • RESULTS: In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease.
  • Median age at primary diagnosis was 58 years (range 16-93) and 406 patients (77.6%) had a high-grade serous ovarian cancer.
  • In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes.
  • The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse.
  • The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients ≥60 years.
  • Family history was positive in 43% of all patients.
  • Patients with a positive family history had a prevalence of deleterious variants of 31.6% (36.0%) versus 11.4% (17.6%) and histologic subtype of high grade serous ovarian cancer versus other showed a prevalence of deleterious variants of 23.2% (29.1%) and 10.2% (14.8%), respectively.
  • Testing only for BRCA1/2 would miss in our series more than 5% of the patients with a deleterious variant in established risk genes.
  • CONCLUSIONS: 26.4% of all patients harbor at least one deleterious variant in established risk genes.
  • The threshold of 10% mutation rate which is accepted for reimbursement by health care providers in Germany was observed in all subgroups analyzed and neither age at primary diagnosis nor histo-type or family history sufficiently enough could identify a subgroup not eligible for genetic counselling and testing.
  • Genetic testing should therefore be offered to every patient with invasive epithelial ovarian cancer and limiting testing to BRCA1/2 seems to be not sufficient.


7. Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM: Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis; 2018 Feb;68:203-208

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment.
  • More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment.
  • Based on a literature review and with input from patients, 65 potential goals were formulated as statements.
  • When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28274788.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MR/K015338/1; United Kingdom / Medical Research Council / / MR/K025570/1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Delphi study / Gaucher disease / Management goals / PROMs / Therapy
  •  go-up   go-down


8. Andrade DM, Bassett AS, Bercovici E, Borlot F, Bui E, Camfield P, Clozza GQ, Cohen E, Gofine T, Graves L, Greenaway J, Guttman B, Guttman-Slater M, Hassan A, Henze M, Kaufman M, Lawless B, Lee H, Lindzon L, Lomax LB, McAndrews MP, Menna-Dack D, Minassian BA, Mulligan J, Nabbout R, Nejm T, Secco M, Sellers L, Shapiro M, Slegr M, Smith R, Szatmari P, Tao L, Vogt A, Whiting S, Carter Snead O 3rd: Epilepsy: Transition from pediatric to adult care. Recommendations of the Ontario epilepsy implementation task force. Epilepsia; 2017 Sep;58(9):1502-1517
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy: Transition from pediatric to adult care. Recommendations of the Ontario epilepsy implementation task force.
  • The transition from a pediatric to adult health care system is challenging for many youths with epilepsy and their families.
  • Recently, the Ministry of Health and Long-Term Care of the Province of Ontario, Canada, created a transition working group (TWG) to develop recommendations for the transition process for patients with epilepsy in the Province of Ontario.
  • The TWG was composed of a multidisciplinary group of pediatric and adult epileptologists, psychiatrists, and family doctors from academia and from the community; neurologists from the community; nurses and social workers from pediatric and adult epilepsy programs; adolescent medicine physician specialists; a team of physicians, nurses, and social workers dedicated to patients with complex care needs; a lawyer; an occupational therapist; representatives from community epilepsy agencies; patients with epilepsy; parents of patients with epilepsy and severe intellectual disability; and project managers.
  • The care coordination between pediatric and adult neurologists and other specialists should begin before the actual transfer.
  • The transition period is the ideal time to rethink the diagnosis and repeat diagnostic testing where indicated (particularly genetic testing, which now can uncover more etiologies than when patients were initially evaluated many years ago).
  • The seven steps proposed herein may facilitate transition, thereby promoting uninterrupted and adequate care for youth with epilepsy leaving the pediatric system.
  • [MeSH-major] Epilepsy / therapy. Transition to Adult Care / standards

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Wiley Periodicals, Inc. © 2017 International League Against Epilepsy.
  • (PMID = 28681381.001).
  • [ISSN] 1528-1167
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Discharge package / Epilepsy / Genetics / Teenager / Transition / Transition readiness questionnaire / Youth
  •  go-up   go-down


9. Christie SA, Kornblith LZ, Howard BM, Conroy AS, Kunitake RC, Nelson MF, Hendrickson CM, Calfee CS, Callcut RA, Cohen MJ: Characterization of distinct coagulopathic phenotypes in injury: Pathway-specific drivers and implications for individualized treatment. J Trauma Acute Care Surg; 2017 Jun;82(6):1055-1062
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we identified injury/patient characteristics and coagulation factors that drive contact pathway, tissue factor pathway (TF), and common pathway dysfunction by examining injured patients with discordant coagulopathies.
  • We hypothesized that patients with INR/PTT discordance reflect differing phenotypes representing contact versus tissue factor pathway perturbations and that characterization will provide targets to guide individualized resuscitation.
  • METHODS: Plasma samples were prospectively collected from 1,262 critically injured patients at a single Level I trauma center.
  • RESULTS: Fourteen percent of patients were coagulopathic on admission.
  • All coagulopathic patients had factor V deficits, but activity was lowest in BOTH, suggesting an additive downstream effect of disordered activation pathways.
  • Patients with PTT-CONTACT received half as much packed red blood cell and fresh frozen plasma as did the other groups (p < 0.001).
  • Despite resuscitation, mortality was higher for coagulopathic patients; mortality was highest in BOTH and higher in PTT-CONTACT than in INR-TF (71%, 60%, 41%; p = 0.04).
  • Recognition and treatment of pathway-specific factor deficiencies driving different coagulopathic phenotypes in injured patients may individualize resuscitation and improve outcomes.

  • MedlinePlus Health Information. consumer health - Bleeding Disorders.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28338598.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / K01 ES026834
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-25-6 / Factor VII; 9001-27-8 / Factor VIII
  •  go-up   go-down


10. Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M: Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol; 2017 Oct;4(10):e475-e486
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The combined use of genetic markers and detectable minimal residual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy.
  • We aimed to assess lenalidomide maintenance therapy in these high-risk patients.
  • METHODS: In this randomised, double-blind, phase 3 study (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded to chemoimmunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a high risk for an early progression with at least a partial response after four or more cycles of first-line chemoimmunotherapy, were eligible if they had high minimal residual disease levels or intermediate levels combined with an unmutated IGHV gene status or TP53 alterations.
  • Patients were randomly assigned (2:1) to receive either lenalidomide (5 mg) or placebo.
  • FINDINGS: Between July 5, 2012, and March 15, 2016, 468 previously untreated patients with chronic lymphocytic leukaemia were screened for the study; 379 (81%) were not eligible.
  • Recruitment was closed prematurely due to poor accrual after 89 of 200 planned patients were randomly assigned: 60 (67%) enrolled patients were assigned to the lenalidomide group and 29 (33%) to the placebo group, of whom 56 (63%) received lenalidomide and 29 (33%) placebo, with a median of 11·0 (IQR 4·5-20·5) treatment cycles at data cutoff.
  • The most frequent adverse events were skin disorders (35 patients [63%] in the lenalidomide group vs eight patients [28%] in the placebo group), gastrointestinal disorders (34 [61%] vs eight [28%]), infections (30 [54%] vs 19 [66%]), haematological toxicity (28 [50%] vs five [17%]), and general disorders (28 [50%] vs nine [31%]).
  • One fatal adverse event was reported in each of the treatment groups (one [2%] patient with fatal acute lymphocytic leukaemia in the lenalidomide group and one patient (3%) with fatal multifocal leukoencephalopathy in the placebo group).
  • INTERPRETATION: Lenalidomide is an efficacious maintenance therapy reducing the relative risk of progression in first-line patients with chronic lymphocytic leukaemia who do not achieve minimal residual disease negative disease state following chemoimmunotherapy approaches.
  • The toxicity seems to be acceptable considering the poor prognosis of the eligible patients.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28916311.001).
  • [ISSN] 2352-3026
  • [Journal-full-title] The Lancet. Haematology
  • [ISO-abbreviation] Lancet Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Giustiniano E, Procopio F, Costa G, Rocchi L, Ruggieri N, Cantoni S, Zito PC, Gollo Y, Torzilli G, Raimondi F: Serum lactate in liver resection with intermittent Pringle maneuver: the "square-root- shape. J Hepatobiliary Pancreat Sci; 2017 Nov;24(11):627-636

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 133 patients who underwent liver resection were enrolled.
  • More than 76 min of cumulative Pringle Time (cPT) exposed patients to a worse cLac at the end of the resection phase (P < 0.0001).
  • Normal liver may expose the patient to the risk of hyperlactatemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
  • (PMID = 28884958.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Hepatic resection / Lactate clearance / Pringle maneuver
  •  go-up   go-down


22. Tahtali D, Bohmann F, Kurka N, Rostek P, Todorova-Rudolph A, Buchkremer M, Abruscato M, Hartmetz AK, Kuhlmann A, Henke C, Stegemann A, Menon S, Misselwitz B, Reihs A, Weidauer S, Thonke S, Meyding-Lamadé U, Singer O, Steinmetz H, Pfeilschifter W: Implementation of stroke teams and simulation training shortened process times in a regional stroke network-A network-wide prospective trial. PLoS One; 2017;12(12):e0188231

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To meet the requirements imposed by the time-dependency of acute stroke therapies, it is necessary 1) to initiate structural and cultural changes in the breadth of stroke-ready hospitals and 2) to find new ways to train the personnel treating patients with acute stroke.
  • METHODS: We recorded door-to-needle times of all consecutive stroke patients receiving thrombolysis at seven stroke units for 3 months before and after a 2 month intervention which included setting up a team-based stroke workflow at each stroke unit, a train-the-trainer seminar for stroke team simulation training and a stroke team simulation training session at each hospital as well as a recommendation to take up regular stroke team trainings.
  • RESULTS: The intervention reduced the network-wide median door-to-needle time by 12 minutes from 43,0 (IQR 29,8-60,0, n = 122) to 31,0 (IQR 24,0-42,0, n = 112) minutes (p < 0.001) and substantially increased the share of patients receiving thrombolysis within 30 minutes of hospital arrival from 41.5% to 59.6% (p < 0.001).
  • Stroke team training participants stated a significant increase in knowledge on the topic of acute stroke care and in the perception of patient safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29206838.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Yunos NM, Bellomo R, Taylor DM, Judkins S, Kerr F, Sutcliffe H, Hegarty C, Bailey M: Renal effects of an emergency department chloride-restrictive intravenous fluid strategy in patients admitted to hospital for more than 48 hours. Emerg Med Australas; 2017 Dec;29(6):643-649

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal effects of an emergency department chloride-restrictive intravenous fluid strategy in patients admitted to hospital for more than 48 hours.
  • OBJECTIVE: Patients commonly receive i.v. fluids in the ED.
  • It is still unclear whether the choice of i.v. fluids in this setting influences renal or patient outcomes.
  • During the control period (18 February 2008 to 17 August 2008), patients received standard i.v. fluids.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.
  • (PMID = 28597505.001).
  • [ISSN] 1742-6723
  • [Journal-full-title] Emergency medicine Australasia : EMA
  • [ISO-abbreviation] Emerg Med Australas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; acute kidney injury / chloride / emergency department / saline
  •  go-up   go-down


2
Advertisement
4. Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, Sommer L, Zak M, Benson G: Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. Haemophilia; 2017 Jul;23(4):575-582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
  • Although no confirmed cases of neutralising antibodies to rFVIIa in patients with haemophilia A or B have been observed with the original formulation, changes in formulation or storage condition may alter immunogenicity.
  • AIM: SMART-7™ was designed to investigate the safety of NovoSeven<sup>®</sup> in a real-world setting in patients with haemophilia A or B with inhibitors.
  • Patient baseline information was collected at enrolment.
  • RESULTS: Fifty-one patients were enrolled and 31 completed the study.
  • Forty-one adverse events (AEs) were reported in 23 patients; 25 AEs in 14 patients were serious.
  • Forty-eight patients experienced 618 bleeding episodes and 93.4% of 609 evaluated bleeds were stopped by treatment.
  • CONCLUSION: Data collected during the SMART-7™ study revealed no treatment-related safety issues and no FVII-binding antibodies for patients treated with NovoSeven<sup>®</sup> under real-world conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 28440004.001).
  • [ISSN] 1365-2516
  • [Journal-full-title] Haemophilia : the official journal of the World Federation of Hemophilia
  • [ISO-abbreviation] Haemophilia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; antibodies / haemophilia A / haemophilia B / real world / recombinant FVIIa
  •  go-up   go-down


25. Finnegan MA, Shaffer R, Remington A, Kwong J, Curtin C, Hernandez-Boussard T: Emergency Department Visits Following Elective Total Hip and Knee Replacement Surgery: Identifying Gaps in Continuity of Care. J Bone Joint Surg Am; 2017 Jun 21;99(12):1005-1012
MedlinePlus Health Information. consumer health - Knee Replacement.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency Department Visits Following Elective Total Hip and Knee Replacement Surgery: Identifying Gaps in Continuity of Care.
  • BACKGROUND: Major joint replacement surgical procedures are common, elective procedures with a care episode that includes both inpatient readmissions and postoperative emergency department (ED) visits.
  • Factors associated with increased risk of an ED visit were estimated using hierarchical regression models controlling for patient variables with a fixed hospital effect.
  • RESULTS: Among the 152,783 patients who underwent major joint replacement, 5,229 (3.42%) returned to the inpatient setting and 8,883 (5.81%) presented to the ED for care within 30 days.
  • Patients presenting to the ED for subsequent care had more comorbidities and were more frequently non-white with public insurance relative to those not returning to the ED (p < 0.001).
  • There was a significantly increased risk (p < 0.05) of isolated ED visits with regard to type of insurance when patients with Medicaid (odds ratio [OR], 2.28 [95% confidence interval (CI), 2.04 to 2.55]) and those with Medicare (OR, 1.38 [95% CI, 1.29 to 1.47]) were compared with patients with private insurance and with regard to race when black patients (OR, 1.38 [95% CI, 1.25 to 1.53]) and Hispanic patients (OR, 1.12 [95% CI, 1.03 to 1.22]) were compared with white patients.
  • These increases in risk were stronger for isolated ED visits for patients with a pain diagnosis.
  • Medicaid patients had almost double the risk of an ED or pain-related ED visit following a surgical procedure.
  • The future of U.S. health-care insurance coverage expansions are uncertain; however, there are ongoing attempts to improve quality across the continuum of care.
  • It is therefore essential to ensure that all patients, particularly vulnerable populations, receive appropriate postoperative care, including pain management.
  • [MeSH-minor] California. Continuity of Patient Care. Elective Surgical Procedures / statistics & numerical data. Female. Florida. Humans. Male. Middle Aged. New York. Pain, Postoperative / etiology. Postoperative Care / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Hip Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28632589.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01 HS024096
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  •  go-up   go-down


26. Burjek NE, Nishisaki A, Fiadjoe JE, Adams HD, Peeples KN, Raman VT, Olomu PN, Kovatsis PG, Jagannathan N, Hunyady A, Bosenberg A, Tham S, Low D, Hopkins P, Glover C, Olutoye O, Szmuk P, McCloskey J, Dalesio N, Koka R, Greenberg R, Watkins S, Patel V, Reynolds P, Matuszczak M, Jain R, Khalil S, Polaner D, Zieg J, Szolnoki J, Sathyamoorthy K, Taicher B, Riveros Perez NR, Bhattacharya S, Bhalla T, Stricker P, Lockman J, Galvez J, Rehman M, Von Ungern-Sternberg B, Sommerfield D, Soneru C, Chiao F, Richtsfeld M, Belani K, Sarmiento L, Mireles S, Bilen Rosas G, Park R, Peyton J, PeDI Collaborative Investigators: Videolaryngoscopy versus Fiber-optic Intubation through a Supraglottic Airway in Children with a Difficult Airway: An Analysis from the Multicenter Pediatric Difficult Intubation Registry. Anesthesiology; 2017 Sep;127(3):432-440
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient age, intubation technique, success per attempt, use of continuous ventilation, and complications were recorded for each case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28650415.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  •  go-up   go-down


27. Goobie SM, Cladis FP, Glover CD, Huang H, Reddy SK, Fernandez AM, Zurakowski D, Stricker PA, Gries, the Pediatric Craniofacial Collaborative Group: Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group. Paediatr Anaesth; 2017 03;27(3):271-281
Hazardous Substances Data Bank. 6-AMINOCAPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No significant difference was detected in the incidence of postoperative seizures between patients receiving tranexamic acid and those receiving aminocaproic acid [the odds ratio for seizures being 0.34 (95% confidence interval: 0.07-1.85) controlling for American Society of Anesthesia (ASA) physical class] nor in patients receiving antifibrinolytics compared to those not administered antifibrinolytics (the odds ratio for seizures being 1.02 (confidence interval 0.29-3.63) controlling for ASA physical class).
  • One complicated patient in the antifibrinolytic group with a femoral venous catheter had a postoperative deep venous thrombosis.
  • There was no significant difference in postoperative seizures or seizure-like events in those patients who received the tranexamic acid or aminocaproic acid vs those that did not.
  • Caution should prevail however in using antifibrinolytic in high-risk patients.

  • MedlinePlus Health Information. consumer health - Craniofacial Abnormalities.
  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • [ErratumIn] Paediatr Anaesth. 2017 Jun;27(6):670. Gries, Heike [added]; Meier, Petra [added]; Haberkern, Charlie [added]; Nguyen, Thanh [added]; Benzon, Hubert [added] [28474812.001]
  • (PMID = 28211198.001).
  • [ISSN] 1460-9592
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 6T84R30KC1 / Tranexamic Acid; U6F3787206 / Aminocaproic Acid
  • [Keywords] NOTNLM ; aminocaproic acid (major topic) / antifibrinolytics (major topic) / craniofacial surgery (major topic) / craniosynostosis (major topic) / safety (major topic) / tranexamic acid (major topic)
  • [Investigator] Fiadjoe J; Soneru C; Falcon R; Petersen T; Kowalczyk-Derderian C; Dalesio N; Budac S; Groenewald N; Rubens D; Thompson D; Watts R; Gentry K; Ivanova I; Hetmaniuk M; Hsieh V; Collins M; Wong K; Binstock W; Reid R; Poteet-Schwartz K; Gries H; Hall R; Koh J; Colpitts K; Scott L; Bannister C; Sung W; Jain R; Chaudhry R; Tuite GF; Ruas E; Drozhinin O; Tetreault L; Muldowney B; Ricketts K; Fernandez P; Sohn L; Hajduk J; Taicher B; Burkhart J; Wright A; Kugler J; Barajas-DeLoa L; Gangadharan M; Busso V; Stallworth K; Staudt S; Labovsky K; Glover C; Karlberg-Hippard H; Capehart S; Streckfus C; Nguyen KP; Manyang P; Martinez JL; Hansen J; Mitzel H; Brzenski A; Chiao F; Ingelmo P; Mujallid R; Bosenberg A; Meier P; Haberkern Ch; Nguyen T; Benzon H
  •  go-up   go-down


28. Barsuk JH, Cohen ER, Williams MV, Scher J, Jones SF, Feinglass J, McGaghie WC, O'Hara K, Wayne DB: Simulation-Based Mastery Learning for Thoracentesis Skills Improves Patient Outcomes: A Randomized Trial. Acad Med; 2017 Oct 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simulation-Based Mastery Learning for Thoracentesis Skills Improves Patient Outcomes: A Randomized Trial.
  • This study evaluated the effects of a randomized trial of thoracentesis SBML on patient complications: iatrogenic pneumothorax (IP), hemothorax, and reexpansion pulmonary edema (REPE).
  • METHOD: The authors randomized internal medicine residents to undergo thoracentesis SBML at a tertiary care academic center from December 2012 to May 2016.
  • RESULTS: During the study period, 917 thoracenteses were performed on 709 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29068818.001).
  • [ISSN] 1938-808X
  • [Journal-full-title] Academic medicine : journal of the Association of American Medical Colleges
  • [ISO-abbreviation] Acad Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. PRISM Investigators, Rowan KM, Angus DC, Bailey M, Barnato AE, Bellomo R, Canter RR, Coats TJ, Delaney A, Gimbel E, Grieve RD, Harrison DA, Higgins AM, Howe B, Huang DT, Kellum JA, Mouncey PR, Music E, Peake SL, Pike F, Reade MC, Sadique MZ, Singer M, Yealy DM: Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med; 2017 06 08;376(23):2223-2234
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis.
  • This meta-analysis of individual patient data from the three recent trials was designed prospectively to improve statistical power and explore heterogeneity of treatment effect of EGDT.
  • We tested for treatment-by-subgroup interactions for 16 patient characteristics and 6 care-delivery characteristics.
  • RESULTS: We studied 3723 patients at 138 hospitals in seven countries.
  • Mortality at 90 days was similar for EGDT (462 of 1852 patients [24.9%]) and usual care (475 of 1871 patients [25.4%]); the adjusted odds ratio was 0.97 (95% confidence interval, 0.82 to 1.14; P=0.68).
  • EGDT was associated with greater mean (±SD) use of intensive care (5.3±7.1 vs. 4.9±7.0 days, P=0.04) and cardiovascular support (1.9±3.7 vs. 1.6±2.9 days, P=0.01) than was usual care; other outcomes did not differ significantly, although average costs were higher with EGDT.
  • Subgroup analyses showed no benefit from EGDT for patients with worse shock (higher serum lactate level, combined hypotension and hyperlactatemia, or higher predicted risk of death) or for hospitals with a lower propensity to use vasopressors or fluids during usual resuscitation.
  • CONCLUSIONS: In this meta-analysis of individual patient data, EGDT did not result in better outcomes than usual care and was associated with higher hospitalization costs across a broad range of patient and hospital characteristics. (Funded by the National Institute of General Medical Sciences and others; PRISM ClinicalTrials.gov number, NCT02030158 .).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2017 Sep 7;377(10 ):995 [28877021.001]
  • [CommentIn] N Engl J Med. ;377(10 ):994 [28880501.001]
  • [CommentIn] Ann Intern Med. 2017 Jul 18;167(2):JC6 [28715828.001]
  • (PMID = 28320242.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02030158
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM076659
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Vasoconstrictor Agents
  • [Investigator] Eaton TL; Keener C; Landis K; Stapleton DK; Weissfeld LA; Willochell M; Wofford KA; Kulstad E; Watts H; Venkat A; Hou PC; Massaro A; Parmar S; Limkakeng AT Jr; Brewer K; Delbridge TR; Mainhart A; Chawla LS; Miner JR; Allen TL; Grissom CK; Swadron S; Conrad SA; Carlson R; LoVecchio F; Bajwa EK; Filbin MR; Parry BA; Ellender TJ; Sama AE; Fine J; Nafeei S; Terndrup T; Wojnar M; Pearl RG; Wilber ST; Sinert R; Orban DJ; Wilson JW; Ufberg JW; Albertson T; Panacek EA; Parekh S; Gunn SR; Rittenberger JS; Wadas RJ; Edwards AR; Kelly M; Wang HE; Holmes TM; McCurdy MT; Weinert C; Harris ES; Self WH; Dubinski D; Phillips CA; Migues RM; Cameron PA; Holdgate A; Webb SA; Williams P; Cooper DJ; Cross A; Gomersall C; Graham C; Jacobs I; Johanson S; Jones P; Kruger P; McArthur C; Myburgh J; Nichol A; Pettilä V; Rajbhandari D; Williams A; Williams J; Bives G; Jovanovska A; Lam L; Little L; Newby L; Bennett V; Board J; McCracken P; McGloughlin S; Nanjayya V; Teo A; Hill E; O’Brien E; Sawtell F; Schimanski K; Wilson D; Bolch S; Eastwood G; Kerr F; Peak L; Young H; Edington J; Fletcher J; Smith J; Ghelani D; Nand K; Sara T; Flemming D; Grummisch M; Purdue A; Fulton E; Grove K; Harney A; Milburn K; Millar R; Mitchell I; Rodgers H; Scanlon S; Coles T; Connor H; Dennett J; Van Berkel A; Barrington S; Henderson S; Mehrtens J; Dryburgh J; Tankel A; Braitberg G; O’Bree B; Shepherd K; Vij S; Allsop S; Haji D; Haji K; Vuat J; Bone A; Elderkin T; Orford N; Ragg M; Kelly S; Stewart D; Woodward N; Harjola VP; Okkonen M; Sutinen S; Wilkman E; Fratzia J; Halkhoree J; Treloar S; Ryan K; Sandford T; Walsham J; Jenkins C; Williamson D; Burrows J; Hawkins D; Tang C; Dimakis A; Micallef S; Parr M; White H; Morrison L; Sosnowski K; Ramadoss R; Soar N; Wood J; Franks M; Hogan C; Song R; Tilsley A; Rainsford D; Wells R; Dowling J; Galt P; Lamac T; Lightfoot D; Walker C; Braid K; DeVillecourt T; Tan HS; Seppelt I; Chang LF; Cheung WS; Fok SK; Lam PK; Lam SM; So HM; Yan WW; Altea A; Lancashire B; Gomersall CD; Graham CA; Leung P; Arora S; Bass F; Shehabi Y; Isoardi J; Isoardi K; Powrie D; Lawrence S; Ankor A; Chester L; Davies M; O’Connor S; Poole A; Soulsby T; Sundararajan K; Greenslade JH; MacIsaac C; Gorman K; Jordan A; Moore L; Ankers S; Bird S; Fogg T; Hickson E; Jewell T; Kyneur K; O’Connor A; Townsend J; Yarad E; Brown S; Chamberlain J; Cooper J; Jenkinson E; McDonald E; Webb S; Buhr H; Coakley J; Cowell J; Hutch D; Gattas D; Keir M; Rees C; Baker S; Roberts B; Farone E; Holmes J; Santamaria J; Winter C; Finckh A; Knowles S; McCabe J; Nair P; Reynolds C; Ahmed B; Barton D; Meaney E; Harris R; Shields L; Thomas K; Karlsson S; Kuitunen A; Kukkurainen A; Tenhunen J; Varila S; Ryan N; Trethewy C; Crosdale J; Smith JC; Vellaichamy M; Furyk J; Gordon G; Jones L; Senthuran S; Bates S; Butler J; French C; Tippett A; Kelly J; Kwans J; Murphy M; O’Flynn D; Kurenda C; Otto T; Raniga V; Ho HF; Leung A; Wu H; Bell D; Bion J; Hodgetts T; Young D; Harvey S; Jahan R; Osborn T; Power S; Tan J; Corlett S; Muskett H; Scott R; Ahmed V; Boyle A; Scott-Donkin A; Black H; Smalley C; Jacob R; Wooten A; Humphrey J; Pearson SA; Griffiths J; Subramanyam D; Niblett D; Krishnanankutty S; Gao-Smith F; Melody T; Couper K; Nichani R; Brennan E; Tucker S; Benger J; Edwards J; Pollock K; Arawwawala D; Hieatt A; McNeela F; Weldring T; Carungcong J; MacNaughton P; McMillan H; Tantam K; Doyle T; Moreton S; Jones S; Kendall J; Worner R; Gilbertson A; Borland C; Boys S; Ranjan S; Smith I; Smith N; Mendham V; Smith P; Farras-Araya R; Vallance D; Watt P; Raymode P; Hollos L; Hopkins P; Riozzi P; Couper H; Helyar S; Thompson J; Hales D; Essat Z; Andreou P; Gilby S; Chilton P; Miller R; Butler J; Jefferies A; Clark R; Sanders G; Pinto N; Plowright C; Innes R; Bayford D; Richards P; Gopal S; Pooni JS; Spencer H; Napier J; Warrington E; Kevern L; Hunt J; Barrett C; Sykes E; Connelly K; Yates B; Carle C; Croft T; Jenkins N; Reschreiter H; Camsooksai J; Barcraft-Barnes H; Snelson C; Bergin C; Keats F; Linnett V; Ritzema J; Christian S; Harvey D; Miller P; Woodford C; Bolland A; Keating L; Mossop D; Jones C; Martin D; Willett E; Swallow P; McBride S; Ijaz A; Datta J; Craig J; Owen T; Williams A; McMullan S; Baldwin J; Zuleika M; Carvalho P; Agranoff D; Ingoldby F; Ortiz-Ruiz De Gordoa L; Ridley C; Clement I; Higham C; Martin B; Clayton K; Chadwick J; Frey C; Miller D; Laverick P; Iftikhar K; Higgins D; Katsande V; Chikungwa M; Jackson C; Watters M; Liddiard P; Gannon K; Howard-Griffin R; Bell S; Blaylock H; Gonzalez I; Cirstea E; Bonner S; Moondi P; Wong K; Carter J; Hartley S; Crossingham I; Hinchcliffe J; Phoenix L; Harris T; Pott J; Bellhouse G; Mercer M; Mercer P; Robinson H; Brealey D; Ryu J; Becardes G; Morris AM; Poulson M; Barnett L; Massey I; Skene I; Nee P; Dowling S; McCairn A; Duckitt R; Venn R; Margalef J; Redman J; Milner H; Ma S
  •  go-up   go-down


30. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, Dogné JM, Mullier F: Laboratory Testing In Patients Treated With Direct Oral Anticoagulants: A Practical Guide For Clinicians. J Thromb Haemost; 2017 Nov 29;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory Testing In Patients Treated With Direct Oral Anticoagulants: A Practical Guide For Clinicians.
  • We offer recommendations on the tests to use for measuring DOACs and practical guidance on laboratory testing to help patient management and avoid diagnostic errors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 29193737.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; Apixaban / Dabigatran / Edoxaban / Rivaroxaban / laboratory testing / practical management
  •  go-up   go-down


31. Scott JW, Neiman PU, Najjar PA, Tsai TC, Scott KW, Shrime MG, Cutler DM, Salim A, Haider AH: Potential impact of Affordable Care Act-related insurance expansion on trauma care reimbursement. J Trauma Acute Care Surg; 2017 May;82(5):887-895

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential impact of Affordable Care Act-related insurance expansion on trauma care reimbursement.
  • BACKGROUND: Nearly one quarter of trauma patients are uninsured and hospitals recoup less than 20% of inpatient costs for their care.
  • This study examines changes to hospital reimbursement for inpatient trauma care if the full coverage expansion provisions of the Affordable Care Act (ACA) were in effect.
  • Using US census data, we developed a probabilistic microsimulation model to determine the proportion of pre-ACA uninsured trauma patients that would be expected to gain private insurance, Medicaid, or remain uninsured after full implementation of the ACA.
  • RESULTS: There were 145,849 patients (representing 737,852 patients nationwide) included.
  • National inpatient trauma costs for patients aged 18 years to 64 years totaled US $14.8 billion (95% confidence interval [CI], 12.5,17.1).
  • CONCLUSION: Health insurance coverage expansion for uninsured trauma patients has the potential to increase national reimbursement for inpatient trauma care by over one billion dollars and nearly double the proportion of hospitals with a positive margin for trauma care.
  • These data suggest that insurance coverage expansion has the potential to improve trauma centers' financial viability and their ability to provide care for their communities.
  • [MeSH-major] Insurance, Health, Reimbursement / legislation & jurisprudence. Patient Protection and Affordable Care Act / economics. Trauma Centers / legislation & jurisprudence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Trauma. 2011 Apr;70(4):978-84 [21610399.001]
  • [Cites] Br J Surg. 2016 Oct;103(11):1453-61 [27428044.001]
  • [Cites] JAMA Surg. 2014 May;149(5):422-30 [24554059.001]
  • [Cites] Lancet. 2004 May 29;363(9423):1794-801 [15172780.001]
  • [Cites] Arch Surg. 2008 Oct;143(10):945-9 [18936372.001]
  • [Cites] Health Aff (Millwood). 2015 Jan;34(1):125-33 [25561653.001]
  • [Cites] J Trauma Acute Care Surg. 2016 Jun;80(6):1010-4 [27015573.001]
  • [Cites] Lancet Glob Health. 2015 Apr 27;3 Suppl 2:S38-44 [25926319.001]
  • [Cites] J Trauma. 2000 Jan;48(1):25-30; discussion 30-1 [10647561.001]
  • [Cites] J Trauma Acute Care Surg. 2013 May;74(5):1195-205 [23609267.001]
  • [Cites] Health Aff (Millwood). 2014 May;33(5):792-9 [24799576.001]
  • [Cites] Ann Surg. 2015 Jul;262(1):16-7 [26020114.001]
  • [Cites] J Trauma Acute Care Surg. 2015 May;78(5):1026-33 [25909426.001]
  • [Cites] Health Aff (Millwood). 2014 Jun;33(6):988-96 [24889948.001]
  • [Cites] JAMA. 2001 Mar 7;285(9):1164-71 [11231745.001]
  • [Cites] J Trauma Acute Care Surg. 2013 Sep;75(3):512-5 [23823607.001]
  • [Cites] Ann Surg. 2015 Jul;262(1):9-15 [26020113.001]
  • [Cites] Int J Health Serv. 2016;46(1):166-84 [25995304.001]
  • [Cites] Arch Surg. 2012 Jan;147(1):63-70 [21930976.001]
  • [Cites] Bull Am Coll Surg. 2015 Jan;100(1):51-2 [25626271.001]
  • [Cites] Med Care. 2009 Sep;47(9):968-78 [19704354.001]
  • [Cites] Ann Surg. 2013 Oct;258(4):572-9; discussion 579-81 [23979271.001]
  • [Cites] N Engl J Med. 2006 Jan 26;354(4):366-78 [16436768.001]
  • [Cites] J Am Coll Surg. 2010 May;210(5):817-21, 821-3 [20421057.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Nov;73(5):1303-7 [23032805.001]
  • [Cites] J Trauma Acute Care Surg. 2016 Sep;81(3):427-34 [27355684.001]
  • [Cites] Health Aff (Millwood). 2012 May;31(5):909-19 [22566429.001]
  • (PMID = 28431415.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / K23 GM093112
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Frisoli TM, Nowak R, Evans KL, Harrison M, Alani M, Varghese S, Rahman M, Noll S, Flannery KR, Michaels A, Tabaku M, Jacobsen G, McCord J: Henry Ford HEART Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction. Circ Cardiovasc Qual Outcomes; 2017 Oct;10(10)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Henry Ford HEART Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction.
  • BACKGROUND: Hospital evaluation of patients with chest pain is common and costly.
  • The HEART score risk stratification tool that merges troponin testing into a clinical risk model for evaluation emergency department patients with possible acute myocardial infarction (AMI) has been shown to effectively identify a substantial low-risk subset of patients possibly safe for early discharge without stress testing, a strategy that could have tremendous healthcare savings implications.
  • METHOD AND RESULTS: A total of 105 patients evaluated for AMI in the emergency departments of 2 teaching hospitals in the Henry Ford Health System (Detroit and West Bloomfield, MI), between February 2014 and May 2015, with a modified HEART score ≤3 (which includes cardiac troponin I <0.04 ng/mL at 0 and 3 hours) were randomized to immediate discharge (n=53) versus management in an observation unit with stress testing (n=52).
  • Patients randomized to early discharge, compared with those who were admitted for observation and cardiac testing, spent less time in the hospital (median 6.3 hours versus 25.9 hours; <i>P</i><0.001) with an associated reduction in median total charges of care ($2953 versus $9616; <i>P</i><0.001).
  • One patient in each group was lost to follow-up.
  • CONCLUSIONS: Among patients evaluated for possible AMI in the emergency department with a modified HEART score ≤3, early discharge without stress testing as compared with transfer to an observation unit for stress testing was associated with significant reductions in length of stay and total charges, a finding that has tremendous potential national healthcare expenditure implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28954802.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; acute coronary syndrome / chest pain / length of stay / myocardial infarction / troponin
  •  go-up   go-down


33. Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, Thoralsson E, Al Thawadi S, Al Jedai A, Al Kahtani K: HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study. Saudi J Gastroenterol; 2017 May-Jun;23(3):190-198

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
  • We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance.
  • PATIENTS AND METHODS: In this randomized controlled trial, chronic HBV patients who have been receiving tenofovir for >6 months with HBV viral load <2000 IU/ml were randomized into two groups.
  • Patients in the other group received only tenofovir 300 mg orally on a daily basis.
  • Patients in both groups were followed up for a total of two years, and patients in both groups were given tenofovir 300 mg daily indefinitely until they developed HBsAg clearance.
  • RESULTS: Twenty-three patients were allocated to the PEG IFN and tenofovir (add-on therapy) group, and another 25 patients were recruited to the tenofovir monotherapy group.
  • Before randomization, patients had received tenofovir for 1135 mean days (range203 to 1542 days).
  • One patient (4.3%) in add-on therapy lost HBsAg and seroconverted.
  • More patients in the add-on group developed serious side effects, with treatment discontinuation, and dose reductions (P = 0.3).
  • CONCLUSION: PEG IFN and tenofovir add-on therapy was successful in achieving HBsAg clearance and seroconversion in 4.3% of the patients.
  • Add-on therapy patients had a significant decrease in HBsAg levels in two years; and no significant decrease in HBsAg levels with the tenofovir monotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2016 Jan;150(1):134-144.e10 [26453773.001]
  • [Cites] J Hepatol. 2013 Feb;58(2):205-9 [23159772.001]
  • [Cites] World J Gastroenterol. 2014 Jul 7;20(25):8195-200 [25009392.001]
  • [Cites] Antivir Ther. 2009;14 (8):1165-74 [20032546.001]
  • [Cites] J Clin Virol. 2013 Dec;58(4):713-7 [24183313.001]
  • [Cites] Gut. 2015 Apr;64(4):667-72 [24833635.001]
  • [Cites] Hepatology. 2015 May;61(5):1459-61 [25645624.001]
  • [Cites] Hepatology. 2015 May;61(5):1512-22 [25348661.001]
  • [Cites] Annu Rev Immunol. 1995;13:29-60 [7612225.001]
  • [Cites] Hepatology. 2016 Jan;63(1):261-83 [26566064.001]
  • [Cites] Hepatol Int. 2016 Jan;10 (1):1-98 [26563120.001]
  • [Cites] Liver Int. 2014 Feb;34 Suppl 1:97-107 [24373085.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Dec;32(11-12):1323-31 [21050234.001]
  • [Cites] Liver Int. 2015 Jan;35 Suppl 1:82-90 [25529092.001]
  • [Cites] J Hepatol. 2014 Oct;61(4):777-84 [24915612.001]
  • [Cites] Aliment Pharmacol Ther. 2015 May;41(9):867-76 [25752878.001]
  • [Cites] J Dig Dis. 2013 Aug;14 (8):446-50 [23615131.001]
  • [Cites] Ann Intern Med. 2005 Feb 15;142(4):240-50 [15710957.001]
  • [Cites] J Hepatol. 2009 Jun;50(6):1084-92 [19376603.001]
  • [Cites] Hepatology. 2001 Apr;33(4):963-71 [11283861.001]
  • [Cites] J Hepatol. 2012 Jul;57(1):167-85 [22436845.001]
  • [Cites] Liver Int. 2015 Jan;35 Suppl 1:114-20 [25529096.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2682-95 [15987917.001]
  • [Cites] J Viral Hepat. 2014 Dec;21(12):825-34 [25402543.001]
  • [Cites] J Clin Virol. 2012 May;54(1):93-5 [22365367.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):123-9 [15639293.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12 ):1206-17 [15371578.001]
  • [Cites] Hepatology. 2009 Apr;49(4):1141-50 [19338056.001]
  • [Cites] Liver Int. 2013 Apr;33(4):580-5 [23311449.001]
  • (PMID = 28611343.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


34. Ueda K, Maeno Y, Miyoshi T, Inamura N, Kawataki M, Taketazu M, Nii M, Hagiwara A, Horigome H, Shozu M, Shimizu W, Yasukochi S, Yoda H, Shiraishi I, Sakaguchi H, Katsuragi S, Sago H, Ikeda T, ; on behalf of Japan Fetal Arrhythmia Group: The impact of intrauterine treatment on fetal tachycardia: a nationwide survey in Japan. J Matern Fetal Neonatal Med; 2017 Jul 19;:1-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the clinical course of fetal tachycardia and analyze the impact of intrauterine treatment on the postnatal treatment and patient outcomes.
  • Data were collected from questionnaires that were sent to all 750 secondary or tertiary perinatal care centers in Japan.
  • Intrauterine treatment significantly reduced the incidence of cesarean delivery (29.3 vs. 70.7%, p < .01), preterm birth (12.2 vs. 41.5%, p = .02) and neonatal arrhythmias (48.8 vs. 78.0%, p = .01) in comparison to untreated fetuses.
  • CONCLUSIONS: This nationwide survey revealed that intrauterine treatment was performed for approximately half of the cases of fetal tachycardia and was associated with lower rates of cesarean delivery, premature birth and neonatal arrhythmias in comparison to untreated fetuses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28720014.001).
  • [ISSN] 1476-4954
  • [Journal-full-title] The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • [ISO-abbreviation] J. Matern. Fetal. Neonatal. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antiarrhythmic drugs / fetal tachycardia / intrauterine treatment / prenatal diagnosis
  •  go-up   go-down


35. Grubbs SS, Go RS, Berger MZ, Gonzalez M, Thompson MA, Enos R, St Germain DC, Denicoff A, Servididio C, Bearden JD, Zaren H, Wilkinson K, Krasna M, McCaskill-Stevens W, Bell M, Freeman RK, Miesfeldt S, Ravikumar TS, Nair SG, Bashey A: Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). J Clin Oncol; 2011 May 20;29(15_suppl):6110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data included patient demographics, trial eligibility, trial enrollment, and reasons for non-enrollment.
  • This abstract addresses patient demographics.
  • RESULTS: Of the 1,589 patients screened during this period, 359 were enrolled, for an overall accrual rate of 23%.
  • No disparity based on gender, ethnicity, or race between Whites and African Americans (P value for the latter comparison 0.59) was found and the disparity gap between the young and elderly appears narrowed when compared to historical data (3-fold difference; Murthy VH, et al JAMA 2004).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Liu F, Zhang J, Zhang HK, Zhao YQ, Liang P, Zuo YX: [Thoracic paravertebral block in the PACU for immediate postoperative pain relief after video-assisted thoracoscopic surgery]. Zhonghua Yi Xue Za Zhi; 2017 Jan 10;97(2):119-122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Objective:</b> To investigate the effectiveness and safety of the thoracic paravertebral block(TPVB) in the post postanesthesia care unit(PACU) for patients suffered moderate to severe pain after Video-Assisted Thoracoscopic Surgery(VATS).
  • The VAS Pain score at rest and movement, heart rate, blood pressure, and pulse oximetry 1 hour after treatment and duration of patients staying in the PACU after treatment were recorded.
  • Sufentanil comsumption, patient satisfaction and related complications were also recorded.
  • <b>Results:</b> A successful TPVB was achieved in all patients in P group without puncture related complications.
  • The VAS pain scores at rest and on coughing 1 hour, 8 hours, 24 hours and 48 hours after treatment in P group were significantly lower than the patients in S group.
  • Systolic blood pressure 1 hour after treatment in P group was also lower than the patients in S group(118mmHg±14mmHg vs 128 mmHg±14 mmHg, <i>P</i>=0.021).
  • SPO2 1 hour after treatment in P group was much higher than the patients in S group(95%±3% vs 92%±4%, <i>P</i>=0.015).
  • The duration of patients staying in the PACU after treatment in both groups were similar.
  • <b>Conclusion:</b> In the postanesthesia care unit, TPVB could provide effective and safe analgesia therapy for patients suffered from moderate to severe pain after VATS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28088956.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; English Abstract
  • [Publication-country] China
  •  go-up   go-down


37. Mohammed MF, Marais O, Min A, Ferguson D, Jalal S, Khosa F, OʼKeeffe M, OʼConnell T, Schmiedeskamp H, Krauss B, Rohr A, Nicolaou S: Unenhanced Dual-Energy Computed Tomography: Visualization of Brain Edema. Invest Radiol; 2017 09 14;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: This was a retrospective, single-center study of 40 patients who presented to the emergency department (ED) of a major, acute care, teaching center with signs and symptoms of acute stroke.
  • Only those patients who presented to the ED within 4 hours of symptom onset were included in this study.
  • All 40 patients received a noncontrast DECT of the head at the time of presentation.
  • Each patient also received standard noncontrast CT of the head 24 hours after their initial presentation to the ED.
  • RESULTS: Of the 40 patients, 28 (70%) were diagnosed with an acute infarction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28915161.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Breathett K, D'Amico R, Adesanya TMA, Hatfield S, Willis S, Sturdivant RX, Foraker RE, Smith S, Binkley P, Abraham WT, Peterson PN: Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. Circ Heart Fail; 2017 Jun;10(6)
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization.
  • Patient-centered solutions for facilitating follow-up post-HF hospitalization have not been extensively evaluated.
  • METHODS AND RESULTS: Face-to-face surveys were conducted between 2015 and 2016 among 83 racially diverse adult patients (61% African American, 34% Caucasian, and 5% Other) hospitalized for HF at a university hospital centered in a low-income area of Columbus, Ohio.
  • Patient perceptions of methods to facilitate follow-up post-HF hospitalization and likelihood of using interventions were investigated using a Likert scale: 1=very much to 5=not at all.
  • The annual household income was <$35 000 for 49% of patients.
  • An appointment near the patient's home was the most desired intervention (77%), followed by reminder message (73%), transportation to appointment (63%), and elimination of copayment (59%).
  • CONCLUSIONS: Among this cohort of racially diverse low-income patients hospitalized with HF, an appointment near the patient's home and a reminder message were the most desired interventions to facilitate follow-up.
  • [MeSH-major] Appointments and Schedules. Heart Failure / therapy. Hospitalization / statistics & numerical data. Patient Compliance. Reminder Systems / instrumentation

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Cardiovasc Nurs. 1999 Oct;14(1):55-74 [10533692.001]
  • [Cites] Med Care. 2016 Apr;54(4):365-72 [26978568.001]
  • [Cites] J Am Geriatr Soc. 1990 Dec;38(12):1290-5 [2254567.001]
  • [Cites] Am Heart J. 2006 Aug;152(2):371-8 [16875925.001]
  • [Cites] Health Aff (Millwood). 2011 Apr;30(4):746-54 [21471497.001]
  • [Cites] Patient Educ Couns. 2002 Apr;46(4):287-95 [11932128.001]
  • [Cites] Am J Cardiol. 2001 Jun 15;87(12):1367-71 [11397355.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1248-54 [16160133.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):444-50 [23861483.001]
  • [Cites] Ann Fam Med. 2015 Nov;13(6):562-71 [26553896.001]
  • [Cites] J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239 [23747642.001]
  • [Cites] Heart Lung. 2002 May-Jun;31(3):161-72 [12011807.001]
  • [Cites] Clin Interv Aging. 2016 Sep 26;11:1325-1332 [27713623.001]
  • [Cites] JAMA. 2010 May 5;303(17):1716-22 [20442387.001]
  • [Cites] Heart. 2005 Jul;91(7):899-906 [15958358.001]
  • [Cites] Circulation. 2002 Jun 18;105(24):2861-6 [12070114.001]
  • [Cites] Am J Med. 2010 Jun;123(6):542-8 [20569761.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):171-7 [23386663.001]
  • [Cites] Eur Heart J. 2004 Sep;25(18):1570-95 [15351157.001]
  • [Cites] Am Heart J. 2001 Oct;142(4):E7 [11579371.001]
  • [Cites] Circ Heart Fail. 2013 May;6(3):606-19 [23616602.001]
  • [Cites] Am J Med. 2014 Sep;127(9):886.e15-20 [24768966.001]
  • [Cites] J Multidiscip Healthc. 2011 Mar 31;4:39-51 [21544247.001]
  • [Cites] Ann Fam Med. 2015 Mar;13(2):115-22 [25755032.001]
  • [Cites] Circulation. 1997 Feb 18;95(4):1085-90 [9054774.001]
  • [Cites] J Gen Intern Med. 2013 Feb;28(2):269-82 [23054925.001]
  • (PMID = 28615367.001).
  • [ISSN] 1941-3297
  • [Journal-full-title] Circulation. Heart failure
  • [ISO-abbreviation] Circ Heart Fail
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL135437; United States / NIMHD NIH HHS / MD / L60 MD010857; United States / NHLBI NIH HHS / HL / T32 HL116276
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; adult / heart failure / hospitalization / poverty / survey / transportation
  •  go-up   go-down


39. Rubenstein R, Chang B, Yue JK, Chiu A, Winkler EA, Puccio AM, Diaz-Arrastia R, Yuh EL, Mukherjee P, Valadka AB, Gordon WA, Okonkwo DO, Davies P, Agarwal S, Lin F, Sarkis G, Yadikar H, Yang Z, Manley GT, Wang KKW, and the TRACK-TBI Investigators, Cooper SR, Dams-O'Connor K, Borrasso AJ, Inoue T, Maas AIR, Menon DK, Schnyer DM, Vassar MJ: Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers. JAMA Neurol; 2017 Sep 01;74(9):1063-1072
MedlinePlus Health Information. consumer health - Traumatic Brain Injury.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated.
  • Objective: To examine the associations between plasma P-tau and total-tau (T-tau) levels and injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in acute and chronic TBI.
  • Design, Setting, and Participants: In the TRACK-TBI Pilot study, plasma was collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma centers (<24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units (mean [SD], 176.4 [44.5] days after injury).
  • Results: In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) years.
  • The P-tau and T-tau levels and P-tau-T-tau ratio in patients with acute TBI were higher than those in healthy controls.
  • Acute P-tau levels and P-tau-T-tau ratio weakly distinguished patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC = 0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, ≤4 vs >4) (AUC = 0.771 and 0.777, respectively).
  • Plasma samples from patients with chronic TBI also showed elevated P-tau levels and a P-tau-T-tau ratio significantly higher than that of healthy controls, with both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC = 1.000 and 0.963, respectively).
  • Compared with T-tau levels alone, P-tau levels and P-tau-T-tau ratios show more robust and sustained elevations among patients with chronic TBI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sci Transl Med. 2012 May 16;4(134):134ra60 [22593173.001]
  • [Cites] Neurocrit Care. 2014 Oct;21(2):259-65 [24515639.001]
  • [Cites] J Neurotrauma. 2013 Nov 15;30(22):1831-44 [23815563.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1139-50 [26572762.001]
  • [Cites] Br Med J. 1957 Feb 16;1(5015):357-62 [13396257.001]
  • [Cites] Brain. 2015 Sep;138(Pt 9):2701-15 [26220940.001]
  • [Cites] Acta Neurol Scand. 2013 Oct;128(4):220-7 [23621298.001]
  • [Cites] Acta Neurol Scand. 2012 Jun;125(6):416-23 [21954973.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Sep;58(9):982-92 [10499440.001]
  • [Cites] Transl Neurodegener. 2012 Dec 15;1(1):24 [23241453.001]
  • [Cites] JAMA Neurol. 2014 Jun;71(6):684-92 [24627036.001]
  • [Cites] J Forensic Nurs. 2010 Fall;6(3):130-6 [21175533.001]
  • [Cites] Neurology. 2013 Sep 24;81(13):1122-9 [23966253.001]
  • [Cites] Crit Care Med. 2015 Jul;43(7):1405-14 [25803654.001]
  • [Cites] J Neurotrauma. 2011 Jun;28(6):861-70 [21309726.001]
  • [Cites] World J Biol Psychiatry. 2008;9(3):172-82 [17886169.001]
  • [Cites] Neuroscience. 2007 Jan 5;144(1):119-27 [17055174.001]
  • [Cites] Neurochem Res. 2008 Mar;33(3):518-25 [17768677.001]
  • [Cites] J Neurotrauma. 2015 Mar 1;32(5):342-52 [25177776.001]
  • [Cites] J Emerg Nurs. 2009 Apr;35(2):e5-40 [19285163.001]
  • [Cites] Nat Rev Neurol. 2013 Apr;9(4):211-21 [23458973.001]
  • [Cites] J Neurotrauma. 2014 Jan 1;31(1):19-25 [23865516.001]
  • [Cites] Sci Rep. 2015 Jun 10;5:11178 [26058556.001]
  • [Cites] J Neurotrauma. 2016 Jan 15;33(2):203-14 [26467555.001]
  • [Cites] Neurology. 2003 May 13;60(9):1457-61 [12743231.001]
  • [Cites] ASN Neuro. 2011 Feb 16;3(1):e00051 [21359008.001]
  • [Cites] JAMA Neurol. 2015 Oct;72(10):1109-16 [26237304.001]
  • [Cites] J Neurotrauma. 2016 Jul 1;33(13):1270-7 [26560343.001]
  • [Cites] Arch Phys Med Rehabil. 2010 Nov;91(11):1667-72 [21044710.001]
  • [Cites] Front Neurol. 2013 Jun 26;4:79 [23805125.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Jul;68(7):709-35 [19535999.001]
  • [Cites] J Forensic Nurs. 2010 Spring;6(1):40-6 [20201914.001]
  • [Cites] Neurosci Biobehav Rev. 2012 May;36(5):1376-81 [22390915.001]
  • [Cites] Alzheimers Res Ther. 2014 Sep 24;6(5):68 [25580160.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2013 Jul 12;62(27):549-52 [23842444.001]
  • [Cites] JAMA Neurol. 2016 May 1;73(5):551-60 [27018834.001]
  • [Cites] Brain. 2013 Jan;136(Pt 1):43-64 [23208308.001]
  • [Cites] Neurology. 2004 Jan 13;62(1):159; author reply 159-60 [14718730.001]
  • [Cites] Cancer Epidemiol. 2017 Feb;46:9-13 [27871006.001]
  • [Cites] Psychol Med. 1973 Aug;3(3):270-303 [4729191.001]
  • [Cites] Acta Neuropathol. 2016 Jan;131(1):75-86 [26667418.001]
  • [Cites] Neurobiol Dis. 2002 Nov;11(2):341-54 [12505426.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1021-31 [12937143.001]
  • [Cites] Lancet Neurol. 2013 Jun;12(6):609-22 [23684085.001]
  • [Cites] Neurobiol Dis. 2008 Aug;31(2):198-208 [18562203.001]
  • [Cites] Semin Clin Neuropsychiatry. 1998 Jul;3(3):176-185 [10085205.001]
  • (PMID = 28738126.001).
  • [ISSN] 2168-6157
  • [Journal-full-title] JAMA neurology
  • [ISO-abbreviation] JAMA Neurol
  • [Language] eng
  • [Grant] United States / RRD VA / RX / I01 RX001859; United States / NINDS NIH HHS / NS / R21 NS085455; United States / NINDS NIH HHS / NS / RC2 NS069409; United States / NINDS NIH HHS / NS / U01 NS086090
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / tau Proteins
  •  go-up   go-down


40. Chanques G, Conseil M, Roger C, Constantin JM, Prades A, Carr J, Muller L, Jung B, Belafia F, Cissé M, Delay JM, de Jong A, Lefrant JY, Futier E, Mercier G, Molinari N, Jaber S, SOS-Ventilation study investigators: Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial. Lancet Respir Med; 2017 Oct;5(10):795-805
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate interruption of sedation compared with usual sedation care in critically ill postoperative patients (SOS-Ventilation): a randomised, parallel-group clinical trial.
  • BACKGROUND: Avoidance of excessive sedation and subsequent prolonged mechanical ventilation in intensive care units (ICUs) is recommended, but no data are available for critically ill postoperative patients.
  • We hypothesised that in such patients stopping sedation immediately after admission to the ICU could reduce unnecessary sedation and improve patient outcomes.
  • Stratified randomisation with minimisation (1:1 via a restricted web platform) was used to assign eligible patients (aged ≥18 years, admitted to an ICU after abdominal surgery, and expected to require at least 12 h of mechanical ventilation because of a critical illness defined by a Sequential Organ Failure Assessment score >1 for any organ, but without severe acute respiratory distress syndrome or brain injury) to usual sedation care provided according to recommended practices (control group) or to immediate interruption of sedation (intervention group).
  • All patients who underwent randomisation (except for those who were excluded after randomisation) were included in the intention-to-treat analysis.
  • FINDINGS: Between Dec 2, 2011, and Feb 27, 2014, 137 patients were randomly assigned to the control (n=68) or intervention groups (n=69).
  • INTERPRETATION: Immediate interruption of sedation in critically ill postoperative patients with organ dysfunction who were admitted to the ICU after abdominal surgery improved outcomes compared with usual sedation care.
  • These findings support interruption of sedation in these patients following transfer from the operating room.
  • FUNDING: Délégation à la Recherche Clinique et à l'Innovation du Groupement de Coopération Sanitaire de la Mission d'Enseignement, de Recherche, de Référence et d'Innovation (DRCI-GCS-MERRI) de Montpellier-Nîmes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28935558.001).
  • [ISSN] 2213-2619
  • [Journal-full-title] The Lancet. Respiratory medicine
  • [ISO-abbreviation] Lancet Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Chanques G; Conseil M; Prades A; Carr J; Jung B; Belafia F; Cissé M; Delay JM; De Jong A; Verzilli D; Clavieras N; Jaber S; Mercier G; Molinari N; Mathieu E; Bertet H; Roger C; Muller L; Lefrant JY; Boutin C; Constantin JM; Futier E; Cayot S; Perbet S; Jabaudon M
  •  go-up   go-down


41. Omorodion JO, Algahtani RM, Zocchi MS, Fox ER, Pines JM, Kaminski HJ: Shortage of generic neurologic therapeutics: An escalating threat to patient care. Neurology; 2017 Dec 12;89(24):2431-2437

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shortage of generic neurologic therapeutics: An escalating threat to patient care.
  • Medications were included that were likely to be prescribed by a neurologist to treat a primary neurologic condition or critical for care of a patient with a neurologic condition.
  • CONCLUSIONS: Continued drug shortages may compromise the care of patients with neurologic conditions.
  • Manufacturers, together with professional organizations, patient advocacy groups, and the government, need to continue to address this issue, which may escalate with a growing burden of neurologic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • (PMID = 29142086.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kalfon P, Baumstarck K, Estagnasie P, Geantot MA, Berric A, Simon G, Floccard B, Signouret T, Boucekine M, Fromentin M, Nyunga M, Sossou A, Venot M, Robert R, Follin A, Audibert J, Renault A, Garrouste-Orgeas M, Collange O, Levrat Q, Villard I, Thevenin D, Pottecher J, Patrigeon RG, Revel N, Vigne C, Azoulay E, Mimoz O, Auquier P, IPREA Study group: A tailored multicomponent program to reduce discomfort in critically ill patients: a cluster-randomized controlled trial. Intensive Care Med; 2017 Dec;43(12):1829-1840

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tailored multicomponent program to reduce discomfort in critically ill patients: a cluster-randomized controlled trial.
  • PURPOSE: Critically ill patients are exposed to stressful conditions and experience several discomforts.
  • METHODS: In a cluster-randomized two-arm parallel trial, 34 French adult intensive care units (ICUs) without planned interventions to reduce discomfort were randomized, 17 to the arm including a 6-month period of program implementation followed by a 6-month period without the program (experimental group), and 17 to the arm with an inversed sequence (control group).
  • RESULTS: During a 1-month assessment period, 398 and 360 patients were included in the experimental group and the control group, respectively.
  • CONCLUSIONS: This tailored multicomponent program decreased self-perceived discomfort in adult critically ill patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intensive Care Med. 2014 Sep;40(9):1295-302 [24894026.001]
  • [Cites] Crit Care Med. 1981 Aug;9(8):591-7 [7261642.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):714-24 [14966096.001]
  • [Cites] Am J Crit Care. 1995 Jan;4(1):71-6 [7894560.001]
  • [Cites] Gen Hosp Psychiatry. 2013 May-Jun;35(3):226-32 [23369507.001]
  • [Cites] Crit Care Med. 2009 Jan;37(1 Suppl):S147-53 [19104215.001]
  • [Cites] Nurs Crit Care. 2013 Nov;18(6):307-18 [24165072.001]
  • [Cites] Intensive Care Med. 2010 Oct;36(10):1751-8 [20502874.001]
  • [Cites] Trials. 2016 Feb 16;17 :87 [26880373.001]
  • [Cites] Intensive Care Med. 1997 Dec;23(12):1282-5 [9470087.001]
  • [Cites] Crit Care. 2004 Dec;8(6):R467-73 [15566593.001]
  • [Cites] Arch Intern Med. 1962 Nov;110:63-75 [13957202.001]
  • [Cites] Crit Care Med. 2006 Jun;34(6):1691-9 [16625136.001]
  • [Cites] Am J Perinatol. 2006 Jul;23(5):265-71 [16685609.001]
  • [Cites] Br J Psychiatry. 2013 Jun;202:447-53 [23661768.001]
  • [Cites] Crit Care Med. 1998 Apr;26(4):651-9 [9559601.001]
  • [Cites] Crit Care Med. 2008 Jan;36(1):30-5 [18090167.001]
  • [Cites] Lancet. 2011 Nov 12;378(9804):1699-706 [21996470.001]
  • [Cites] Crit Care Med. 2016 Jan;44(1):147-52 [26457750.001]
  • [Cites] J Pediatr. 2002 Feb;140(2):192-9 [11865270.001]
  • [Cites] Br J Anaesth. 2014 Jan;112(1):89-95 [24172057.001]
  • [Cites] Crit Care. 2011 Jun 09;15(3):R142 [21658221.001]
  • [Cites] Intensive Care Med. 2009 May;35(5):796-809 [19165464.001]
  • [Cites] Crit Care Med. 2001 Feb;29(2):277-82 [11246306.001]
  • [Cites] Anaesthesia. 2014 Jun;69(6):540-9 [24813132.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):571-2 [10470711.001]
  • [Cites] JAMA. 2014 Oct 1;312(13):1342-3 [25268441.001]
  • [Cites] Crit Care Med. 2002 Apr;30(4):746-52 [11940739.001]
  • [Cites] Cochrane Database Syst Rev. 2011 Aug 10;(8):CD000125 [21833939.001]
  • [Cites] Crit Care Med. 1993 Sep;21(9 Suppl):S361-2 [8365227.001]
  • [Cites] JAMA. 2013 Jun 12;309(22):2335-44 [23689789.001]
  • [Cites] BMJ. 2012 Sep 04;345:e5661 [22951546.001]
  • [Cites] Crit Care. 2005 Apr;9(2):R96-109 [15774056.001]
  • (PMID = 29181557.001).
  • [ISSN] 1432-1238
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02442934
  • [Grant] United States / French Ministry of Health, Programme Hospitalier de Recherche Clinique National / / 12-010-0554
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cluster-randomized controlled trial / Critical care / Discomfort / ICU / Patient-reported outcome / Tailored program
  • [Investigator] Vie K; Lannuzel G; Bout H; Parthiot JP; Parthiot JP; Chazal I; Charve P; Prum C; Quenot JP; Perrot N; Augier F; Behechti N; Cocusse C; Foulon C; Goncalves L; Hanchi A; Legros E; Mercier AI; Meunier-Beillard N; Nuzillat N; Richard A; Boulle C; Kowalski B; Klusek E; Sharshar T; Polito A; Duvallet C; Krim S; Girard N; Audibert-Souhaid J; Jourdain C; Techer S; Chauvel C; Bruchet C; Temime J; Beaussart S; Jarosz F; Crozon-Clauzel J; Olousouzian S; Pereira S; Argentin L; Cerro V; Levy D; Andre S; Guervilly C; Papazian L; Moussa M; Renoult S; Biet D; Novak S; Orban JC; Diop A; Ichai C; Tesniere A; Goupil JP; Laville F; Rutter N; Brochon S; Tiercelet K; Amour J; Ait-Hamou N; Leger M; Souppart V; Griffault E; Debarre ML; Deletage C; Guerin AL; Guignon C; Seguin S; Hart C; Dernivoix K; Wuiot C; Sanches K; Hecketsweiler S; Sylvestre-Marconville C; Gardan V; Deparis-Dusautois S; Chaban Y
  •  go-up   go-down


43. Horvat N, Marcelino ASZ, Horvat JV, Yamanari TR, Batista Araújo-Filho JA, Panizza P, Seda-Neto J, Antunes da Fonseca E, Carnevale FC, Mendes de Oliveira Cerri L, Chapchap P, Cerri GG: Pediatric Liver Transplant: Techniques and Complications. Radiographics; 2017 Oct;37(6):1612-1631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver transplant is considered to be the last-resort treatment approach for pediatric patients with end-stage liver disease.
  • Early diagnosis of complications is crucial for patient survival but is challenging given the lack of specificity in clinical presentation.
  • The authors review surgical techniques, the role of each imaging modality, normal posttransplant imaging features, types of complications after liver transplant, and information required in the radiology report that is critical to patient care.
  • They present an algorithm for an imaging approach for pediatric patients after liver transplant and describe key points that should be included in radiologic reports in the pre- and postoperative settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29019744.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Moore L, Boukar KM, Tardif PA, Stelfox HT, Champion H, Cameron P, Gabbe B, Yanchar N, Kortbeek J, Lauzier F, Légaré F, Archambault P, Turgeon AF: Low-value clinical practices in injury care: a scoping review protocol. BMJ Open; 2017 Jul 12;7(7):e016024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-value clinical practices in injury care: a scoping review protocol.
  • Overall, potentially unnecessary medical interventions are estimated to consume up to 30% of healthcare resources and may expose patients to avoidable harm.
  • However, little is known about overuse for acute injury care.
  • We aim to identify low-value clinical practices in injury care.
  • We will search Medline, EMBASE, COCHRANE central, and BIOSIS/Web of Knowledge databases, websites of government agencies, professional societies and patient advocacy organisations, thesis holdings and conference proceedings.
  • This review will contribute new knowledge on low-value clinical practices in acute injury care.
  • Our results will support the development indicators to measure resource overuse and inform policy makers on potential targets for deadoption in injury care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
  • (PMID = 28706101.001).
  • [ISSN] 2044-6055
  • [Journal-full-title] BMJ open
  • [ISO-abbreviation] BMJ Open
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Injury / Low-value clinical practise / Quality in health care / medical overuse
  •  go-up   go-down


45. Klosky JL, Wang F, Russell KM, Zhang H, Flynn JS, Huang L, Wasilewski-Masker K, Landier W, Leonard M, Albritton KH, Gupta AA, Casillas J, Colte P, Kutteh WH, Schover LR: Prevalence and Predictors of Sperm Banking in Adolescents Newly Diagnosed With Cancer: Examination of Adolescent, Parent, and Provider Factors Influencing Fertility Preservation Outcomes. J Clin Oncol; 2017 Dec 01;35(34):3830-3836

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients and Methods A prospective, single-group, observational study design was used to test the contribution of sociodemographic, medical, psychological/health belief, communication, and developmental factors to fertility preservation outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Educ Prev. 1997 Dec;9(6):551-63 [9451482.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):653-63 [25834148.001]
  • [Cites] J Pediatr Oncol Nurs. 2014 Jul;31(4):211-222 [24799444.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):521-4 [15968690.001]
  • [Cites] Arch Dis Child. 2006 Aug;91(8):715-6 [16861494.001]
  • [Cites] Klin Padiatr. 2008 May-Jun;220(3):159-65 [18478488.001]
  • [Cites] BMC Cancer. 2016 Aug 09;16:620 [27506811.001]
  • [Cites] J Stat Softw. 2010;33(1):1-22 [20808728.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):613-21 [11169946.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):697-709 [10440699.001]
  • [Cites] Pediatr Blood Cancer. 2014 Jan;61(1):53-67 [23940101.001]
  • [Cites] Child Abuse Negl. 1999 Dec;23(12):1295-306 [10626612.001]
  • [Cites] J Adolesc Health. 2010 Aug;47(2):115-25 [20638003.001]
  • [Cites] Mol Cell Endocrinol. 2000 Nov 27;169(1-2):117-22 [11155943.001]
  • [Cites] Fertil Steril. 2013 Nov;100(5):1224-31 [24094423.001]
  • [Cites] Pediatr Hematol Oncol. 2009 Jun;26(4):252-60 [19437327.001]
  • [Cites] J Pediatr Hematol Oncol. 2012 Nov;34(8):e315-9 [22983421.001]
  • [Cites] Lancet Oncol. 2014 Oct;15(11):1215-23 [25239573.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):347-55 [2299374.001]
  • [Cites] Clin J Oncol Nurs. 2004 Apr;8(2):127-31, 145 [15108413.001]
  • [Cites] Psychooncology. 2004 Oct;13(10):689-99 [15386645.001]
  • [Cites] JAMA. 2013 Jun 12;309(22):2371-2381 [23757085.001]
  • [Cites] J Clin Oncol. 2013 Jul 1;31(19):2500-10 [23715580.001]
  • [Cites] J Clin Oncol. 2010 Jan 10;28(2):332-9 [19949008.001]
  • [Cites] CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103 [24488779.001]
  • [Cites] J Pediatr Health Care. 2001 Sep-Oct;15(5):223-8 [11562639.001]
  • [Cites] J Adolesc Health. 2007 Jan;40(1):69-75 [17185208.001]
  • [Cites] Transl Androl Urol. 2014 Mar;3(1):27-40 [26816750.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1890-7 [11919249.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):594-8 [17514733.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):350-4 [16794502.001]
  • [Cites] Health Educ Q. 1984 Spring;11(1):1-47 [6392204.001]
  • [Cites] Hum Reprod. 2006 Dec;21(12):3206-16 [16887922.001]
  • [Cites] Ann Oncol. 2011 May;22(5):1209-14 [21030380.001]
  • [Cites] BJU Int. 2007 Jan;99(1):33-6 [17034492.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):801-7 [10360658.001]
  • [Cites] Eur J Cancer Care (Engl). 2010 Sep;19(5):610-20 [20088919.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):192-9 [16642490.001]
  • [Cites] Patient Educ Couns. 2009 Dec;77(3):338-43 [19796912.001]
  • [Cites] Support Care Cancer. 2015 Feb;23(2):333-41 [25082365.001]
  • [Cites] Pediatrics. 2008 May;121(5):e1461-9 [18450888.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):779-85 [15963629.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):53-9 [10401498.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5952-7 [19826115.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1880-9 [11919248.001]
  • [Cites] Arch Dis Child. 2006 Feb;91(2):149-52 [16174641.001]
  • [Cites] J Assist Reprod Genet. 2011 Mar;28(3):269-77 [21110080.001]
  • (PMID = 28976795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  •  go-up   go-down


46. Mylvaganam S, Conroy E, Williamson PR, Barnes NLP, Cutress RI, Gardiner MD, Jain A, Skillman JM, Thrush S, Whisker LJ, Blazeby JM, Potter S, Holcombe C, iBRA Steering Group, Breast Reconstruction Research Collaborative: Variation in the provision and practice of implant-based breast reconstruction in the UK: Results from the iBRA national practice questionnaire. Breast; 2017 Oct;35:182-190

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Summary data for each survey item were calculated and variation between centres and overall provision of care examined.
  • Variation was demonstrated in the provision of novel different techniques for IBBR especially the use of biological (n = 62) and synthetic (n = 25) meshes and in patient selection for these procedures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
  • [Cites] N Engl J Med. 2008 Oct 9;359(15):1590-601 [18843123.001]
  • [Cites] Plast Reconstr Surg. 2013 Jul;132(1):8e-19e [23806958.001]
  • [Cites] Pilot Feasibility Stud. 2016 Aug 4;2:41 [27965859.001]
  • [Cites] J Biomed Inform. 2009 Apr;42(2):377-81 [18929686.001]
  • [Cites] Ann Plast Surg. 2006 Jul;57(1):1-5 [16799299.001]
  • [Cites] Eur J Plast Surg. 2014;37(11):599-604 [25339795.001]
  • [Cites] Eur J Surg Oncol. 2015 Jan;41(1):100-5 [25238954.001]
  • [Cites] Eur J Surg Oncol. 2016 May;42(5):665-71 [26947961.001]
  • [Cites] Lancet Oncol. 2017 Apr;18(4):e189 [28368251.001]
  • [Cites] Eur J Surg Oncol. 2016 Nov;42(11):1767-1768 [27424788.001]
  • [Cites] Gland Surg. 2017 Feb;6(1):49-56 [28210552.001]
  • [Cites] ANZ J Surg. 2017 Jun;87(6):493-498 [25266930.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):335-40 [11872059.001]
  • [Cites] Breast. 2017 Feb;31:208-213 [27914261.001]
  • [Cites] Arch Gynecol Obstet. 2012 Jul;286(1):273-6 [22366804.001]
  • [Cites] Lancet Oncol. 2017 Apr;18(4):e190 [28368252.001]
  • [Cites] Plast Reconstr Surg. 2008 Jun;121(6):1886-92 [18520873.001]
  • [Cites] Ann Plast Surg. 2007 Sep;59(3):250-5 [17721209.001]
  • [Cites] Plast Reconstr Surg. 2015 Jan;135(1):29e-42e [25539349.001]
  • [Cites] Eur J Surg Oncol. 2012 Dec;38(12):1225-30 [22981749.001]
  • [Cites] Eur J Surg Oncol. 2013 May;39(5):425-9 [23321393.001]
  • [Cites] Ann Plast Surg. 2005 Sep;55(3):232-9 [16106158.001]
  • [Cites] Lancet Oncol. 2017 Feb;18(2):251-258 [28012977.001]
  • [Cites] Br J Surg. 2015 Aug;102(9):1010-25 [26109277.001]
  • [Cites] Eur J Plast Surg. 2015;38(6):459-462 [26635446.001]
  • [Cites] Trials. 2013 Oct 28;14:356 [24165392.001]
  • [Cites] Plast Reconstr Surg. 2012 Nov;130(5 Suppl 2):27S-34S [23096982.001]
  • [Cites] Plast Reconstr Surg. 2012 Nov;130(5 Suppl 2):57S-66S [23096987.001]
  • [Cites] Ann Plast Surg. 2012 Aug;69(2):134-8 [21734545.001]
  • [Cites] Plast Reconstr Surg. 2012 Oct;130(4):513e-523e [23018711.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):893-907 [16862569.001]
  • [Cites] Ann Plast Surg. 2006 Jan;56(1):22-5 [16374090.001]
  • [Cites] BMJ. 2013 Oct 15;347:f5903 [24128977.001]
  • [Cites] Br J Surg. 2016 Aug;103(9):1147-56 [27324317.001]
  • (PMID = 28768227.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Acellular dermal matrix / Breast reconstruction / Current practice / Dermal sling / Implant-based reconstruction / Survey
  • [Investigator] Barnes NLP; Blazeby JM; Branford OA; Conroy EJ; Cutress RI; Gardiner MD; Holcombe C; Jain A; McEvoy K; Mills N; Mylvaganam S; Potter S; Skillman JM; Teasdale EM; Thrush S; Whisker LJ; Williamson PR; Tang L; Nguyen D; Johnson R; Muralikrishnan V; Chopra S; Reid A; Benyon S; Murphy C; Soliman F; Lefemine V; Saha S; Ogedegbe K; Olyinka OS; Dicks JR; Manoloudakis N; Conroy F; Irwin G; McIntosh S; Michalakis I; Hignett S; Linforth R; Rathinaezhil R; Osman H; Anesti K; Griffiths M; Jacklin R; Waterworth A; Foulkes R; Davies E; Bisarya K; Allan A; Leon-Villapalos J; Mazari FAK; Azmy I; George S; Fahmy FS; Hargreaves A; Seward J; Hignett S; Henton J; Collin T; Irwin G; Mallon P; Turner J; Sarakbi W; Athanasiou I; Rogers C; Youssef M; Graja T; Huf S; Deol H; Brindle R; Gawne S; Egbeare D; Dash I; Galea M; Laws S; Tayeh S; Parvanta L; Down S; Westbroek D; Roberts JW; Massey J; Turton P; Achuthan R; Fawzy M; Dickson M; Carmichael AR; Akingboye A; James R; Kirkpatrick K; Nael E; Vidya R; Potter S; Thorne A; Rostom M; Depasquale I; Cawthorn SJ; Gangamihardja T; Joglekar S; Smith J; Halka A; MacMillan D; Clark S; Pearce B; Mansfield L; King I; Hazari A; Smith B; Volleamere AJ; Egbeare D; Ferguson D; Barnes N; Holcombe C; Knight A; MacNeill F; Conway A; Irvine T; Mylavaganam S; Dunne N; Kohlhardt S; Hoo C; Kirk S; Hu J; Ledwidge S; Tang S; Banerjee D; Waheed S; Voynov V; Soumian S; Henderson J; Harvey J; Robertson S; Cutress RI; Mylvaganam S; Waters R; Carbone A; Skillman J; Farooq A; Tafazal H; Clarke D; Cocker D; Lai LM; Winter Beatty J; Barkeji M; Vinayagam R; McEvoy K; Mullan M; Osborne C; Baker E; Piper J
  •  go-up   go-down


47. Kahan BC, Koulenti D, Arvaniti K, Beavis V, Campbell D, Chan M, Moreno R, Pearse RM, International Surgical Outcomes Study (ISOS) group: Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries. Intensive Care Med; 2017 Jul;43(7):971-979

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries.
  • PURPOSE: As global initiatives increase patient access to surgical treatments, there is a need to define optimal levels of perioperative care.
  • Our aim was to describe the relationship between the provision and use of critical care resources and postoperative mortality.
  • METHODS: Planned analysis of data collected during an international 7-day cohort study of adults undergoing elective in-patient surgery.
  • We used risk-adjusted mixed-effects logistic regression models to evaluate the association between admission to critical care immediately after surgery and in-hospital mortality.
  • We evaluated hospital-level associations between mortality and critical care admission immediately after surgery, critical care admission to treat life-threatening complications, and hospital provision of critical care beds.
  • RESULTS: 44,814 patients from 474 hospitals in 27 countries were available for analysis.
  • Death was more frequent amongst patients admitted directly to critical care after surgery (critical care: 103/4317 patients [2%], standard ward: 99/39,566 patients [0.3%]; adjusted OR 3.01 [2.10-5.21]; p < 0.001).
  • At hospital level, there was no association between mortality and critical care admission directly after surgery (p = 0.26), critical care admission to treat complications (p = 0.33), or provision of critical care beds (p = 0.70).
  • A sensitivity analysis including only high-risk patients yielded similar findings.
  • CONCLUSIONS: We did not identify any survival benefit from critical care admission following surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2011 Oct 05;343:d5759 [21976704.001]
  • [Cites] Lancet Glob Health. 2015 Apr 27;3 Suppl 2:S13-20 [25926315.001]
  • [Cites] Nurs Res. 2003 Mar-Apr;52(2):71-9 [12657982.001]
  • [Cites] Lancet Glob Health. 2015 Jun;3(6):e316-23 [25926087.001]
  • [Cites] Lancet. 2015 Apr 27;385 Suppl 2:S11 [26313057.001]
  • [Cites] Med Care. 2011 Apr;49(4):406-14 [21407034.001]
  • [Cites] Br J Anaesth. 2017 Jan;118(1):123-131 [28039249.001]
  • [Cites] Ann Surg. 2012 Apr;255(4):696-702 [22418007.001]
  • [Cites] Lancet. 2008 Jul 12;372(9633):139-44 [18582931.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1418-28 [19339721.001]
  • [Cites] Br J Anaesth. 2016 Nov;117(5):601-609 [27799174.001]
  • [Cites] Br J Anaesth. 2014 Mar;112(3):491-7 [24148323.001]
  • [Cites] J Nurs Adm. 2004 Jan;34(1):41-5 [14737034.001]
  • [Cites] Lancet. 2012 Sep 22;380(9847):1059-65 [22998715.001]
  • [Cites] Stat Methods Med Res. 2016 Dec;25(6):3069 [27852809.001]
  • [Cites] Intensive Care Med. 2015 Oct;41(10 ):1809-16 [26202040.001]
  • [Cites] Anesthesiology. 2016 Apr;124(4):761-2 [26825150.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1617-23 [14506121.001]
  • [Cites] Eur J Anaesthesiol. 2015 Feb;32(2):88-105 [25058504.001]
  • [Cites] PLoS One. 2010 May 12;5(5):e10607 [20485549.001]
  • [Cites] Br J Anaesth. 2016 Jan;116(1):54-62 [26675949.001]
  • [Cites] Crit Care. 2006;10 (3):R81 [16749940.001]
  • [Cites] JAMA Surg. 2016 Jun 1;151(6):527-36 [26791112.001]
  • [Cites] Anesthesiology. 2016 Apr;124(4):899-907 [26825149.001]
  • [Cites] Anaesthesia. 2008 Jul;63(7):695-700 [18489613.001]
  • [Cites] N Engl J Med. 2009 Oct 1;361(14):1368-75 [19797283.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):491-507 [9790339.001]
  • [Cites] Anesthesiology. 2010 May;112(5):1105-15 [20418691.001]
  • (PMID = 28439646.001).
  • [ISSN] 1432-1238
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Critical care/utilisation / Postoperative care/methods / Postoperative care/statistics and numerical data / Surgical procedures, operative/mortality
  • [Investigator] Pearse RM; Beattie S; Clavien PA; Demartines N; Fleisher LA; Grocott M; Haddow J; Hoeft A; Holt P; Moreno R; Pritchard N; Rhodes A; Wijeysundera D; Wilson M; Ahmed T; Everingham K; Hewson R; Januszewska M; Pearse RM; Phull MK; Halliwell R; Shulman M; Myles P; Schmid W; Hiesmayr M; Wouters P; de Hert S; Lobo S; Beattie S; Wijeysundera D; Fang X; Rasmussen L; Futier E; Biais M; Venara A; Slim K; Sander M; Koulenti D; Arvaniti K; Chan M; Kulkarni A; Chandra S; Tantri A; Geddoa E; Abbas M; Della Rocca G; Sivasakthi D; Mansor M; Luna P; Bouwman A; Buhre W; Beavis V; Campbell D; Short T; Osinaike T; Matos R; Grigoras I; Kirov M; Protsenko D; Biccard B; Aldecoa C; Chew M; Hofer C; Hubner M; Ditai J; Szakmany T; Fleisher L; Ferguson M; MacMahon M; Shulman M; Cherian R; Currow H; Kanathiban K; Gillespie D; Pathmanathan E; Phillips K; Reynolds J; Rowley J; Douglas J; Kerridge R; Currow H; Garg S; Bennett M; Jain M; Alcock D; Terblanche N; Cotter R; Leslie K; Stewart M; Zingerle N; Clyde A; Hambidge O; Rehak A; Cotterell S; Binh Quan Huynh W; McCulloch T; Ben-Menachem E; Egan T; Cope J; Halliwell R; Fellinger P; Haselberger S; Holaubek C; Lichtenegger P; Scherz F; Schmid W; Hoffer F; Cakova V; Eichwalder A; Fischbach N; Klug R; Schneider E; Vesely M; Wickenhauser R; Grubmueller KG; Leitgeb M; Lang F; Toro N; Bauer M; Laengle F; Mayrhofer T; Buerkle C; Forstner K; Germann R; Rinoesl H; Schindler E; Trampitsch E; Fritsch G; Szabo C; Bidgoli J; Verdoodt H; Forget P; Kahn D; Lois F; Momeni M; Prégardien C; Pospiech A; Steyaert A; Veevaete L; De Kegel D; De Jongh K; Foubert L; Smitz C; Vercauteren M; Poelaert J; Van Mossevelde V; Abeloos J; Bouchez S; Coppens M; De Baerdemaeker L; Deblaere I; De Bruyne A; De Hert S; Fonck K; Heyse B; Jacobs T; Lapage K; Moerman A; Neckebroek M; Parashchanka A; Roels N; Van Den Eynde N; Vandenheuvel M; Van Limmen J; Vanluchene A; Vanpeteghem C; Wouters P; Wyffels P; Huygens C; Vandenbempt P; Van de Velde M; Dylst D; Janssen B; Schreurs E; Aleixo FB; Candido K; Dias Batista H; Guimarães M; Guizeline J; Hoffmann J; Lobo SM; Lobo FR; Nascimento V; Nishiyama K; Pazetto L; Souza D; Souza Rodrigues R; Vilela Dos Santos AM; Jardim J; Silva J; do Nascimento Junior P; Baio TH; Pereira de Castro GI; Watanabe Oliveira HR; Amendola CP; Cardoso G; Ortega D; Brotto AF; De Oliveira MC; Réa-Neto Á; Dias F; Azambuja P; Knibel MF; Martins A; Almeida W; Neto CN; Tardelli MA; Caser E; Machado M; Aguzzoli C; Baldisserotto S; Beck Tabajara F; Bettega F; Rodrigues Júnior HC; de Gasperi J; Faina L; Nolasco MF; da Costa Fischer BF; de Campos Ferreira MF; Hartmann C; Kliemann M; Ribeiro GLH; Fraga JM; Netto TM; Pozza LV; Wendling PR; Azevedo C; Garcia J; Lopes M; Maia B; Maselli P; Melo R; Mendes W; Neves M; Ney J; Piras C; Applewhaite C; Carr A; Chow L; Duttchen K; Foglia J; Greene M; Hinther A; Houston K; McCormick TJ; Mikhayel J; Montasser S; Ragan A; Suen A; Woolsey A; Yu HC; Funk D; Kowalski S; Legaspi R; McDonald H; Siddiqui F; Pridham J; Rowe B; Sampson S; Thiessen B; Zbitnew G; Bernard A; George R; Jones P; Moor R; Siddiqui N; Wolfer A; Tran D; Winch D; Dobson G; Hinther A; McCormick T; Montasser O; Suen A; Woolsey A; Bernard A; George R; Hall R; Bernard A; George R; Hall R; Applewhaite C; Baghirzada L; McCormick TJ; Suen A; Dai SY; Hare G; Lee E; Shastri U; Tsui A; Yagnik A; Alvares D; Choi S; Dwyer H; Flores K; McCartney C; Somascanthan P; Beattie S; Carroll J; Pazmino-Canizares J; Wijeysundera D; Wolfer A; Ami N; Chan V; Perlas A; Argue R; Lavis K; Mayson K; Cao Y; Gao H; Hu T; Lv J; Yang J; Yang Y; Zhong Y; Zhou J; Zou X; He M; Li X; Luo D; Wang H; Yu T; Chen L; Wang L; Cai Y; Cao Z; Li Y; Lian J; Sun H; Wang S; Wang Z; Wang K; Zhu Y; Du X; Fan H; Fu Y; Huang L; Huang Y; Hwan H; Luo H; Qu PS; Tao F; Wang Z; Wang G; Wang S; Zhang Y; Zhang X; Chen C; Wang W; Liu Z; Fan L; Tang J; Chen Y; Chen Y; Han Y; Huang C; Liang G; Shen J; Wang J; Yang Q; Zhen J; Zhou H; Chen J; Chen Z; Li X; Meng B; Ye H; Zhang X; Bi Y; Cao J; Guo F; Lin H; Liu Y; Lv M; Shi P; Song X; Sun C; Sun Y; Wang Y; Wang S; Zhang M; Chen R; Hou J; Leng Y; Meng QT; Qian L; Shen ZY; Xia ZY; Xue R; Zhang Y; Zhao B; Zhou XJ; Chen Q; Guo H; Guo Y; Qi Y; Wang Z; Wei J; Zhang W; Zheng L; Bao Q; Chen Y; Chen Y; Fei Y; Hu N; Hu X; Lei M; Li X; Lv X; Lv J; Miao F; Ouyang L; Qian L; Shen C; Sun Y; Wang Y; Wang D; Wu C; Xu L; Yuan J; Zhang L; Zhang H; Zhang Y; Zhao J; Zhao C; Zhao L; Zheng T; Zhou D; Zhou H; Zhou C; Lu K; Zhao T; He C; Chen H; Chen S; Cheng B; He J; Jin L; Li C; Li H; Pan Y; Shi Y; Wen XH; Wu S; Xie G; Zhang K; Zhao B; Lu X; Chen F; Liang Q; Lin X; Ling Y; Liu G; Tao J; Yang L; Zhou J; Chen F; Feng Y; Hou B; Lin J; Liu M; Luo F; Shi X; Xiong Y; Xu L; Yang S; Zhang Q; Zhang H; Zhao W; Zhao W; Bai Y; Chen L; Chen S; Dai Q; Geng W; Han K; He X; Huang L; Ji B; Jia D; Jin S; Li Q; Liang D; Luo S; Lwang L; Mo Y; Pan Y; Qi X; Qian M; Qin J; Ren Y; Shi Y; Wang J; Wang J; Wang L; Xie J; Yan Y; Yao Y; Zhang M; Zhao J; Zhuang X; Ai Y; Du F; He L; Huang L; Li Z; Li H; Li Y; Li L; Meng S; Yuan Y; Zhang E; Zhang J; Zhao S; Ji Z; Pei L; Wang L; Chen C; Dong B; Li J; Miao Z; Mu H; Qin C; Su L; Wen Z; Xie K; Yu Y; Yuan F; Hu X; Zhang Y; Xiao W; Zhu Z; Dai Q; Fu K; Hu R; Hu X; Huang S; Li Y; Liang Y; Yu S; Guo Z; Jing Y; Tang N; Wu J; Yuan D; Zhang R; Zhao X; Li Y; Bai HP; Liu CX; Liu FF; Ren W; Wang XL; Xu GJ; Hu N; Li B; Ou Y; Tang Y; Yao S; Zhang S; Kong CC; Liu B; Wang T; Xiao W; Lu B; Xia Y; Zhou J; Cai F; Chen P; Hu S; Wang H; Wu J; Xu Q; Hu L; Jing L; Li J; Li B; Liu Q; Liu Y; Lu X; Peng ZD; Qiu X; Ren Q; Tong Y; Wang Z; Wang J; Wen Y; Wu Q; Xia J; Xie J; Xiong X; Xu S; Yang T; Ye H; Yin N; Yuan J; Zeng Q; Zhang B; Zheng K; Cang J; Chen S; Du F; Fan Y; Fu S; Ge X; Guo B; Huang W; Jiang L; Jiang X; Jin L; Liu Y; Pan Y; Ren Y; Shan Q; Wang J; Wang F; Wu C; Zhang X; Christiansen IC; Granum SN; Rasmussen BS; Daugaard M; Gambhir R; Steingrímsdóttir GE; Jensen-Gadegaard P; Olsen KS; Siegel H; Zwicky Eskildsen K; Gätke MR; Wibrandt I; Heintzelmann SB; Lange KHW; Lundsgaard RS; Amstrup-Hansen L; Hovendal C; Larsen M; Lenstrup M; Kobborg T; Larsen JR; Pedersen AB; Larsen JR; Smith SH; Oestervig RM; Rasmussen L; Afshari A; Andersen C; Ekelund K; Secher EL; Brandsborg B; Beloeil H; Lasocki S; Venara A; Biais M; Ouattara A; Sineus M; Molliex S; Legouge ML; Wallet F; Tesniere A; Gaudin C; Lehur P; Forsans E; de Rudnicki S; Serra Maudet V; Mutter D; Sojod G; Ouaissi M; Regimbeau JM; Futier E; Desbordes J; Comptaer N; El Manser D; Ethgen S; Lebuffe G; Auer P; Härtl C; Deja M; Legashov K; Sonnemann S; Wiegand-Loehnert C; Falk E; Habicher M; Angermair S; Laetsch B; Schmidt K; Sonnemann S; Von Heymann C; Ramminger A; Jelschen F; Pabel S; Weyland A; Czeslick E; Gille J; Malcharek M; Sablotzki A; Lueke K; Wetzel P; Weimann J; Lenhart FP; Reichle F; Schirmer F; Hüppe M; Klotz K; Nau C; Schön J; Mencke T; Wasmund C; Bankewitz C; Baumgarten G; Fleischer A; Guttenthaler V; Hack Y; Hoeft A; Kirchgaessner K; Männer O; Schurig-Urbaniak M; Struck R; van Zyl R; Wittmann M; Goebel U; Harris S; Veit S; Andreadaki E; Souri F; Katsiadramis I; Skoufi A; Vasileiou M; Aimoniotou-Georgiou E; Katsourakis A; Veroniki F; Vlachogianni G; Petra K; Chlorou D; Oloktsidou E; Ourailoglou V; Papapostolou K; Tsaousi G; Daikou P; Dedemadi G; Kalaitzopoulos I; Loumpias C; Bristogiannis S; Dafnios N; Gkiokas G; Kontis E; Kozompoli D; Papailia A; Theodosopoulos T; Bizios C; Koutsikou A; Moustaka A; Plaitakis I; Armaganidis A; Christodoulopoulou T; Lignos M; Theodorakopoulou M; Asimakos A; Ischaki E; Tsagkaraki A; Zakynthinos S; Antoniadou E; Koutelidakis I; Lathyris D; Pozidou I; Voloudakis N; Dalamagka M; Gkonezou E; Chronis C; Manolakaki D; Mosxogiannidis D; Slepova T; Tsakiridou IS; Lampiri CL; Vachlioti AV; Panagiotakis CP; Sfyras DS; Tsimpoukas FT; Tsirogianni A; Axioti E; Filippopoulos A; Kalliafa E; Kassavetis G; Katralis P; Komnos I; Pilichos G; Ravani I; Totis A; Apagaki E; Efthymiadi A; Kampagiannis N; Paraforou T; Tsioka A; Georgiou G; Vakalos A; Bairaktari A; Charitos E; Markou G; Niforopoulou P; Papakonstantinou N; Tsigou E; Xifara A; Zoulamoglou M; Gkioni P; Karatzas S; Kyparissi A; Mainas E; Papapanagiotou I; Papavasilopoulou T; Fragandreas G; Georgopoulou E; Katsika E; Psarras K; Synekidou E; Verroiotou M; Vetsiou E; Zaimi D; Anagnou A; Apostolou K; Melissopoulou T; Rozenberg T; Tsigris C; Boutsikos G; Kalles V; Kotsalas N; Lavdaiou C; Paikou F; Panagou GL; Spring A; Arvaniti K; Botis I; Drimala M; Georgakakis G; Kiourtzieva E; Ntouma P; Prionas A; Xouplidis K; Dalampini E; Giannaki C; Iasonidou C; Ioannidis O; Lavrentieva A; Lavrentieva A; Papageorgiou G; Kokkinoy M; Stafylaraki M; Gaitanakis S; Karydakis P; Paltoglou J; Ponireas P; Chaloulis P; Provatidis A; Sousana A; Gardikou VV; Konstantivelli M; Lataniotou O; Lisari E; Margaroni M; Stamatiou K; Nikolaidis E; Pnevmatikos I; Sertaridou E; Andreou A; Arkalaki E; Athanasakis E; Chaniotaki F; Chatzimichali A; Christofaki M; Dermitzaki D; Fiorentza K; Frantzeskos G; Geromarkaki E; Kafkalaki K; Kalogridaki M; Karydi K; Kokkini S; Kougentakis G; Lefaki T; Lilitsis E; Makatounaki A; Malliotakis P; Michelakis D; Neonaki M; Nyktari V; Palikyra I; Papadakis E; Papaioannou A; Sfakianakis K; Sgouraki M; Souvatzis X; Spartinou A; Stefanidou N; Syrogianni P; Tsagkaraki G; Arnaoutoglou E; Arnaoutoglou C; Bali C; Bouris V; Doumos R; Gkini KP; Kapaktsi C; Koulouras V; Lena A; Lepida D; Michos E; Papadopoulos D; Paschopoulos M; Rompou VA; Siouti I; Tsampalas S; Ververidou O; Zilis G; Charlalampidoy A; Christodoulidis G; Flossos A; Stamoulis K; Chan M; Tsang MSC; Tsang MS; Lai ML; Yip CP; Chan HMH; Law B; Li WS; Chu HM; Koo EGY; Lam CCJ; Cheng KH; Chan M; Lam T; Chu S; Lai ML; Lam WY; Wong KWK; Kwok D; Hung CYJ; Chan WKJ; LamWong W; Chung CKE; Lai ML; Ma SK; Kaushik S; Shah B; Shah D; Shah S; Ar P; Muthuchellappan R; Agarwal V; Divatia J; Kulkarni A; Mishra S; Nimje G; Pande S; Savarkar S; Shrivastava A; Thomas M; Yegnaram S; Hidayatullah R; Chandra S; Tantri A; Puar N; Niman S; Indra I; Hamzah Z; Yuliana A; Abidin UN; Dursin AN; Kurnia A; Susanti A; Handayani D; Aribawa MA; Arya A; Senapathi TGA; Utara UH; Wid WM; Wima S; Wir WM; Jehosua B; Kaunang J; Lantang EY; Najoan R; Waworuntu N; Awad H; Fuad A; Geddoa E; Geddoa B; Khalaf AR; Al Hussaini S; Albaj S; Kenber M; Bettinelli A; Spadaro S; Volta CA; Giancarlo L; Sottosanti V; Della Rocca G; Spagnesi L; Toretti I; Alloj C; Cardellino S; Carmino L; Costanzo E; Fanfani LC; Novelli MT; Roasio A; Bellandi M; Beretta L; Bignami E; Bocchino S; Cabrini L; Corti D; Landoni G; Meroni R; Moizo E; Monti G; Pintaudi M; Plumari VP; Taddeo D; Testa V; Winterton D; Zangrillo A; Cloro LM; Colangelo C; Colangelo A; Rotunno G; Angel MP; Maria CP; Pata A; Parrini V; Gatta A; Nastasi M; Tinti C; Spagnesi L; Arrigo M; Benevento A; Bottini C; Cannavo' M; Gastaldi C; Marchesi A; Pascazio A; Pata F; Pozzi E; Premoli A; Tessera G; Boschi L; D'Andrea R; Ghignone F; Poggioli G; Sibilio A; Taffurelli M; Ugolini G; Ab Majid MA; Ab Rahman R; Joseph J; Pathan F; Shah MHS; Yap HL; Cheah S; Chin II; Looi JK; Tan SC; Visvalingam S; Kwok FY; Lee CK; Tan TS; Wong SM; Abdullah NH; Liew CF; Luxuman L; Mohd Zin NH; Norddin MF; Alias RLR; Wong JY; Yong J; Bin Mustapha MT; Chan WK; Dzulkipli N; Kuan PX; Lee YC; Alias A; Guok EC; Jee CC; Ramon BR; Weng CW; Abd Ghafar FNI; Aziz FZ; Hussain N; Lee HS; Sukawi I; Woon YL; Abd Hadi HZ; Ahmad Azam UA; Alias AH; Kesut SA; Lee JM; Ooi DV; Sulaiman HA; Tengku Lih TA; Mansor M; Veerakumaran J; Luna P; Rojas E; Resendiz GEA; Zapata DDM; Aguilar López JCJ; Flores AAA; Amador JCB; Avila EJD; Aquino LPG; Rodriguez RL; Landa MT; Urias E; Hollmann M; Hulst A; Kirzner O; Preckel B; Koopman-van Gemert A; Bouwman A; Buise M; Tolenaar N; Weber E; de Fretes J; Houweling P; Ormskerk P; Van Bommel J; Buhre W; Lance M; Smit-Fun V; van Zundert T; Baas P; de Boer HD; Sprakel J; Elferink-Vonk R; Noordzij P; van Zeggeren L; Brand B; Spanjersberg R; Ten Bokkel-Andela J; Numan J; van Klei W; van Zaane B; Boer C; van Duivenvoorde Y; Hering JP; Zonneveldt H; Campbell D; Hoare S; Santa S; Allen SJ; Beavis V; Bell R; Choi HD; Drake M; Farrell H; Higgie K; Holmes K; Jenkins N; Kim CJ; Kim S; Law KC; McAllister D; Park K; Pedersen K; Pfeifer L; Salmond T; Steynor M; Tan M; Waymouth E; Ab Rahman AS; Armstrong J; Dudson R; Jenkins N; Nilakant J; Richard S; Virdi P; Dixon L; Donohue R; Farrow M; Kennedy R; Marissa H; McKellow M; Nicola D; Pascoe R; Roberts SJ; Rowell G; Sumner M; Templer P; Chandrasekharan S; Fulton G; Jammer I; Ali M; More R; Wilson L; Chang YH; Chang J; Fowler C; Panckhurst J; Sara R; Stapelberg F; Campbell D; Cherrett V; Ganter DL; McAllister D; McCann L; Foley J; Gilmour F; Lumsden R; Moores M; Olliff S; Sardareva E; Stapelberg F; Tai J; Wikner M; Wong C; Chaddock M; Czepanski C; McKendry P; Polakovic D; Polakovich D; Robert A; Tormo Belda M; Norton T; Stapelberg F; Alherz F; Barneto L; Ramirez A; Sayeed A; Smith N; Bennett C; McQuoid S; Bell R; Jansen TL; Nico Z; Scott J; Freschini D; Freschini A; Hopkins B; Manson L; Stoltz D; Bates A; Davis S; Freeman V; McGaughran L; Baskar Sharma S; Burrows T; Byrne K; English D; Johnson R; Chai Law K; Manikkam B; McAllister D; Naidoo S; Rumball M; Whittle N; Franks R; Gibson-Lapsley H; McAllister D; Salter R; Walsh D; Cooper R; Perry K; Obobolo A; Sule UM; Ahmad A; Atiku M; Mohammed AD; Sarki AM; Adekola O; Akanmu O; Durodola A; Olukoju O; Raji V; Olajumoke T; Oyebamiji E; Adenekan A; Adetoye A; Faponle F; Olateju S; Owojuyigbe A; Talabi A; Adenike O; Adewale B; Collins N; Ezekiel E; Fatungase OM; Grace A; Sola S; Stella O; Ademola A; Adeolu AA; Adigun T; Akinwale M; Fasina O; Gbolahan O; Idowu O; Olonisakin RP; Osinaike BB; Asudo F; Mshelia D; Abdur-Rahman L; Agodirin O; Bello J; Bolaji B; Oyedepo OO; Ezike H; Iloabachie I; Okonkwo I; Onuora E; Onyeka T; Ugwu I; Umeh F; Alagbe-Briggs O; Dodiyi-Manuel A; Echem R; Obasuyi B; Onajin-Obembe B; Bandeira ME; Martins A; Tomé M; Martins Costa ACM; Krystopchuk A; Branco T; Esteves S; Melo MA; Monte J; Rua F; Martins I; Pinho-Oliveira VM; Rodrigues CM; Cabral R; Marques S; Rêgo S; Teixeira Jesus JS; Conceição Marques M; Romao C; Dias S; Santos AM; Alves MJ; Salta C; Cruz S; Duarte C; Furtado Paiva AA; do Nascimento Cabral T; Fariae Maia D; Correia da Silva RFM; Langner A; Oliveira Resendes H; da Conceição Soares M; Abrunhosa A; Faria F; Miranda L; Pereira H; Serra S; Ionescu D; Margarit S; Mitre C; Vasian H; Manga G; Stefan A; Tomescu D; Filipescu D; Paunescu MA; Stefan M; Stoica R; Gavril L; Pătrăşcanu E; Ristescu I; Rusu D; Diaconescu C; Iosep GF; Pulbere D; Ursu I; Balanescu A; Grintescu I; Mirea L; Rentea I; Vartic M; Lupu MN; Stanescu D; Streanga L; Antal O; Hagau N; Patras D; Petrisor C; Tosa F; Tranca S; Copotoiu SM; Ungureanu LL; Harsan CR; Papurica M; Cernea DD; Dragoescu NA; Aflori L; Vaida C; Ciobotaru OR; Aignatoaie M; Carp CP; Cobzaru I; Mardare O; Purcarin B; Tutunaru V; Ionita V; Arustei M; Codita A; Busuioc M; Chilinciuc I; Ciobanu C; Belciu I; Tincu E; Blaj M; Grosu RM; Sandu G; Bruma D; Corneci D; Dutu M; Krepil A; Copaciu E; Dumitrascu CO; Jemna R; Mihaescu F; Petre R; Tudor C; Ursache E; Kulikov A; Lubnin A; Grigoryev E; Pugachev S; Protsenko D; Tolmasov A; Hussain A; Ilyina Y; Kirov M; Roshchina A; Iurin A; Chazova E; Dunay A; Karelov A; Khvedelidze I; Voldaeva O; Belskiy V; Dzhamullaev P; Grishkowez E; Kretov V; Levin V; Molkov A; Puzanov S; Samoilenko A; Tchekulaev A; Tulupova V; Utkin I; Allorto NL; Bishop DG; Builu PM; Cairns C; Dasrath A; de Wet J; den Hoedt M; Grey B; Hayes MP; Küsel BS; Shangase N; Wise R; Cacala S; Farina Z; Govindasamy V; Kruse CH; Lee C; Marais L; Naidoo TD; Rajah C; Rodseth RN; Ryan L; von Rhaden R; Adam S; Alphonsus C; Ameer Y; Anderson F; Basanth S; Bechan S; Bhula C; Biccard BM; Biyase T; Buccimazza I; Cardosa J; Chen J; Daya B; Drummond L; Elabib A; Goad EHA; Goga IE; Goga R; Harrichandparsad R; Hodgson RE; Jordaan J; Kalafatis N; Kampik C; Landers AT; Loots E; Madansein R; Madaree A; Madiba TE; Manzini VT; Mbuyisa M; Moodley R; Msomi M; Mukama I; Naidoo D; Naidoo R; Naidu TK; Ntloko S; Padayachee E; Padayachee L; Phaff M; Pillay B; Pillay D; Pillay L; Ramnarain A; Ramphal SR; Ryan P; Saloojee A; Sebitloane M; Sigcu N; Taylor JL; Torborg A; Visser L; Anderson P; Conradie A; de Swardt M; de Villiers M; Eikman J; Liebenberg R; Mouton J; Paton A; van der Merwe L; Wilscott-Davids C; Barrett WJ; Bester M; de Beer J; Geldenhuys J; Gouws H; Potgieter JH; Strydom M; Wilberforce-Turton E; Chetty RR; Chirkut S; Cronje L; de Vasconcellos K; Dube NZ; Sibusiso Gama N; Green GM; Green-Thompson R; Kinoo SM; Kistnasami P; Maharaj K; Moodley MS; Mothae SJ; Naidoo R; Aslam M; Noorbhai F; Rughubar V; Reddy J; Singh A; Skinner DL; Smith MJ; Singh B; Misra R; Naidoo M; Ramdharee P; Selibea Y; Sewpersad S; Sham S; Wessels JD; Africander C; Bejia T; Blakemore SP; Botes M; Bunwarie B; Hernandez CB; Jeeraz MA; Legutko DA; Lopez AG; De Meyer JN; Muzenda T; Naidoo N; Patel M; Pentela R; Junge M; Mansoor N; Rademan L; Scislowski P; Seedat I; van den Berg B; van der Merwe D; van Wyk S; Govender K; Naicker D; Ramjee R; Saley M; Kuhn WP; Matos-Puig R; Moolla Z; Lisi A; Perez G; Valle Beltran A; Lozano A; Delgado Navarro C; Duca A; Pastor Martinez E; Ferrando C; Fuentes I; García-Pérez ML; Gracia E; Izquierdo Palomares A; Katime A; Miñana A; Incertis R; Romero E; Romero Garcia CS; Rubio C; Socorro Artiles T; Soro M; Valls P; Laguarda GA; Benavent P; Cuenca VC; Cueva A; Lafuente M; Parra AM; Rodrigo AR; Sanchez-Morcillo S; Tormo S; Redondo FJ; De Andres J; Gómez Diago L; Hernández Cádiz MJ; Manuel GG; Peris R; Saiz C; Tatay J; Tebar Soto MT; Brunete T; Cancho D; Delgado García DR; Zamudio D; Garcia Del Valle S; Luz Serrano M; Alonso E; Anillo V; Maseda E; Salgado P; Suarez L; Suarez-de-la-Rica A; Villagrán MJ; Aldecoa C; Alonso JI; Cabezuelo E; Garcia-Saiz I; Lopez Del Moral O; Martín S; Perez Gonzalez A; Tovar Doncel S; Vera MA; Ávila Sánchez FJ; Castaño B; Castaño Moreira B; Flores Risco S; Paz Martín D; Pérez Martín F; Poza P; Ruiz A; Serna Martínez WF; Vicente BV; Dominguez SV; Fernández S; Munoz-López A; Bernat MJ; Mas A; Planas K; Jawad M; Saeed Y; Hedin A; Levander H; Chew M; Holmström S; Lönn D; Zoerner F; Åkring I; Widmark C; Zettergren J; Liljequist VA; Nystrom L; Odeberg-Wernerman S; Oldner A; Reje P; Lyckner S; Sperber J; Adolfsson A; Klarin B; Hedin A; Ögren K; Barras JP; Bührer T; Despotidis V; Helmy N; Holliger S; Raptis DA; Schmid R; Meyer A; Jaquet Y; Kessler U; Muradbegovic M; Nahum SR; Rotunno T; Schiltz B; Voruz F; Worreth M; Christoforidis D; Popeskou SG; Furrer M; Prevost GA; Stocker A; Lang K; Breitenstein S; Ganter MT; Geisen M; Soll C; Korkmaz M; Lubach I; Schmitz M; Meyer Zu Schwabedissen M; Zingg U; Hillermann T; Wildi S; Hofer C; Pinto BB; Walder B; Hübner M; Mariotti G; Slankamenac K; Namuyuga M; Kyomugisha E; Kituuka O; Wesonga Shikanda A; Kakembo N; Otim Tom C; Webombesa A; Bua E; Ditai J; Ssettabi EM; Epodoi J; Kabagenyi F; Kirya F; Dempsey G; Seasman C; Basit Nawaz Khan R; Kurasz C; Macgregor M; Shawki B; Hariharan V; Chau S; Ellis K; Butt G; Chicken DW; Christmas N; Allen S; Daniel GD; Dempster A; Kemp J; Matthews L; Mcglone P; Tambellini J; Trodd D; Freitas K; Garg A; Karpate S; Kulkarni A; O'Hara C; Troko J; Angus K; Bradley J; Brennan E; Brooks C; Brown J; Brown G; Finch A; Gratrix K; Hesketh S; Hill G; Jeffs C; Morgan M; Pemberton C; Slawson N; Spickett H; Swarbrick G; Thomas M; Van Duyvenvoorde G; Brennan A; Briscoe R; Cooper S; Lawton T; Northey M; Senaratne R; Stanworth H; Burrows L; Cain H; Craven R; Davies K; Jonas A; Pachucki M; Walkden G; Davies H; Gudaca M; Hobrok M; Arawwawala D; Fergey L; Gardiner M; Gunn J; Johnson L; Lofting A; Lyle A; Mc Neela F; Smolen S; Topliffe J; Williams S; Bland M; Kaura V; Lanka P; Naylor C; Smith N; Ahmed A; Myatt J; Shenoy R; Soon WC; Tan J; Karadia S; Self J; Durant E; Tripathi S; Bullock C; Campbell D; Ghosh A; Hughes T; Zsisku L; Bengeri S; Cowton A; Khalid MS; Limb J; McAdam C; Porritt M; Rafi MA; Shekar P; Harden C; Hollands H; King A; March L; Minto G; Patrick A; Waugh D; Kumara P; Simeson K; Yarwood J; Browning J; Hatton J; Julian H; Mitra A; Newton M; Pernu P; Wilson A; Commey T; Foot H; Glover L; Gupta A; Lancaster N; Levin J; Mackenzie F; Mestanza C; Nofal E; Pout L; Varden R; Wild J; Jones S; Moreton S; Pulletz M; Davies C; Martin M; Thomas S; Burns K; McArthur C; Patel P; Lau G; Rich N; Davis F; Self J; Lyons R; Port B; Prout R; Smith C; Adelaja Y; Bennett V; Bidd H; Dumitrescu A; Murphy JF; Keen A; Mguni N; Ong C; Adams G; Boshier P; Brown R; Butryn I; Chatterjee J; Freethy A; Lockwood G; Tsakok M; Tsiligiannis S; Peat W; Stephenson L; Bradburn M; Pick S; Cunha P; Olagbaiye O; Tayeh S; Abernethy C; Balasubramaniam M; Bennett R; Bolton D; Martinson V; Naylor C; Smith N; Bell S; Heather B; Kushakovsky V; Alcock L; Alexander H; Anderson C; Baker P; Brookes M; Cawthorn L; Cirstea E; Colling K; Coulter I; Das S; Haigh K; Hamdan A; Hugill K; Kottam L; Lisseter E; Mawdsley M; McGivern J; Padala K; Phelps V; Kumar VR; Stewart K; Towse K; Tregonning J; Vahedi A; Walker A; Baines D; Bilolikar A; Chande S; Copley E; Dunk N; Kulkarni R; Kumar P; Metodiev Y; Ncomanzi D; Raithatha B; Raymode P; Szafranski J; Twohey L; Watt P; Weatherall L; Weatherill J; Whitman Z; Wighton E; Abayasinghe C; Chan A; Darwish S; Gill J; Glasgow E; Hadfield D; Harris C; Kochhar A; Mellis C; Pool A; Riozzi P; Selman A; Smith EJ; Vele L; Gercek Y; Guy K; Holden D; Watson N; Whysall K; Andreou P; Hales D; Thompson J; Bowrey S; McDonald S; Thompson J; Gilmore J; Hills V; Kelly C; Kelly S; Lloyd G; Abbott T; Gall L; Torrance H; Vivian M; Berntsen E; Nolan T; Turner A; Vohra A; Brown A; Clark R; Coughlan E; Daniel C; Patvardhan C; Pearson R; Predeep S; Saad H; Shanmugam M; Varley S; Vohra A; Wylie K; Cooper L; Makowski A; Misztal B; Moldovan E; Pegg C; Donovan A; Foot J; Large S; Claxton A; Netke B; Armstrong R; Calderwood C; Kwok A; Mohr O; Oyeniyi P; Patnaik L; Post B; Ali S; Arshad H; Baker G; Brenner L; Brincat M; Brunswicker A; Cox H; Cozar OI; Durst A; Fengas L; Flatt J; Glister G; Narwani V; Photi E; Rankin A; Rosbergen M; Tan M; Beaton C; Horn R; Hunt J; Rousseau G; Stancombe L; Absar M; Allsop J; Drinkwater Z; Hodgkiss T; Smith K; Brown J; Pick S; Alexander-Sefre F; Campey L; Dudgeon L; Hall K; Hitchcock R; James L; Smith K; Winstone U; Ahmad N; Bauchmuller K; Harrison J; Jeffery H; Miller D; Pinder A; Pothuneedi S; Rosser J; Sanghera S; Swift D; Walker R; Bester D; Cavanagh S; Cripps H; Daniel H; Lynch J; Paton A; Pyke S; Scholefield J; Whitworth H; Bottrill F; Ramalingam G; Webb S; Akerman N; Antill P; Bourner L; Buckley S; Castle G; Charles R; Eggleston C; Foster R; Gill S; Lindley K; Lklouk M; Lowery T; Martin O; Milne D; O'Connor P; Ratcliffe A; Rose A; Simeson K; Smith A; Varma S; Ward J; Simeson K; Barcraft-Barnes H; Camsooksai J; Colvin C; Reschreiter H; Tbaily L; Venner N; Hamilton C; Kelly L; Toth-Tarsoly P; Dodsworth K; Foord D; Gordon P; Hawes E; Lamb N; Mouland J; Nightingale J; Rose S; Schrieber J; Al 'Amri K; Aladin H; Arshad MA; Barraclough J; Bentley C; Bergin C; Carrera R; Clarkson A; Collins M; Cooper L; Denham S; Griffiths E; Ip P; Jeyanthan S; Joory K; Kaur S; Marriott P; Mitchell N; Nagaiah S; Nilsson A; Parekh N; Pope M; Seager J; Serag H; Tameem A; Thomas A; Thunder J; Torrance A; Vohra R; Whitehouse A; Wong T; Blunt M; Wong K; Giles J; Reed I; Weller D; Bell G; Birch J; Damant R; Maiden J; Mewies C; Prince C; Radford J; Balain B; Banerjee R; Barnett A; Burston B; Davies K; Edwards J; Evans C; Ford D; Gallacher P; Hill S; Jaffray D; Karlakki S; Kelly C; Kennedy J; Kiely N; Lewthwaite S; Marquis C; Ockendon M; Phillips S; Pickard S; Richardson J; Roach R; Smith T; Spencer-Jones R; Steele N; Steen J; Van Liefland M; White S; Faulds M; Harris M; Kelly C; Nicol S; Pearson SA; Chukkambotla S; Andrew A; Attrill E; Campbell G; Datson A; Fouracres A; Graterol J; Graves L; Hong B; Ishimaru A; Karthikeyan A; King H; Lawson T; Lee G; Lyons S; Macalister Hall A; Mathoulin S; Mcintyre E; Mclaughlin D; Mulcahy K; Ratcliffe A; Robbins J; Sung W; Tayo A; Trembath L; Venugopal S; Walker R; Wigmore G; Boereboom C; Downes C; Humphries R; Melbourne S; Smith C; Tou S; Ullah S; Batchelor N; Boxall L; Broomby R; Deen T; Hellewell A; Helliwell L; Hutchings M; Hutchins D; Keenan S; Mackie D; Donna A; Smith F; Stone L; Thorpe K; Wassall R; Woodgate A; Baillie S; Campbell T; James S; King C; Marques de Araujo D; Martin D; Morkane C; Neely J; Rajendram R; Burton M; James K; Keevil E; Minik O; Morgan J; Musgrave A; Rajanna H; Roberts T; Szakmany T; Adamson M; Jumbe S; Kendall J; Muthuswamy MB; Anderson C; Cruikshanks A; Pothuneedi S; Walker R; Wrench I; Zeidan L; Ardern D; Harris B; Hellstrom J; Martin J; Thomas R; Varsani N; Wrey Brown C; Docherty P; Gillies M; McGregor E; Usher H; Craig J; Smith A; Ahmad T; Bodger P; Creary T; Everingham K; Fowler A; Hewson R; Ijuo E; Januszewska M; Jones T; Kantsedikas I; Lahiri S; McLean AL; Niebrzegowska E; Phull M; Wang D; Wickboldt N; Baldwin J; Doyle D; Mcmullan S; Oladapo M; Owen T; Tripathi S; Williams A; Daniel H; Gregory P; Husain T; Kirk-Bayley J; Mathers E; Montague L; White S; Avis J; Cook T; Dali-Kemmery L; Kerslake I; Lambourne V; Pearson A; Boyd C; Callaghan M; Lawson C; McCrossan R; Nesbitt V; O'connor L; Scott J; Sinclair R; Farid N; Morgese C; Bhatia K; Karmarkar S; Vohra A; Ahmed J; Branagan G; Hutton M; Swain A; Brookes J; Cornell J; Dolan R; Hulme J; Jansen van Vuuren A; Jowitt T; Kalashetty G; Lloyd F; Patel K; Sherwood N; Brown L; Chandler B; Deighton K; Emma T; Haunch K; Cheeseman M; Dent K; Garg S; Gray C; Hood M; Jones D; Juj J; Mitra A; Rao R; Walker T; Al Anizi M; Cheah C; Cheing Y; Coutinho F; Gondo P; Hadebe B; Onie Hove M; Khader A; Krishnachetty B; Rhodes K; Sokhi J; Baker KA; Bertram W; Looseley A; Mouton R; Arnold G; Arya S; Balfoussia D; Baxter L; Harris J; Jones C; Knaggs A; Markar S; Perera A; Scott A; Shida A; Sirha R; Wright S; Frost V; Gray C; MacGregor M; Andrews E; Arrandale L; Barrett S; Bidd H; Cifra E; Cooper M; Dragnea D; Elna C; Maclean J; Meier S; Milliken D; Munns C; Ratanshi N; Salvana A; Watson A; Ali H; Campbell G; Critchley R; Hicks C; Liddle A; Pass M; Ritchie C; Thomas C; Too L; Welsh S; Gill T; Johnson J; Reed J; Davis E; Papadopoullos S; Attwood C; Biffen A; Boulton K; Gray S; Hay D; Mills S; Montgomery J; Riddell R; Simpson J; Bhardwaj N; Paul E; Uwubamwen N; Vohra A; Berntsen E; Nolan T; Turner A; Alexander M; Arrich J; Arumugam S; Blackwood D; Boggiano V; Brown R; Lam Chan Y; Chatterjee D; Chhabra A; Christian R; Costelloe H; Coxwell Matthewman M; Dalton E; Darko J; Davari M; Dave T; Deacon M; Deepak S; Edmond H; Ellis J; El-Sayed A; Eneje P; English R; Ewe R; Foers W; Franklin J; Gallego L; Garrett E; Goldberg O; Goss H; Greaves R; Harris R; Hennings C; Jones E; Kamali N; Kokkinos N; Lewis C; Lignos L; Malgapo EV; Malik R; Milne A; Mulligan JP; Nicklin P; Palipane N; Parsons T; Piper R; Prakash R; Ramesh B; Rasip S; Reading J; Rela M; Reyes A; Robert S; Rooms M; Shah K; Simons H; Solanki S; Spowart E; Stevens A; Thomas C; Waggett H; Yassaee A; Kennedy A; Scott S; Somanath S; Berg A; Hernandez M; Nanda R; Tank G; Wilson N; Wilson D; Al-Soudaine Y; Baldwin M; Cornish J; Davies Z; Davies L; Edwards M; Frewer N; Gallard S; Glasbey J; Harries R; Hopkins L; Kim T; Koompirochana V; Lawson S; Lewis M; Makzal Z; Scourfield S; Ahmad Y; Bates S; Blackwell C; Bryant H; Coulter S; Cruickshank R; Daniel S; Daubeny T; Edwards M; Golder K; Hawkins L; Helen B; Hinxman H; Levett D; Skinner B; Walsgrove J; Bradburn M; Dickson J; Constantin K; Karen M; O'Brien P; O'Donohoe L; Payne H; Sundayi S; Walker E; Brooke J; Cardy J; Humphreys S; Kessack L; Kubitzek C; Kumar S; Cotterill D; Hodzovic E; Hosdurga G; Miles E; Saunders G; Campbell M; Chan P; Jemmett K; Raj A; Naik A; Ramamoorthy R; Shah N; Sylvan A; Blyth K; Burtenshaw A; Freeman D; Johnson E; Lo P; Martin T; Plunkett E; Wollaston J; Allison J; Carroll C; Craw N; Craw S; Pitt-Kerby T; Rowland-Axe R; Spurdle K; McDonald A; Simon D; Sinha V; Smith T; Banner-Goodspeed V; Boone M; Campbell K; Lu F; Scannell J; Sobol J; Balajonda N; Clemmons K; Conde C; Funk B; Hall R; Hopkins T; Olaleye O; Omer O; Pender M; Porto A; Stevens A; Waweru P; Yeh E; Bodansky D; Evans A; Kleopoulos S; Maril R; Mathney E; Sanchez A; Tinuoye E; Bateman B; Eng K; Jiang N; Ladha K; Needleman J; Chen LL; Chen LL; Lane R; Robinowitz D; Ghushe N; Irshad M; Patel S; Takemoto S; Wallace A; Mazzeffi M; Rock P; Wallace K; Zhu X; Chua P; Fleisher L; Mattera M; Sharar R; Thilen S; Treggiari M; Morgan A; Sofjan I; Subramaniam K; Avidan M; Maybrier H; Muench M; Wildes T
  •  go-up   go-down


48. Evangelidis N, Tong A, Manns B, Hemmelgarn B, Wheeler DC, Tugwell P, Crowe S, Harris T, Van Biesen W, Winkelmayer WC, Sautenet B, O'Donoghue D, Tam-Tham H, Youssouf S, Mandayam S, Ju A, Hawley C, Pollock C, Harris DC, Johnson DW, Rifkin DE, Tentori F, Agar J, Polkinghorne KR, Gallagher M, Kerr PG, McDonald SP, Howard K, Howell M, Craig JC, Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Initiative: Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. Am J Kidney Dis; 2017 Oct;70(4):464-475
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Survival and quality of life for patients on hemodialysis therapy remain poor despite substantial research efforts.
  • Existing trials often report surrogate outcomes that may not be relevant to patients and clinicians.
  • SETTING & PARTICIPANTS: 1,181 participants (202 [17%] patients/caregivers, 979 health professionals) from 73 countries completed round 1, with 838 (71%) completing round 3.
  • OUTCOMES & MEASUREMENTS: Outcomes included in the potential core outcome set met the following criteria for both patients/caregivers and health professionals: median score ≥ 8, mean score ≥ 7.5, proportion rating the outcome as critically important ≥ 75%, and median score in the forced ranking question < 10.
  • RESULTS: Patients/caregivers rated 4 outcomes higher than health professionals: ability to travel, dialysis-free time, dialysis adequacy, and washed out after dialysis (mean differences of 0.9, 0.5, 0.3, and 0.2, respectively).
  • CONCLUSIONS: Patients/caregivers gave higher priority to lifestyle-related outcomes than health professionals.
  • [MeSH-major] Clinical Trials as Topic. Delphi Technique. Outcome Assessment (Health Care) / standards. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28238554.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Delphi survey / Hemodialysis (HD) / Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) / biochemical end point / cardiovascular disease (CVD) / core outcome set / dialysis adequacy / lifestyle-related outcomes / mortality / outcome domains / outcomes / patient-centered care / quality of life / research priorities / surrogate end points / trials / vascular access problems / well-being
  •  go-up   go-down


49. Schaefer F, Trachtman H, Wühl E, Kirchner M, Hayek SS, Anarat A, Duzova A, Mir S, Paripovic D, Yilmaz A, Lugani F, Arbeiter K, Litwin M, Oh J, Matteucci MC, Gellermann J, Wygoda S, Jankauskiene A, Klaus G, Dusek J, Testa S, Zurowska A, Caldas Afonso A, Tracy M, Wei C, Sever S, Smoyer W, Reiser J, ESCAPE Trial Consortium and the 4C Study Group: Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatr; 2017 Nov 06;171(11):e172914
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importance: Conventional methods to diagnose and monitor chronic kidney disease (CKD) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate (eGFR) and assessment of proteinuria in spot or timed urine samples, are of limited value in identifying patients at risk of progressive kidney function loss.
  • In the 2 trials, a total of 898 children were observed at 30 (ESCAPE Trial; n = 256) and 55 (4C Study; n = 642) tertiary care hospitals in 13 European countries.
  • Results: Of the 898 included children, 560 (62.4%) were male, and the mean (SD) patient age at enrollment was 11.9 (3.5) years.
  • In patients with baseline eGFR greater than 40 mL/min/1.73 m2, higher log-transformed suPAR levels were associated with a higher risk of CKD progression after adjustment for traditional risk factors (hazard ratio, 5.12; 95% CI, 1.56-16.7; P = .007).
  • Conclusions and Relevance: Patients with high suPAR levels were more likely to have progression of their kidney disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28873129.001).
  • [ISSN] 2168-6211
  • [Journal-full-title] JAMA pediatrics
  • [ISO-abbreviation] JAMA Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Observational Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Receptors, Urokinase Plasminogen Activator
  •  go-up   go-down


50. Sagnelli C, Uberti-Foppa C, Hasson H, Bellini G, Minichini C, Salpietro S, Messina E, Barbanotti D, Merli M, Punzo F, Coppola N, Lazzarin A, Sagnelli E, Rossi F: Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PLoS One; 2017;12(7):e0181890
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
  • OBJECTIVE: This is the first study to analyze the impact of the rs35761398 variant of the CNR2 gene leading to the substitution of GLN (Q) of codon 63 of the cannabinoid receptor 2 (CB2) with ARG (R) on the clinical presentation of chronic hepatitis in HIV/HCV coinfected patients.
  • METHODS: Enrolled in this study were 166 consecutive HIV/HCV coinfected patients, naïve for HCV treatment.
  • A pathologist unaware of the patients' condition graded liver fibrosis, necroinflammation (Ishak) and steatosis.
  • All patients were screened for the CB2 rs35761398 polymorphism.
  • RESULTS: Of the 166 HIV/HCV coinfected patients, 72.9% were males, 42.5% were infected with HCV-genotype-3 and 60.2% had been intravenous drug users.
  • Thirty-five (21.1%) patients were naive for ART and 131(78.9%) were on ART.
  • The CB2-RR variant was detected in 45.8% of patients, QR in 38.6% and QQ in 15.7%.
  • Patients with CB2-RR showed a necroinflammation score (HAI) ≥9 more frequently than those with CB2-QQ or CB2-QR (32.9% vs. 11.5% and 14.1%, respectively, p≤0.001).
  • CONCLUSION: This study shows interesting interplay between the CB2-RR variant and liver necroinflammation in chronic hepatitis patients with HIV/HCV coinfection, an observation of clinical value that coincides with the interest in the use of the CB2 agonists and antagonists in clinical practice emerging from the literature.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2009 Jul;7(4):447-55 [19601782.001]
  • [Cites] Clin Microbiol Infect. 2016 Apr;22(4):372-8 [26806136.001]
  • [Cites] AIDS Patient Care STDS. 2009 Nov;23(11):915-23 [19877800.001]
  • [Cites] Int Immunopharmacol. 2015 May;26(1):86-91 [25791728.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] PLoS One. 2014 Jun 18;9(6):e99450 [24940753.001]
  • [Cites] Mol Immunol. 2006 Jul;43(14 ):2169-79 [16503355.001]
  • [Cites] Handb Exp Pharmacol. 2005;(168):385-423 [16596782.001]
  • [Cites] Hepatology. 2009 Apr;49(4):1090-7 [19263473.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):798-801 [19759533.001]
  • [Cites] N Engl J Med. 1992 Dec 31;327(27):1899-905 [1280771.001]
  • [Cites] J Urban Health. 2011 Jun;88(3):507-16 [21302140.001]
  • [Cites] Life Sci. 2014 May 28;104(1-2):15-23 [24742657.001]
  • [Cites] PLoS One. 2012;7(3):e33961 [22448282.001]
  • [Cites] AIDS. 2008 Oct 1;22(15):1979-91 [18784461.001]
  • [Cites] Haematologica. 2011 Dec;96(12):1883-5 [21828121.001]
  • [Cites] Hepatology. 2011 Oct;54(4):1217-26 [21735467.001]
  • [Cites] Hepatology. 2011 Sep 2;54(3):1102; author reply 1102-3 [21608006.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):831-7 [11833007.001]
  • [Cites] Aliment Pharmacol Ther. 2014 Apr;39(8):790-801 [24612021.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):47-55 [16182404.001]
  • [Cites] Ann Intern Med. 2014 Mar 18;160(6):369-79 [24723077.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Dig Liver Dis. 2016 Nov;48(11):1364-1369 [27476469.001]
  • [Cites] Braz J Infect Dis. 2014 Mar-Apr;18(2):164-9 [24650995.001]
  • [Cites] Pharmacogenet Genomics. 2010 Mar;20(3):157-66 [20124950.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e492 [17194190.001]
  • [Cites] Hepat Mon. 2011 Jul 1;11(7):525-31 [22706343.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Feb;12(2):334-40 [23707465.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1145-55 [18178718.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):63-7 [16340475.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000633 [19851458.001]
  • [Cites] Hepatology. 2007 Sep;46(3):622-30 [17659577.001]
  • [Cites] Clin Infect Dis. 2001 Aug 15;33(4):562-9 [11462196.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):107-8 [20418725.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):69-75 [18166478.001]
  • [Cites] PLoS One. 2010 Jan 14;5(1):e8688 [20098669.001]
  • [Cites] J Hepatol. 2006;44(1 Suppl):S14-8 [16338026.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1358-64 [11391523.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] Br J Pharmacol. 2008 Jan;153(2):299-308 [17982478.001]
  • [Cites] World J Clin Cases. 2015 Sep 16;3(9):807-22 [26380828.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2008 Sep;8(3):159-72 [18782012.001]
  • [Cites] Lancet. 2003 Nov 22;362(9397):1708-13 [14643119.001]
  • [Cites] J Neuroimmune Pharmacol. 2013 Jun;8(3):608-20 [23471521.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1054-8 [10498659.001]
  • [Cites] Hepatology. 1998 Sep;28(3):805-9 [9731576.001]
  • [Cites] Pharmacol Res. 2012 Jul;66(1):88-94 [22465144.001]
  • [Cites] Sex Transm Dis. 2011 Mar;38(3):219-20 [20938373.001]
  • [Cites] Nature. 2009 Sep 17;461(7262):399-401 [19684573.001]
  • [Cites] J Leukoc Biol. 2005 Jul;78(1):231-8 [15845647.001]
  • [Cites] World J Gastroenterol. 2016 Oct 14;22(38):8509-8518 [27784963.001]
  • [Cites] J Neuroimmune Pharmacol. 2007 Jun;2(2):178-83 [18040842.001]
  • [Cites] Infection. 2013 Oct;41(5):959-67 [23839212.001]
  • [Cites] Hepatology. 2001 Aug;34(2):283-7 [11481613.001]
  • [Cites] World J Hepatol. 2015 Oct 28;7(24):2510-21 [26523204.001]
  • (PMID = 28759568.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


51. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet; 2017 Oct 21;390(10105):1853-1862
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma.
  • METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and USA).
  • Eligible patients were at least 18 years old, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, at least one measurable lesion per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), unresectable stage III or IV melanoma (excluding ocular melanoma), and up to one previous systemic therapy (excluding anti-CTLA-4, PD-1, or PD-L1 agents).
  • Patients were excluded if they had active brain metastases or active autoimmune disease requiring systemic steroids.
  • Survival was assessed every 12 weeks, and final analysis occurred after all patients were followed up for at least 21 months.
  • Primary analysis was done on the intention-to-treat population (all randomly assigned patients) and safety analyses were done in the treated population (all randomly assigned patients who received at least one dose of study treatment).
  • FINDINGS: Between Sept 18, 2013, and March 3, 2014, 834 patients with advanced melanoma were enrolled and randomly assigned to receive intravenous pembrolizumab every 2 weeks (n=279), intravenous pembrolizumab every 3 weeks (n=277), or intravenous ipilimumab every 3 weeks (ipilimumab for four doses; n=278).
  • One patient in the pembrolizumab 2 week group and 22 patients in the ipilimumab group withdrew consent and did not receive treatment.
  • A total of 811 patients received at least one dose of study treatment.
  • Median follow-up was 22·9 months; 383 patients died.
  • These conclusions further support the use of pembrolizumab as a standard of care for advanced melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28822576.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Katus H, Ziegler A, Ekinci O, Giannitsis E, Stough WG, Achenbach S, Blankenberg S, Brueckmann M, Collinson P, Comaniciu D, Crea F, Dinh W, Ducrocq G, Flachskampf FA, Fox KAA, Friedrich MG, Hebert KA, Himmelmann A, Hlatky M, Lautsch D, Lindahl B, Lindholm D, Mills NL, Minotti G, Möckel M, Omland T, Semjonow V: Early diagnosis of acute coronary syndrome. Eur Heart J; 2017 Nov 01;38(41):3049-3055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This progress has enabled physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient presentation, usually in emergency department settings, which may facilitate prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare resources.
  • A non-trivial proportion of patients fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients.
  • The Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early strategies in clinical practice to improve patient care following the review of recent advances in the early diagnosis of acute coronary syndrome.
  • The following specific 'indeterminate' patient categories were considered: (i) patients with symptoms and high-sensitivity cardiac troponin <99th percentile;.
  • (ii) patients with symptoms and high-sensitivity troponin <99th percentile but above the limit of detection;.
  • (iii) patients with symptoms and high-sensitivity troponin >99th percentile but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin >99th percentile and dynamic change but without coronary plaque rupture/erosion/dissection.
  • Definitive evidence is currently lacking to manage these patients whose early diagnosis is 'indeterminate' and these areas of uncertainty should be assigned a high priority for research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 29029109.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Acute coronary syndrome / Troponin
  •  go-up   go-down


53. Ekstrand ML, Rawat S, Patankar P, Heylen E, Banu A, Rosser BRS, Wilkerson JM: Sexual identity and behavior in an online sample of Indian men who have sex with men. AIDS Care; 2017 07;29(7):905-913

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positive attitudes toward UAS and lower self-efficacy were associated with sexual risk in both groups; however, substance use was associated with sexual risk only among bisexually identified men.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2014 Sep 11;9(9):e107439 [25211511.001]
  • [Cites] AIDS Educ Prev. 2006 Aug;18(4):323-32 [16961449.001]
  • [Cites] AIDS Behav. 2014 Aug;18(8):1428-35 [24077974.001]
  • [Cites] Am J Mens Health. 2014 Nov;8(6):510-20 [24658284.001]
  • [Cites] Health Psychol. 1997 Sep;16(5):458-67 [9302543.001]
  • [Cites] Arch Intern Med. 1998 Sep 14;158(16):1789-95 [9738608.001]
  • [Cites] PLoS One. 2012;7(7):e40793 [22829885.001]
  • [Cites] PLoS One. 2015 May 14;10(5):e0126658 [25973907.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):187-92 [20522632.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Feb;53(2):227-33 [19934765.001]
  • [Cites] Soc Sci Med. 2001 Mar;52(5):707-21 [11218175.001]
  • [Cites] AIDS Patient Care STDS. 2009 Nov;23(11):981-6 [19821722.001]
  • [Cites] Indian J Med Res. 2011 Dec;134(6):920-9 [22310824.001]
  • [Cites] AIDS Behav. 2016 Feb;20(2):304-16 [26386592.001]
  • [Cites] Am J Mens Health. 2014 May;8(3):190-204 [23832954.001]
  • [Cites] AIDS Behav. 2009 Aug;13(4):746-56 [18512143.001]
  • [Cites] Glob Public Health. 2017 Feb;12 (2):250-265 [26457339.001]
  • [Cites] AIDS Educ Prev. 2008 Dec;20(6):547-57 [19072529.001]
  • [Cites] Int J Sex Health. 2016;28(3):221-227 [27668029.001]
  • [Cites] J LGBT Health Res. 2008;4(2-3):111-26 [19856744.001]
  • [Cites] Am J Public Health. 2001 Jun;91(6):988-9 [11392947.001]
  • [Cites] AIDS Care. 2013;25(9):1109-13 [23339580.001]
  • [Cites] Psychol Health Med. 2011 Aug;16(4):450-62 [21749242.001]
  • [Cites] BMJ Open. 2013 Feb 04;3(2):null [23386580.001]
  • [Cites] AIDS Educ Prev. 2009 Aug;21(4):372-83 [19670971.001]
  • [Cites] JMIR Mhealth Uhealth. 2016 Oct 31;4(4):e120 [27799139.001]
  • [Cites] J Stud Alcohol. 2004 Nov;65(6):794-800 [15700518.001]
  • [Cites] AIDS. 2010 Aug 24;24(13):2099-107 [20601853.001]
  • [Cites] Arch Sex Behav. 2002 Apr;31(2):177-83 [11974643.001]
  • [Cites] J Postgrad Med. 2014 Apr-Jun;60(2):130-4 [24823510.001]
  • [Cites] Arch Sex Behav. 2016 Jul;45(5):1269-77 [26292840.001]
  • [Cites] Health Educ Res. 2007 Feb;22(1):120-7 [16849391.001]
  • [Cites] AIDS Behav. 2015 Dec;19(12):2255-69 [25893657.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 Nov-Dec;72(6):425-31 [17179617.001]
  • [Cites] Int J Sex Health. 2016 Jan 1;28(1):70-84 [27073588.001]
  • [Cites] Cyberpsychol Behav. 2005 Apr;8(2):131-9 [15938652.001]
  • [Cites] Arch Sex Behav. 2003 Aug;32(4):351-7 [12856896.001]
  • (PMID = 28027656.001).
  • [ISSN] 1360-0451
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R21 AI094676
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Keywords] NOTNLM ; India (major topic) / Sexual identity (major topic) / bisexual (major topic) / gay (major topic) / men who have sex with men (major topic) / sexual behavior (major topic)
  •  go-up   go-down


54. Funk M, Fennie KP, Stephens KE, May JL, Winkler CG, Drew BJ, PULSE Site Investigators: Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial. Circ Cardiovasc Qual Outcomes; 2017 Feb;10(2)
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Implementation of Practice Standards for Electrocardiographic Monitoring With Nurses' Knowledge, Quality of Care, and Patient Outcomes: Findings From the Practical Use of the Latest Standards of Electrocardiography (PULSE) Trial.
  • We evaluated implementation of American Heart Association practice standards for ECG monitoring on nurses' knowledge, quality of care, and patient outcomes.
  • Nurses' knowledge (N=3013 nurses) was measured by a validated 20-item online test, quality of care related to ECG monitoring (N=4587 patients) by on-site observation, and patient outcomes (mortality, in-hospital myocardial infarction, and not surviving a cardiac arrest; N=95 884 hospital admissions) by review of administrative, laboratory, and medical record data.
  • For most measures of quality of care (accurate electrode placement, accurate rhythm interpretation, appropriate monitoring, and ST-segment monitoring when indicated), the intervention was associated with significant improvement, which was sustained 15 months later.
  • Of the 3 patient outcomes, only in-hospital myocardial infarction declined significantly after the intervention and was sustained.
  • CONCLUSIONS: Online ECG monitoring education and strategies to change practice can lead to improved nurses' knowledge, quality of care, and patient outcomes.
  • [MeSH-major] Cardiology / education. Education, Nursing, Continuing / methods. Electrocardiography, Ambulatory / nursing. Health Knowledge, Attitudes, Practice. Heart Diseases / diagnosis. Heart Diseases / nursing. Nursing Staff, Hospital / education. Outcome Assessment (Health Care). Practice Guidelines as Topic. Quality Indicators, Health Care

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] Ann Noninvasive Electrocardiol. 2002 Jul;7(3):219-21 [12167182.001]
  • [Cites] Am J Crit Care. 2012 May;21(3):195-200; quiz 201 [22549576.001]
  • [Cites] Clin Nurse Spec. 2016 Jan-Feb;30(1):45-50 [26626747.001]
  • [Cites] Crit Pathw Cardiol. 2013 Mar;12(1):6-8 [23411601.001]
  • [Cites] Adv Emerg Nurs J. 2015 Oct-Dec;37(4):290-300 [26509726.001]
  • [Cites] J Contin Educ Nurs. 2012 Feb;43(2):81-9 [21985075.001]
  • [Cites] Resuscitation. 2014 Feb;85(2):260-5 [24128798.001]
  • [Cites] Am J Crit Care. 2011 May;20(3):226-37; quiz 238 [21532043.001]
  • [Cites] AACN Adv Crit Care. 2014 Apr-Jun;25(2):104-13 [24752022.001]
  • [Cites] Am J Cardiol. 2013 Oct 15;112(8):1219-23 [23831162.001]
  • [Cites] J Nurs Educ. 2005 Jan;44(1):35-9 [15673173.001]
  • [Cites] Am J Crit Care. 2001 Jan;10(1):23-32; quiz 33-4 [11153181.001]
  • [Cites] Heart Lung. 2005 Sep-Oct;34(5):309-16 [16157185.001]
  • [Cites] Circulation. 2004 Oct 26;110(17):2721-46 [15505110.001]
  • [Cites] Eur Heart J. 2001 Nov;22(21):1997-2006 [11603907.001]
  • [Cites] JAMA Intern Med. 2014 Nov;174(11):1855-6 [25243346.001]
  • [Cites] Med Educ. 2011 Apr;45(4):347-53 [21401682.001]
  • [Cites] Am J Manag Care. 2013 Jun 01;19(6):e225-32 [23844751.001]
  • [Cites] J Am Coll Cardiol. 2010 Mar 2;55(9):934-47 [20185054.001]
  • [Cites] J Contin Educ Nurs. 2014 Jul;45(7):327-32 [24999976.001]
  • [Cites] Eur J Cardiovasc Nurs. 2014 Dec;13(6):515-23 [24304659.001]
  • [Cites] Int J Clin Pract. 2008 Jan;62(1):65-70 [17764456.001]
  • [Cites] Am J Crit Care. 2015 Jul;24(4):360-4 [26134337.001]
  • [Cites] Arch Intern Med. 2012 Sep 24;172(17):1349-50 [22892708.001]
  • [Cites] JAMA Intern Med. 2014 Nov;174(11):1852-4 [25243419.001]
  • [Cites] Am J Crit Care. 2016 Jan;25(1):61-7 [26724296.001]
  • [Cites] Am J Crit Care. 2015 Mar;24(2):e6-e15 [25727282.001]
  • [Cites] J Lancet. 1963 Feb;83:53-5 [14025617.001]
  • [Cites] Crit Care Nurs Clin North Am. 2006 Jun;18(2):157-68, ix [16728301.001]
  • (PMID = 28174175.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01269736
  • [Grant] United States / NIA NIH HHS / AG / P30 AG021342; United States / NHLBI NIH HHS / HL / R01 HL081642
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Keywords] NOTNLM ; electrocardiography / nursing / outcome assessment (health care) / quality of health care / randomized controlled trial
  • [Investigator] Borman B; Calcasola S; Carey M; Currie L; Davis L; Fitzpatrick E; Fleischman R; Hawkins D; Hazlewood E; Henry R; Honess C; Kalowes P; Ann Kearns S; Leeper B; Liggett J; Lusardi P; Lynn C; Man M; McCauley K; Hing M; Pang A; Parkosewich J; Phillips J; Robinson A; Salazar N; Sandau K; Piper Sandoval C; Sangkachand P; Shaffer R; Sherrard H; Smith M; Stamm R; Strang V; Tee N; Wells K; White P
  •  go-up   go-down


55. Bouida W, Baccouche H, Sassi M, Dridi Z, Chakroun T, Hellara I, Boukef R, Hassine M, Added F, Razgallah R, Khochtali I, Nouira S, Ramadan Research Group: Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel. Thromb J; 2017;15:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel.
  • The present study evaluated the influence of RF on platelet reactivity in patients with high cardiovascular risk (CVR) in particular those with type 2 diabetes mellitus (DM).
  • METHODS: A total of 98 stable patients with ≥2 CVR factors were recruited.
  • All patients observed RF and were taking clopidogrel at a maintenance dose of 75 mg.
  • During each patient visit, nutrients intakes were calculated and platelet reactivity assessment using Verify Now P2Y12 assay was performed.
  • RESULTS: In DM patients, the absolute PRU changes from baseline were +27 (<i>p</i> = 0.01) and +16 (<i>p</i> = 0.02) respectively at R and Post-R.
  • In non DM patients there was no significant change in absolute PRU values and metabolic parameters.
  • Clopidogrel resistance rate using 2 cut-off PRU values (235 and 208) did not change significantly in DM and non DM patients.
  • CONCLUSIONS: RF significantly decreased platelet sensitivity to clopidogrel in DM patients during and after Ramadan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Health Popul Nutr. 2011 Oct;29(5):486-93 [22106754.001]
  • [Cites] Diabetes Care. 2004 Oct;27(10):2306-11 [15451892.001]
  • [Cites] Circulation. 2004 Jun 29;109 (25):3171-5 [15184279.001]
  • [Cites] Thromb Haemost. 2015 Feb;113(2):221-30 [25413597.001]
  • [Cites] Circulation. 2011 Sep 6;124(10):1132-7 [21875913.001]
  • [Cites] Am Heart J. 2009 Nov;158(5):784.e1-6 [19853698.001]
  • [Cites] Br J Haematol. 2014 Sep;166(5):792-4 [24749553.001]
  • [Cites] Vasc Health Risk Manag. 2012;8:65-75 [22371653.001]
  • [Cites] Expert Opin Pharmacother. 2014 Dec;15(17):2553-64 [25297833.001]
  • [Cites] Int Clin Psychopharmacol. 2010 Nov;25(6):323-7 [20827213.001]
  • [Cites] Lancet. 2013 Aug 17;382(9892):614-23 [23890998.001]
  • [Cites] BMJ. 1992 Feb 29;304(6826):521-2 [1559053.001]
  • [Cites] J Am Coll Cardiol. 2014 Sep 9;64(10):1015-8 [25190237.001]
  • [Cites] Thromb Haemost. 1992 Nov 10;68(5):577-82 [1455404.001]
  • [Cites] Circulation. 1999 Sep 28;100(13):1481-92 [10500053.001]
  • [Cites] JAMA. 2010 Feb 24;303(8):754-62 [20179285.001]
  • [Cites] J Diabetes Complications. 2009 Mar-Apr;23(2):89-94 [18358749.001]
  • [Cites] Circulation. 2003 Jun 17;107(23):2908-13 [12796140.001]
  • [Cites] Cardiovasc Diabetol. 2015 Feb 03;14:15 [25645908.001]
  • [Cites] J Thromb Haemost. 2014;12(3):349-54 [24354801.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Jun;23(3):375-88 [19520310.001]
  • [Cites] Diabetes Res Clin Pract. 2006 Aug;73(2):117-25 [16647781.001]
  • [Cites] J Intern Med. 2007 Aug;262(2):157-72 [17645584.001]
  • [Cites] Thromb Res. 2004;113(2):101-13 [15115665.001]
  • [Cites] Eur Heart J. 2008 Apr;29(8):992-1000 [18263931.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1282-91 [15304032.001]
  • [Cites] Public Health. 1986 Jan;100(1):49-53 [3749438.001]
  • [Cites] JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28 [24262612.001]
  • [Cites] Clin Res Cardiol. 2010 Nov;99(11):743-52 [20526607.001]
  • (PMID = 28588426.001).
  • [ISSN] 1477-9560
  • [Journal-full-title] Thrombosis journal
  • [ISO-abbreviation] Thromb J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clopidogrel / Diabetes mellitus / Fasting / Platelet activation / Platelet aggregation inhibitors
  •  go-up   go-down


56. Chookalayi H, Heidarzadeh M, Hasanpour M, Jabrailzadeh S, Sadeghpour F: A Study on the Psychometric Properties of Revised-nonverbal Pain Scale and Original-nonverbal Pain Scale in Iranian Nonverbal-ventilated Patients. Indian J Crit Care Med; 2017 Jul;21(7):429-435

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Study on the Psychometric Properties of Revised-nonverbal Pain Scale and Original-nonverbal Pain Scale in Iranian Nonverbal-ventilated Patients.
  • BACKGROUND AND AIMS: The nonverbal pain scale is one of the instruments which study pain in nonverbal-ventilated patients with regard to the changes of behavioral and physiological indices.
  • The purpose of the study is to survey the psychometric properties of revised-nonverbal pain scale (R-NVPS) and original-nonverbal pain scale (O-NVPS) in ventilated patients hospitalized in critical care units.
  • MATERIALS AND METHODS: Four nurses studied pain in sixty patients hospitalized in trauma, medical, neurology, and surgical critical care units using R-NVPS and O-NVPS at six times (before, during, and after nociceptive and nonnociceptive procedures).
  • The test was repeated in 37 patients after 8-12 h.
  • The meaningful difference in pain score between nociceptive and nonnociceptive procedures (<i>P</i> < 0.001) and a higher pain score in patients who confirmed pain (<i>P</i> < 0.001) showed a discriminant and criterion validity for both scales of NVPS, respectively.
  • CONCLUSIONS: R-NVPS and O-NVPS can both be used as valid and reliable scales in studying pain in ventilated patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pain Res Manag. 2013 Nov-Dec;18(6):e107-14 [24308026.001]
  • [Cites] Crit Care Nurse. 2005 Feb;25(1):14-5 [15756730.001]
  • [Cites] Anesth Analg. 2009 May;108(5):1546-52 [19372334.001]
  • [Cites] Dimens Crit Care Nurs. 2010 Nov-Dec;29(6):307-15 [20940589.001]
  • [Cites] Dimens Crit Care Nurs. 2003 Nov-Dec;22(6):260-7 [14639117.001]
  • [Cites] Intensive Crit Care Nurs. 2010 Apr;26(2):83-90 [20044256.001]
  • [Cites] Am J Nurs. 2002 Jan;102(1):59-60 [11839910.001]
  • [Cites] Crit Care Nurs Clin North Am. 2001 Jun;13(2):181-94 [11866401.001]
  • [Cites] Pain Manag Nurs. 2006 Jun;7(2):44-52 [16730317.001]
  • [Cites] Crit Care. 2014 Jul 25;18(5):R160 [25063269.001]
  • [Cites] J Crit Care. 2015 Feb;30(1):167-72 [25446372.001]
  • [Cites] Pain Pract. 2016 Apr;16(4):451-8 [25857484.001]
  • [Cites] Pain. 2010 Dec;151(3):711-21 [20843604.001]
  • [Cites] Crit Care Med. 2001 Dec;29(12):2258-63 [11801819.001]
  • [Cites] Pain Med. 2015 Aug;16(8):1622-8 [25800546.001]
  • [Cites] Pain Res Treat. 2014;2014:175794 [24639895.001]
  • [Cites] Am J Nurs. 2002 Oct;102(10):55-8 [12394307.001]
  • [Cites] Crit Care Nurse. 2009 Feb;29(1):59-66 [19182281.001]
  • [Cites] Pain Manag Nurs. 2003 Mar;4(1):23-30 [12707865.001]
  • [Cites] J Pain Symptom Manage. 2014 Nov;48(5):975-82 [24793506.001]
  • [Cites] Intensive Crit Care Nurs. 2006 Feb;22(1):32-9 [16198570.001]
  • [Cites] Clin J Pain. 2007 Jul-Aug;23(6):497-505 [17575489.001]
  • [Cites] Pain Manag Nurs. 2010 Sep;11(3):134-40 [20728062.001]
  • [Cites] Int J Nurs Stud. 2011 Apr;48(4):438-48 [20728886.001]
  • [Cites] Am J Crit Care. 2006 Jul;15(4):420-7 [16823021.001]
  • (PMID = 28808362.001).
  • [ISSN] 0972-5229
  • [Journal-full-title] Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
  • [ISO-abbreviation] Indian J Crit Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Instrument / Intensive Care Unit / mechanical ventilation / pain / pain measurement
  •  go-up   go-down


57. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol; 2017 Aug 01;28(8):1700-1712
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
  • Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology.
  • The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer.
  • The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients.
  • The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer.
  • However, low-risk patients can avoid these treatments.
  • The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations.
  • Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
  • (PMID = 28838210.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; St Gallen Consensus / early breast cancer / radiation therapy / surgery / systemic adjuvant therapies
  •  go-up   go-down


58. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Group: Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med; 2017 08 24;377(8):733-744
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.
  • Whether such intensive treatment affected patient-reported outcomes was uncertain; those results from the trial are reported here.
  • Patient-reported outcome measures included the scores on the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the Veterans RAND 12-Item Health Survey, the Patient Health Questionnaire 9-item depression scale (PHQ-9), patient-reported satisfaction with their blood-pressure care and blood-pressure medications, and adherence to blood-pressure medications.
  • Satisfaction with blood-pressure care was high in both treatment groups, and we found no significant difference in adherence to blood-pressure medications.
  • CONCLUSIONS: Patient-reported outcomes among participants who received intensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were similar to those among participants who received standard treatment, including among participants with decreased physical or cognitive function. (Funded by the National Institutes of Health; SPRINT ClinicalTrials.gov number, NCT01206062 .).
  • [MeSH-major] Antihypertensive Agents / administration & dosage. Cardiovascular Diseases / prevention & control. Hypertension / drug therapy. Patient Reported Outcome Measures
  • [MeSH-minor] Aged. Blood Pressure / drug effects. Drug Therapy, Combination. Female. Health Status. Humans. Male. Medication Adherence. Middle Aged. Patient Outcome Assessment. Patient Satisfaction

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. ;377(21):2096-7 [29182238.001]
  • [Cites] JAMA Intern Med. 2015 Oct;175(10 ):1622-30 [26301603.001]
  • [Cites] J Gen Intern Med. 2001 Sep;16(9):606-13 [11556941.001]
  • [Cites] J Ambul Care Manage. 2004 Jul-Sep;27(3):281-95 [15287217.001]
  • [Cites] J Am Coll Cardiol. 2016 Feb 9;67(5):463-72 [26562046.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2016 May;71(5):649-55 [26755682.001]
  • [Cites] JAMA. 2013 Aug 21;310(7):699-705 [23989679.001]
  • [Cites] N Engl J Med. 1986 Jun 26;314(26):1657-64 [3520318.001]
  • [Cites] Med Care. 2004 Dec;42(12):1194-201 [15550799.001]
  • [Cites] Ann Neurol. 2015 Nov;78(5):665-6 [26395548.001]
  • [Cites] Health Serv Res. 2010 Apr;45(2):376-96 [20050934.001]
  • [Cites] Clin Trials. 2014 Oct;11(5):532-46 [24902920.001]
  • [Cites] Stroke. 2013 Jan;44(1):15-20 [23132780.001]
  • [Cites] J Am Geriatr Soc. 2005 Apr;53(4):695-9 [15817019.001]
  • [Cites] Qual Life Res. 2009 Feb;18(1):43-52 [19051059.001]
  • [Cites] JAMA. 1996 Oct 2;276(13):1039-47 [8847764.001]
  • [Cites] Am J Hypertens. 2016 Jan;29(1):2-4 [26597221.001]
  • [Cites] J Clin Hypertens (Greenwich). 2008 May;10(5):348-54 [18453793.001]
  • [Cites] JAMA. 2016 Jun 28;315 (24):2673-82 [27195814.001]
  • [Cites] Ann Intern Med. 2014 Apr 1;160(7):499-503 [24424788.001]
  • [Cites] N Engl J Med. 2015 Nov 26;373(22):2093-5 [26550920.001]
  • [Cites] Diabetes Care. 2012 Jul;35(7):1479-81 [22584134.001]
  • [Cites] J Clin Hypertens (Greenwich). 2006 May;8(5):313-4 [16687938.001]
  • [Cites] Ann Pharmacother. 2011 May;45(5):569-75 [21521862.001]
  • [Cites] Arch Intern Med. 1997 Mar 24;157(6):638-48 [9080918.001]
  • [Cites] J Am Geriatr Soc. 2011 Mar;59(3):383-9 [21391928.001]
  • [Cites] J Am Geriatr Soc. 2013 May;61 Suppl 2:S279-90 [23662720.001]
  • [Cites] N Engl J Med. 2015 Nov 26;373(22):2103-16 [26551272.001]
  • [Cites] Hypertension. 2015 Jul;66(1):183-9 [25941341.001]
  • [Cites] Ann Intern Med. 2017 Mar 21;166(6):430-437 [28135725.001]
  • [Cites] Ann Intern Med. 2016 Dec 20;165(12 ):889-890 [27992903.001]
  • [Cites] Arch Intern Med. 2012 Aug 13;172(15):1162-8 [22801930.001]
  • [Cites] Hypertension. 2013 Jun;61(6):1309-15 [23529166.001]
  • [Cites] J Epidemiol Community Health. 2007 Jan;61(1):53-8 [17183016.001]
  • (PMID = 28834483.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01206062
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000433; United States / NCATS NIH HHS / TR / UL1 TR000445; United States / NHLBI NIH HHS / HL / HHSN268200900048C; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NHLBI NIH HHS / HL / HHSN268200900040C; United States / NHLBI NIH HHS / HL / HHSN268200900046C; United States / NCATS NIH HHS / TR / UL1 TR000064; United States / NCATS NIH HHS / TR / UL1 TR000075; United States / NIGMS NIH HHS / GM / P30 GM103337; United States / NCATS NIH HHS / TR / UL1 TR001064; United States / NCRR NIH HHS / RR / UL1 RR025752; United States / NCRR NIH HHS / RR / UL1 RR025771; United States / NCATS NIH HHS / TR / UL1 TR000093; United States / NHLBI NIH HHS / HL / HHSN268200900049C; United States / NHLBI NIH HHS / HL / HHSN268200900047C; United States / NCATS NIH HHS / TR / UL1 TR000003; United States / NCATS NIH HHS / NCATS NIH HHS / U54 TR0000017 UNIVERSITY OF TEXAS SOUTHWESTERN; United States / NCATS NIH HHS / TR / UL1 TR000050; United States / NCATS NIH HHS / TR / UL1 TR000439; United States / NCATS NIH HHS / TR / UL1 TR000073; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCATS NIH HHS / TR / UL1 TR000002; United States / NCATS NIH HHS / TR / UL1 TR000105; United States / NCRR NIH HHS / RR / UL1 RR024134
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  • [Investigator] Whelton P; Johnson KC; Fine L; Bild D; Bonds D; Cook N; Cutler J; Kaufmann P; Launer L; Moy C; Riley W; Ryan L; Tolunay E; Yang S; Wright JT Jr; Rahman M; Lerner AJ; Still C; Wiggers A; Zamanian S; Bee A; Dancie R; Cushman W; Wall B; Nichols L; Burns R; Martindale-Adams J; Clark E; Walsh S; Geraci T; Huff C; Shaw L; Lewis CE; Bradley V; Calhoun D; Glasser S; Jenkins K; Cheung AK; Beddhu S; Chelune G; Childs J; Gren L; Randall A; Rocco M; Goff D; Rodriguez C; Coker L; Hawfield A; Yeboah J; Crago L; Summerson J; Hege A; Reboussin D; Williamson J; Ambrosius W; Applegate W; Evans G; Freedman BI; Kitzman D; Lyles M; Rapp S; Rushing S; Shah N; Sink KM; Vitolins M; Wagenknecht L; Wilson V; Perdue L; Woolard N; Craven T; Garcia K; Gaussoin S; Lovato L; Amoroso B; Davis P; Griffin J; Harris D; King M; Lane K; Roberson W; Steinberg D; Ashford D; Babcock P; Chamberlain D; Christensen V; Cloud L; Collins C; Cook D; Currie K; Felton D; Harpe S; Howard M; Lewis M; Nance P; Puccinelli-Ortega N; Russell L; Walker J; Craven B; Goode C; Troxler M; Davis J; Hutchens S; Killeen AA; Lukkari AM; Ringer R; Dillard B; Archibeque N; Warren S; Sather M; Pontzer J; Taylor Z; Soliman EZ; Zhang ZM; Li Y; Campbell C; Hensley S; Hu J; Keasler L; Barr M; Taylor T; Bryan RN; Davatzikos C; Nasarallah I; Desiderio L; Elliott M; Borthakur A; Battapady H; Erus G; Smith A; Wang Z; Doshi J; Townsend R; Cohen D; Huan Y; Duckworth M; Ford V; Sexton K; Lerner A; Stokes DL; Smith S; Sunshine J; Clampitt M; Smith S; Welch B; Donahue M; Dagley A; Pennell D; Cannistraci C; Merkle K; Lewis J; Sika M; Wright C; Sabati M; Campuzano E; Martin H; Roman A; Cruz J; Nagornaya N; Maldjian J; Kaminsky S; Fuller D; Jung Y; Lewis B; Wadley V; Evanochko W; Roberson G; Corbitt T; Fisher W; Clements C; Wells A; Civiletto A; Aurigemma GP; Bodkin N; Norbash A; Lavoye M; Ellison A; Killiany R; Sakai O; Cheung A; Sink K; Thomas G; Schreiber M Jr; Navaneethan SD; Hickner J; Lioudis M; Lard M; Marczewski S; Maraschky J; Colman M; Aaby A; Payne S; Ramos M; Horner C; Drawz P; Raghavendra PP; Ober S; Mourad R; Pallaki M; Russo P; Raghavendra P; Fantauzzo P; Tucker L; Schwing B; Sedor JR; Horwitz EJ; Schellling JR; O’Toole JF; Humbert L; Tutolo W; White S; Gay A; Clark W Jr; Hughes R; Dobre M; Still CH; Williams M; Bhatt U; Hebert L; Agarwal A; Murphy MB; Ford N; Stratton C; Baxter J; Lykins AA; Neal AM; Hirmath L; Kwame O; Soe K; Miser WF; Sagrilla C; Johnston J; Anaya A; Mintos A; Howell AA; Rogers K; Taylor S; Ebersbacher D; Long L; Bednarchik B; Schnall A; Smith J; Peysha L; Leach L; Tribout M; Harwell C; Ellington P; Banerji MA; Ghody P; Rambaud MV; Leshner J; Davison A; Vander Veen S; Gadegbeku CA; Gillespie A; Paranjape A; Amoroso S; Pfeffer Z; Quinn SB; He J; Chen J; Lustigova E; Malone E; Krousel-Wood M; Deichmann R; Ronney P; Muery S; Trapani D; Diamond M; Mulloy L; Hodges M; Collins M; Weathers C; Anderson H; Stone E; Walker W; McWilliams A; Dulin M; Kuhn L; Standridge S; Lowe L; Everett K; Preston K; Norton S; Gaines S; Rizvi AA; Sides AW; Herbert D; Hix MM; Whitmire M; Arnold B; Hutchinson P; Espiritu J; Feinglos M; Kovalik E; Gedon-Lipscomb G; Evans K; Thacker C; Zimmer R; Furst M; Mason M; Bolin P; Zhang J; Pinion M; Davis G; Bryant W; Phelps P; Garris-Sutton C; Atkinson B; Contreras G; Suarez M; Schulman I; Koggan D; Vassallo J; Peruyera G; Bethea C; Mayer S; Gilliam L; Pedley C; Zurek G; Baird M; Herring C; Smoak MM; Williams J; Rogers S; Gordon L; Kennedy E; Belle B; McCorkle-Doomy J; Adams J; Lopez R; Janavs J; Rahbari-Oskoui F; Chapman A; Dollar A; Williams O; Han Y; Haley W; Blackshear J; Shapiro B; Harrell A; Palaj A; Henderson K; Johnson A; Gonzalez H; Robinson J; Tamariz L; Denizard J; Barakat R; Krishnamoorthy D; Greenway F; Monce R; Church T; Hendrick C; Yoches A; Sones L; Baltazar M; Pemu P; Jones C; Akpalu D; Dember L; Soares D; Yee J; Umanath K; Ogletree N; Thaxton S; Campana K; Sheldon D; MacArthur K; Muhlestein JB; Allred N; Clements B; Dhar R; Meredith K; Le V; Miner E; Orford J; Riessen ER; Ballantyne B; Chisum B; Johnson K; Peeler D; Chertow G; Tamura M; Chang T; Erickson K; Shen J; Stafford RS; Zaharchuk G; Del Cid M; Dentinger M; Sabino J; Sahay R; Telminova E; Sarnak M; Chan L; Heath A; Kantor A; Jain P; Kirkpatrick B; Well A; Yuen B; Chonchol M; Farmer B; Farmer H; Greenwald C; Malaczewski M; Lash J; Porter A; Ricardo A; Rosman RT; Cohan J; Lopez Barrera N; Meslar D; Meslar P; Conroy M; Unruh M; Hess R; Jhamb M; Thomas H; Fazio P; Klixbull E; Komlos-Weimer M; Mandich L; Vita T; Toto R; Van Buren P; Inrig J; Cruz M; Lightfoot T; Wang N; Webster L; Raphael K; Stults B; Zaman T; Lavasani T; Filipowicz R; Wei G; Miller GM; Harerra J; Christensen J; Giri A; Chen X; Anderton N; Jensen A; Lewis J; Burgner A; Dwyer JP; Schulman G; Herrud T; Leavell E; McCray T; McNeil-Simaan E; Poudel M; Reed M; Woods D; Zirkenbach JL; Raj DS; Cohen S; Patel S; Velasquez M; Bastian RS; Wing M; Roy-Chaudhury A; Depner T; Dalyrymple L; Kaysen G; Anderson S; Nord J; Ix JH; Goldenstein L; Miracle CM; Forbang N; Mircic M; Thomas B; Tran T; Rastogi A; Kim M; Rashid M; Lizarraga B; Hocza A; Sarmosyan K; Norris J; Sharma T; Chioy A; Bernard E; Cabrera E; Lopez C; Nunez S; Riad J; Schweitzer S; Sirop S; Thomas S; Wada L; Kramer H; Bansal V; Taylor CE; Segal MS; Hall KL; Kazory A; Gilbert L; Owens L; Poulton D; Whidden E; Wiggins J; Blaum C; Nyquist L; Min L; Lewis R; Mawby J; Robinson E; Qureshi N; Ferguson K; Haider S; James M; Jones C; Renfroe K; Seay A; Weigart C; Thornley-Brown D; Rizik D; Cotton B; Fitz-Gerald M; Grimes T; Johnson C; Kennedy S; Mason C; Rosato-Burson L; Willingham R; Judd E; Breaux-Shropshire T; Cook F; Medina J; Lewis J; Brantley R; Brouilette J; Glaze J; Hall S; Hiott N; Tharpe D; Boddy S; Mack C; Womack C; Griffin B; Hendrix C; Johnson K; Jones L; Towers C; Punzi H; Cassidy K; Schumacher K; Irizarry C; Colon I; Colon-Ortiz P; Colon-Hernandez P; Carrasquillo M; Vazquez N; Sosa-Padilla M; Cintron-Pinero A; Ayala M; Pacheco O; Rivera C; Sotomayor-Gonzalez I; Claudio J; Lazaro J; Arce M; Heres L; Perez A; Tavarez-Valle J; Arocho F; Torres M; Vazquez M; Takis-Smith R; Andrieni J; Chaudhary K; Hu P; Kostis J; Kostis WJ; Cosgrove N; Bankowski D; Boleyn M; Casazza L; Giresi V; Patel T; Squindo E; Wu Y; Wofford M; Flessner M; Adair C; Asher J; Loope D; Cobb R; Venegas R; Bigger T; Donovan D; Lopez-Jimenez C; Tirado A; Getaneh A; Tang R; Durant S; Maurer M; Teruya S; Helmke S; Alvarez J; Campbell R; Pisoni R; Sturdivant R; Counts C; Hunt V; Spillers L; Brautigam D; Kitchen T; Gorman T; Sayers J; Button S; Chiarot J; Fischer R; Lyon M; Resnick M; Servilla K; Vigil D; Barrett T; Sweeney ME; Johnson R; McConnell S; Salles KS; Watson F; Schenk C; Whittington L; Maher M; Williams J; Swartz S; Conlin P; Alexis G; Lamkin R; Underwood P; Gomes H; Peters JJ; Rosendorff C; Atlas S; Kwon L; Matar M; Johnson RH; Basile J; John J; Ham D; Baig H; Saklayen M; Yap J; Neff H; Miller C; Zheng-Phelan L; Dingell JD; Gappy S; Rau S; Raman A; Berchou V; Jones E; Olgren E; Yudd M; Sastrasinh S; Michaud J; Fiore J; Kutza M; Randall M; Shorr R; Mount R; Thoms J; Dunn H; Stinson S; Hunter J; DeBakey ME; Taylor A; Bates J; Anderson C; Montgomery GV; Stubbs J; Hinton A; Spencer A; City K; Sharma S; Wiegmann T; Mehta S; Krause M; Dishongh K; Childress R; Gyamlani G; Niakan A; Thompson C; Moody J; Zablocki CJ; Barnas G; Wolfgram D; Cortese H; Johnson J; Roumie C; Hung A; Wharton J; Niesner K; Katz L; Richardson E; Brock G; Holland J; Dixon T; Zias A; Spiller C; Baker P; Felicetta J; Rehman S; Bingham K; Watnick S; Weiss J; Johnston T; Giddings S; Klein A; Rowe C; Vargo K; Waidmann K; Papademetriou V; Elkhoury JP; Gregory B; Amodeo S; Bloom M; Goldfarb-Waysman D; Treger R; Knibloe K; Ishani A; Slinin Y; Rust J; Fanti P; Bansal S; Dunnam M; Dyer C; Hu LL; Zarate-Abbott P
  •  go-up   go-down


59. Nguyen KT, Olgin JE, Pletcher MJ, Ng M, Kaye L, Moturu S, Gladstone RA, Malladi C, Fann AH, Maguire C, Bettencourt L, Christensen MA, Marcus GM: Smartphone-Based Geofencing to Ascertain Hospitalizations. Circ Cardiovasc Qual Outcomes; 2017 Mar;10(3)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ascertainment of hospitalizations is critical to assess quality of care and the effectiveness and adverse effects of various therapies.
  • An in-person study included consecutive consenting patients scheduled for electrophysiology and cardiac catheterization procedures.
  • Of 22 eligible in-person patients, 17 hospitalizations were detected (sensitivity 77%; 95% confidence interval, 55%-92%).
  • This first proof of concept may ultimately be applicable to geofencing other types of prespecified locations to facilitate healthcare research and patient care.
  • [MeSH-minor] Adult. Aged. Appointments and Schedules. Attitude to Computers. Cardiac Catheterization / statistics & numerical data. Electronic Health Records. Electrophysiologic Techniques, Cardiac / statistics & numerical data. Feasibility Studies. Female. Humans. Male. Middle Aged. Patient Satisfaction. Surveys and Questionnaires. Time Factors. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] J Biomed Inform. 2009 Apr;42(2):377-81 [18929686.001]
  • [Cites] Telemed J E Health. 2016 Aug;22(8):655-65 [26958742.001]
  • [Cites] J Am Coll Cardiol. 2012 Aug 14;60(7):569-80 [22796257.001]
  • [Cites] J Vasc Surg. 2014 Jul;60(1):98-105 [24636641.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):969-77 [9596475.001]
  • [Cites] Med Care Res Rev. 2006 Apr;63(2):217-35 [16595412.001]
  • [Cites] J Clin Epidemiol. 1990;43(1):87-91 [2319285.001]
  • [Cites] Gerontologist. 2016 Oct;56(5):807-16 [26035900.001]
  • [Cites] Patient Prefer Adherence. 2016 Jan 27;10:99-106 [26869773.001]
  • [Cites] Am J Hypertens. 2007 Sep;20(9):942-8 [17765133.001]
  • [Cites] JMIR Mhealth Uhealth. 2016 Apr 19;4(2):e41 [27095507.001]
  • [Cites] Soc Sci Med. 2008 Jul;67(1):128-36 [18396367.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):253-60 [16511419.001]
  • [Cites] Lancet. 2012 Dec 15;380(9859):2197-223 [23245608.001]
  • [Cites] Am J Epidemiol. 2004 Dec 15;160(12):1152-8 [15583367.001]
  • [Cites] Biotechnol Adv. 2016 May-Jun;34(3):291-304 [26952640.001]
  • [Cites] Lancet. 2014 Jul 5;384(9937):45-52 [24996589.001]
  • [Cites] Heart Rhythm. 2016 Jan;13(1):3-9 [26340844.001]
  • [Cites] JMIR Mhealth Uhealth. 2014 May 01;2(2):e19 [25099179.001]
  • [Cites] BMJ Open. 2015 Dec 23;5(12):e008896 [26700275.001]
  • [Cites] Health Serv Res. 2002 Jun;37(3):751-74 [12132604.001]
  • (PMID = 28325751.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIMHD NIH HHS / MD / R25 MD006832; United States / NCATS NIH HHS / TR / TL1 TR000144; United States / NIBIB NIH HHS / EB / U2C EB021881
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; fast food / hospitalization / internet / pharmacies / smartphone
  •  go-up   go-down


60. Holcomb JB, Swartz MD, DeSantis SM, Greene TJ, Fox EE, Stein DM, Bulger EM, Kerby JD, Goodman M, Schreiber MA, Zielinski MD, O'Keeffe T, Inaba K, Tomasek JS, Podbielski JM, Appana SN, Yi M, Wade CE, PROHS Study Group: Multicenter observational prehospital resuscitation on helicopter study. J Trauma Acute Care Surg; 2017 07;83(1 Suppl 1):S83-S91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Earlier use of in-hospital plasma, platelets, and red blood cells (RBCs) has improved survival in trauma patients with severe hemorrhage.
  • Retrospective studies have associated improved early survival with prehospital blood product transfusion (PHT).
  • We hypothesized that PHT of plasma and/or RBCs would result in improved survival after injury in patients transported by helicopter.
  • METHODS: Adult trauma patients transported by helicopter from the scene to nine Level 1 trauma centers were prospectively observed from January to November 2015.
  • All patients meeting predetermined high-risk criteria were analyzed.
  • Patients receiving PHT were compared with patients not receiving PHT.
  • Our primary analysis compared mortality at 3 hours, 24 hours, and 30 days, using logistic regression to adjust for confounders and site heterogeneity to model patients who were matched on propensity scores.
  • RESULTS: Twenty-five thousand one hundred eighteen trauma patients were admitted, 2,341 (9%) were transported by helicopter, of which 1,058 (45%) met the highest-risk criteria.
  • Five hundred eighty-five of 1,058 patients were flown on helicopters carrying blood products.
  • Twenty-four percent of eligible patients received a PHT.
  • Of patients receiving PHT, 24% received only plasma, 7% received only RBCs, and 69% received both.
  • With few units transfused to each patient and small outcome differences between groups, it is likely large, multicenter, randomized studies will be required to detect survival differences in this important population.

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transfusion. 2016 Apr;56 Suppl 2:S157-65 [27100752.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S89-94 [22847102.001]
  • [Cites] Transfusion. 2009 Dec;49(12):2625-30 [19682333.001]
  • [Cites] J Am Coll Surg. 2015 May;220(5):797-808 [25840537.001]
  • [Cites] Ann Surg. 2014 Jul;260(1):13-21 [24651132.001]
  • [Cites] Transfusion. 2013 Jan;53 Suppl 1:59S-64S [23301974.001]
  • [Cites] J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S2-6 [26002259.001]
  • [Cites] J Trauma. 2007 Oct;63(4):805-13 [18090009.001]
  • [Cites] Transfusion. 2010 Feb;50(2):493-500 [19804568.001]
  • [Cites] Ann Surg. 2008 Sep;248(3):447-58 [18791365.001]
  • [Cites] Br J Anaesth. 2015 Jul;115(1):76-83 [25991760.001]
  • [Cites] Transfusion. 2013 Jan;53 Suppl 1:9S-16S [23301981.001]
  • [Cites] Transfusion. 2016 Apr;56 Suppl 2:S107-9 [27100745.001]
  • [Cites] Injury. 2017 Jan;48(1):5-12 [27847192.001]
  • [Cites] Shock. 2016 Jul;46(1):3-16 [26825635.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Dec;73(6 Suppl 5):S445-52 [23192068.001]
  • [Cites] BMJ. 2016 Jun 22;353:i3051 [27333868.001]
  • [Cites] Anesth Analg. 2017 Jan;124(1):277-281 [27749352.001]
  • [Cites] JAMA Surg. 2013 Feb;148(2):170-5 [23426594.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:35-8 [24317352.001]
  • [Cites] Vox Sang. 2016 Jan;110(1):36-50 [26178308.001]
  • [Cites] Blood. 2014 Nov 13;124(20):3052-8 [25293771.001]
  • [Cites] Ann Surg. 2015 May;261(5):997-1005 [24670858.001]
  • [Cites] Psychol Methods. 2004 Dec;9(4):403-25 [15598095.001]
  • [Cites] JAMA Surg. 2013 Feb;148(2):127-36 [23560283.001]
  • [Cites] Vox Sang. 2007 Jan;92(1):69-78 [17181593.001]
  • [Cites] J Spec Oper Med. 2014 Fall;14(3):13-38 [25344706.001]
  • [Cites] J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S48-53 [26002263.001]
  • [Cites] JAMA. 2015 Feb 3;313(5):471-82 [25647203.001]
  • [Cites] Transfusion. 2013 Dec;53(12):3088-99 [23614333.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S49-53 [22847094.001]
  • [Cites] Ann Surg. 2013 Feb;257(2):330-4 [23291661.001]
  • [Cites] Prehosp Emerg Care. 2015 January-March;19(1):1-9 [24932734.001]
  • [Cites] Aviat Space Environ Med. 2014 Nov;85(11):1130-5 [25329947.001]
  • [Cites] JAMA. 2012 Apr 18;307(15):1602-10 [22511688.001]
  • [Cites] Surgery. 2015 Dec;158(6):1686-95 [26210224.001]
  • [Cites] Shock. 2013 Dec;40(6):444-50 [24089000.001]
  • [Cites] J Trauma. 2009 Apr;66(4 Suppl):S77-84; discussion S84-5 [19359974.001]
  • [Cites] J Trauma Acute Care Surg. 2013 Jun;74(6):1425-31 [23694868.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Mar;72(3):567-73; discussion 573-5; quiz 803 [22491538.001]
  • [Cites] J Trauma. 2007 Feb;62(2):307-10 [17297317.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:39-43 [24662780.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2013;2013:656-9 [24319247.001]
  • [Cites] Ann Surg. 2011 Oct;254(4):598-605 [21918426.001]
  • [Cites] J Trauma Acute Care Surg. 2016 Oct;81(4):780-94 [27389129.001]
  • [Cites] J Trauma Acute Care Surg. 2012 Jan;72(1):106-11 [22310123.001]
  • [Cites] Ann Surg. 2015 Mar;261(3):586-90 [25072443.001]
  • [Cites] Vox Sang. 2009 Jul;97(1):39-49 [19392782.001]
  • [Cites] J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S26-30 [26002260.001]
  • [Cites] J Trauma. 2008 Aug;65(2):272-6; discussion 276-8 [18695461.001]
  • [Cites] US Army Med Dep J. 2011 Apr-Jun;:18-24 [21607903.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:44-6 [24296431.001]
  • [Cites] Surgery. 2016 Mar;159(3):947-59 [26603848.001]
  • [Cites] Shock. 2014 May;41 Suppl 1:3-12 [24430539.001]
  • (PMID = 28383476.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL077863
  • [Publication-type] Journal Article; Multicenter Study; Observational Study
  • [Publication-country] United States
  • [Investigator] Holcomb JB; Wade CE; Fox EE; Podbielski JM; Tomasek JS; del Junco DJ; Swartz MD; DeSantis SM; Appana SN; Greene TJ; Yi M; Gonzalez MO; Baraniuk S; van Belle G; Leroux BG; Howard CL; Haymaker A; Stein DM; Scalea TM; Ayd B; Das P; Herrera AV; Bulger EM; Robinson BRH; Klotz P; Minhas A; Kerby JD; Melton SM; Williams CR; Stephens SW; Goodman M; Johannigman JA; McMullan J; Branson RD; Gomaa D; Barczak C; Schreiber MA; Underwood SJ; Watson C; Zielinski MD; Stubbs JR; Headlee A; O’Keeffe T; Rhee P; Rokowski LL; Santoro J; Seach A; Bradford D; Fealk M; Latifi F; Inaba K; Kim H; Chudnofsky C; Wong MD
  •  go-up   go-down


61. Volkers EJ, Greving JP, Hendrikse J, Algra A, Kappelle LJ, Becquemin JP, Bonati LH, Brott TG, Bulbulia R, Calvet D, Eckstein HH, Fraedrich G, Gregson J, Halliday A, Howard G, Jansen O, Roubin GS, Brown MM, Mas JL, Ringleb PA, Carotid Stenosis Trialists' Collaboration: Body mass index and outcome after revascularization for symptomatic carotid artery stenosis. Neurology; 2017 May 23;88(21):2052-2060
MedlinePlus Health Information. consumer health - Angioplasty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether the obesity paradox exists in patients who undergo carotid artery stenting (CAS) or carotid endarterectomy (CEA) for symptomatic carotid artery stenosis.
  • METHODS: We combined individual patient data from 2 randomized trials (Endarterectomy vs Angioplasty in Patients with Symptomatic Severe Carotid Stenosis and Stent-Protected Angioplasty vs Carotid Endarterectomy) and 3 centers in a third trial (International Carotid Stenting Study).
  • Baseline body mass index (BMI) was available for 1,969 patients and classified into 4 groups: <20, 20-<25, 25-<30, and ≥30 kg/m<sup>2</sup>.
  • This outcome was compared between different BMI strata in CAS and CEA patients separately, and in the total group.
  • Stroke or death occurred in 159 patients in the periprocedural (cumulative risk 8.1%) and in 270 patients in the postprocedural period (rate 4.8/100 person-years).
  • BMI did not affect periprocedural risk of stroke or death for patients assigned to CAS (<i>p</i><sub>trend</sub> = 0.39) or CEA (<i>p</i><sub>trend</sub> = 0.77) or for the total group (<i>p</i><sub>trend</sub> = 0.48).
  • Within the total group, patients with BMI 25-<30 had lower postprocedural risk of stroke or death than patients with BMI 20-<25 (BMI 25-<30 vs BMI 20-<25; hazard ratio 0.72; 95% confidence interval 0.55-0.94).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • [Cites] J Vasc Surg. 2009 Jan;49(1):140-7, 147.e1; discussion 147 [19028047.001]
  • [Cites] Int J Cardiol. 2014 Apr 1;172(3):600-1 [24491866.001]
  • [Cites] BMJ. 2016 May 04;353:i2156 [27146380.001]
  • [Cites] J Clin Epidemiol. 2013 Feb;66(2):192-6 [23257150.001]
  • [Cites] Stroke. 1988 May;19(5):604-7 [3363593.001]
  • [Cites] Int J Stroke. 2015 Jan;10(1):99-104 [25635277.001]
  • [Cites] Stroke. 2011 Oct;42(10):2872-7 [21836099.001]
  • [Cites] Stroke. 2010 May;41(5):e418-26 [20299666.001]
  • [Cites] Am J Cardiol. 2015 May 15;115(10):1428-34 [25772740.001]
  • [Cites] Stroke. 1989 Jun;20(6):828 [2728057.001]
  • [Cites] Neurology. 2012 Aug 28;79(9):856-63 [22895584.001]
  • [Cites] Lancet. 2016 Aug 20;388(10046):776-86 [27423262.001]
  • [Cites] N Engl J Med. 2006 Oct 19;355(16):1660-71 [17050890.001]
  • [Cites] Lancet. 2006 Oct 7;368(9543):1239-47 [17027729.001]
  • [Cites] Am J Cardiol. 2005 Dec 15;96(12):1743-5 [16360369.001]
  • [Cites] Lancet. 2010 Sep 25;376(9746):1062-73 [20832852.001]
  • [Cites] Stroke. 1991 Jun;22(6):711-20 [2057968.001]
  • [Cites] J Am Coll Surg. 2012 Feb;214(2):148-55 [22192895.001]
  • [Cites] Eur Heart J. 2013 Jan;34(4):268-77 [23076781.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1759-61 [15548500.001]
  • [Cites] Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000515 [22972047.001]
  • [Cites] Lancet. 2010 Mar 20;375(9719):985-97 [20189239.001]
  • [Cites] N Engl J Med. 2008 Nov 13;359(20):2105-20 [19005195.001]
  • [Cites] JAMA. 2011 Feb 23;305(8):822-3 [21343582.001]
  • [Cites] J Vasc Surg. 2012 May;55(5):1306-12 [22542344.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1083-96 [19299006.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):11-23 [20505173.001]
  • [Cites] Chest. 2008 Nov;134(5):925-930 [18641109.001]
  • [Cites] J Hypertens. 2012 Dec;30(12):2271-5 [23151882.001]
  • [Cites] Neuroepidemiology. 2008;30(2):93-100 [18309248.001]
  • (PMID = 28446644.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


62. Hofland J, Ouattara A, Fellahi JL, Gruenewald M, Hazebroucq J, Ecoffey C, Joseph P, Heringlake M, Steib A, Coburn M, Amour J, Rozec B, Liefde I, Meybohm P, Preckel B, Hanouz JL, Tritapepe L, Tonner P, Benhaoua H, Roesner JP, Bein B, Hanouz L, Tenbrinck R, Bogers AJJC, Mik BG, Coiffic A, Renner J, Steinfath M, Francksen H, Broch O, Haneya A, Schaller M, Guinet P, Daviet L, Brianchon C, Rosier S, Lehot JJ, Paarmann H, Schön J, Hanke T, Ettel J, Olsson S, Klotz S, Samet A, Laurinenas G, Thibaud A, Cristinar M, Collanges O, Levy F, Rossaint R, Stevanovic A, Schaelte G, Stoppe C, Hamou NA, Hariri S, Quessard A, Carillion A, Morin H, Silleran J, Robert D, Crouzet AS, Zacharowski K, Reyher C, Iken S, Weber NC, Hollmann M, Eberl S, Carriero G, Collacchi D, Di Persio A, Fourcade O, Bergt S, Alms A, Xenon-CABG Study Group: Effect of Xenon Anesthesia Compared to Sevoflurane and Total Intravenous Anesthesia for Coronary Artery Bypass Graft Surgery on Postoperative Cardiac Troponin Release: An International, Multicenter, Phase 3, Single-blinded, Randomized Noninferiority Trial. Anesthesiology; 2017 Dec;127(6):918-933

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated whether xenon anesthesia could limit myocardial damage in coronary artery bypass graft surgery patients, as has been reported for animal ischemia models.
  • METHODS: In 17 university hospitals in France, Germany, Italy, and The Netherlands, low-risk elective, on-pump coronary artery bypass graft surgery patients were randomized to receive xenon, sevoflurane, or propofol-based total intravenous anesthesia for anesthesia maintenance.
  • RESULTS: The first patient included at each center received xenon anesthesia for practical reasons.
  • For all other patients, anesthesia maintenance was randomized (intention-to-treat: n = 492; per-protocol/without major protocol deviation: n = 446).
  • CONCLUSIONS: In postoperative cardiac troponin I release, xenon was noninferior to sevoflurane in low-risk, on-pump coronary artery bypass graft surgery patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28872484.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; 0 / Biomarkers; 0 / Methyl Ethers; 0 / Troponin I; 38LVP0K73A / sevoflurane; 3H3U766W84 / Xenon
  •  go-up   go-down


63. Turhal NS, Kilickap S, Yalcin S, Sezgin C, Yamac D, Akbulut H, Ozyilkan O, Ozdemir F, Cabuk D, Sevinc A, Turkish Oncology Group: The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study. J Clin Oncol; 2011 May 20;29(15_suppl):e19598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.
  • METHODS: A questionnaire consisting of 32 questions was completed by 872 patients in ten different medical institutions, which included over 90% of the oncological care given in Turkey, were represented.
  • To allay patients' concerns that their answers could influence their treatment, the questionnaire was given to each patient by support people and not by the attending physician.
  • RESULTS: For the sample of 872 patients, 44% were male and 55% were female.
  • The median age of the patients was 55 ± 13 (range 16-89).
  • The average age of the male patients was significantly greater than that of females (57 versus 53; p< 0.001).
  • Of all patients, 165 (18.9%) used some form of complementary interventions during their illnesses.We found no evidence that the use of complementary treatments was associated with any of the remaining demographic variables.
  • Frequency of patients who used complementary interventions varied significantly (p<0.002) among medical institutions.
  • However, complementary interventions were used most frequently by patients with prostate cancer (33%), head and neck cancer (27%), and lung cancer (22%).
  • The patients who were least likely to use complementary interventions were the patients with soft tissue tumors.
  • Forty-one percent of the patients who used complementary interventions were using some sort of it during the time that they filled out the questionnaire.
  • Sources of information regarding complementary interventions included relatives (37%), television (26%), other patients with cancer (22%), and the internet (21%).
  • Fifty-five percent of patients thought that they benefited from these methods.
  • CONCLUSIONS: Approximately 20% of cancer patients in Turkey used complementary interventions and this frequency was lower than expected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022293.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT: Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev; 2016 Dec;35(4):547-573
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
  • Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research.
  • Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics.
  • This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):224-30 [11169869.001]
  • [Cites] Nature. 2015 Feb 19;518(7539):422-6 [25470049.001]
  • [Cites] J Infect Dis. 2013 Nov;208 Suppl 2:S125-30 [24151318.001]
  • [Cites] Mol Oncol. 2014 Mar;8(2):431-43 [24394560.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4307-16 [9192753.001]
  • [Cites] Breast Cancer Res Treat. 2015 Nov;154(1):13-22 [26438141.001]
  • [Cites] Nat Protoc. 2006;1(1):206-14 [17406234.001]
  • [Cites] Cancer J Sci Am. 1996 Sep-Oct;2(5):291-300 [9166547.001]
  • [Cites] Breast Cancer Res. 2002;4(4):155-64 [12100741.001]
  • [Cites] Am J Pathol. 1985 Sep;120(3):464-77 [2412448.001]
  • [Cites] Curr Protoc Mouse Biol. 2013 Mar 01;3(1):21-9 [26069021.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1384-9 [19029987.001]
  • [Cites] Ann Oncol. 2016 Jul;27(7):1190-8 [26912558.001]
  • [Cites] Nat Commun. 2016 Jun 06;7:11908 [27264733.001]
  • [Cites] Leukemia. 1998 Dec;12(12):2029-33 [9844934.001]
  • [Cites] Methods Mol Biol. 2010;596:33-45 [19949919.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(2):301-9 [19603265.001]
  • [Cites] Stem Cells. 2015 Jun;33(6):1696-704 [25694194.001]
  • [Cites] Cell. 2010 Jan 8;140(1):62-73 [20074520.001]
  • [Cites] Anticancer Res. 1995 Jan-Feb;15(1):1-7 [7733618.001]
  • [Cites] Breast Cancer Res. 2015 Jan 09;17:3 [25572662.001]
  • [Cites] Cancer Res. 1983 May;43(5):2223-39 [6831445.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3175-82 [12384415.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1805(1):105-17 [19931353.001]
  • [Cites] Br J Cancer. 1985 Mar;51(3):347-56 [3970811.001]
  • [Cites] Oncotarget. 2015 May 30;6(15):12890-908 [25973541.001]
  • [Cites] Breast Cancer Res Treat. 2010 May;121(1):53-64 [19593635.001]
  • [Cites] Cancer Res. 2013 Aug 1;73(15):4885-97 [23737486.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jul;122(1):35-43 [19701706.001]
  • [Cites] Cancer Res. 2012 Jun 15;72(12):3010-9 [22523036.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Expert Rev Mol Diagn. 2013 Mar;13(2):151-65 [23477556.001]
  • [Cites] J Natl Cancer Inst. 1960 Apr;24:953-69 [13821714.001]
  • [Cites] Blood. 2010 Jul 15;116(2):193-200 [20404133.001]
  • [Cites] Br J Cancer. 1980 Oct;42(4):524-9 [6254552.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3989-98 [17606733.001]
  • [Cites] J Natl Cancer Inst. 1979 Dec;63(6):1331-7 [92586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8):2766-71 [21768359.001]
  • [Cites] Development. 2000 Jun;127(11):2269-82 [10804170.001]
  • [Cites] Eur J Immunol. 1995 Feb;25(2):631-4 [7875225.001]
  • [Cites] Contemp Top Lab Anim Sci. 2003 Nov;42(6):33-5 [14615958.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Breast Care (Basel). 2016 Apr;11(2):108-15 [27239172.001]
  • [Cites] PLoS One. 2015 Sep 01;10(9):e0136851 [26325287.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Hum Immunol. 2009 May;70(5):325-30 [19236898.001]
  • [Cites] J Pathol. 2016 Nov;240(3):256-261 [27447842.001]
  • [Cites] Nature. 2014 Aug 14;512(7513):155-60 [25079324.001]
  • [Cites] Nature. 2011 Apr 7;472(7341):90-4 [21399628.001]
  • [Cites] Breast Cancer Res Treat. 2012 Sep;135(2):415-32 [22821401.001]
  • [Cites] Cancer. 2015 Jan 1;121(1):8-16 [25043972.001]
  • [Cites] Oncotarget. 2016 Jul 26;7(30):48206-48219 [27374081.001]
  • [Cites] Cancer Res. 1959 Jun;19(5):515-20 [13663040.001]
  • [Cites] Arch Pathol Lab Med. 2014 Feb;138(2):241-56 [24099077.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):444-53 [12712433.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1016-33 [3280724.001]
  • [Cites] Blood. 2013 Mar 21;121(12):e90-7 [23349390.001]
  • [Cites] Genet Res. 1966 Dec;8(3):295-309 [5980117.001]
  • [Cites] Breast Cancer Res. 2015 Feb 10;17:17 [25849559.001]
  • [Cites] Cell. 1995 Mar 10;80(5):813-23 [7889575.001]
  • [Cites] Adv Exp Med Biol. 2016;882:169-89 [26987535.001]
  • [Cites] J Exp Med. 1971 Sep 1;134(3 Pt 1):681-92 [15776569.001]
  • [Cites] Nature. 2010 Apr 15;464(7291):999-1005 [20393555.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):1005-9 [19421193.001]
  • [Cites] Oncotarget. 2016 May 3;7(18):26107-19 [27034166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9 [16507413.001]
  • [Cites] Breast Cancer Res. 2009;11(5):R66 [19735549.001]
  • [Cites] N Engl J Med. 2012 Mar 22;366(12):1090-8 [22417201.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Cancer Discov. 2014 Sep;4(9):998-1013 [25185190.001]
  • [Cites] Stem Cells. 2011 Jan;29(1):11-9 [21280155.001]
  • [Cites] PLoS One. 2016 Mar 08;11(3):e0151121 [26953790.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R21 [16611371.001]
  • [Cites] Nat Protoc. 2016 Mar;11(3):616 [26914320.001]
  • [Cites] Cell. 2012 May 25;149(5):994-1007 [22608083.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Curr Protoc Pharmacol. 2012 Dec;Chapter 14:Unit 14.22 [23258598.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):180-91 [7995938.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):917-23 [11830552.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1424-31 [11355958.001]
  • [Cites] Cancer Lett. 2014 Mar 1;344(1):13-9 [24513265.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):3-15 [7820953.001]
  • [Cites] Cancer Res. 2014 Mar 1;74(5):1463-74 [24425047.001]
  • [Cites] Mol Oncol. 2011 Feb;5(1):5-23 [21147047.001]
  • [Cites] Cancer Discov. 2011 Jun;1(1):54-67 [22039576.001]
  • [Cites] Curr Opin Immunol. 2010 Apr;22(2):231-7 [20144856.001]
  • [Cites] Neoplasia. 2015 Sep;17(9):735-41 [26476081.001]
  • [Cites] Nat Protoc. 2012 May 03;7(6):1024-41 [22555242.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):888-902 [7717456.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5152-8 [1406687.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6 [18723673.001]
  • [Cites] Nat Med. 2011 Oct 23;17(11):1514-20 [22019887.001]
  • [Cites] PLoS One. 2008 Apr 02;3(4):e1908 [18382681.001]
  • [Cites] PLoS One. 2016 Jun 16;11(6):e0157368 [27310713.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2062-71 [17332335.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1328-34 [10604729.001]
  • [Cites] Cell Rep. 2013 Sep 26;4(6):1116-30 [24055055.001]
  • [Cites] Genome Res. 2013 Dec;23(12):2115-25 [24056532.001]
  • [Cites] Cancer Lett. 1981 Dec;14(3):309-16 [7332907.001]
  • [Cites] Nat Med. 2010 Sep;16(9):974-5 [20823880.001]
  • [Cites] PLoS One. 2010 Aug 16;5(8):e12180 [20808935.001]
  • [Cites] Cancer Res. 1980 Jan;40(1):95-100 [6243091.001]
  • [Cites] Nat Biotechnol. 2014 Apr;32(4):364-72 [24633240.001]
  • [Cites] Nat Med. 2016 Aug;22(8):933-9 [27322743.001]
  • [Cites] Cancer Lett. 1980 Aug;10(2):177-89 [7459836.001]
  • [Cites] Br J Cancer. 1988 Jan;57(1):19-31 [3348947.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1010-7 [19398888.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):672-9 [18445819.001]
  • [Cites] Exp Cell Biol. 1979;47(4):281-93 [467773.001]
  • [Cites] Breast Cancer Res. 2014 May 20;16(3):210 [25928070.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):845-51 [15120040.001]
  • [Cites] Nature. 1979 Mar 29;278(5703):451-3 [313007.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2317-8 [19625762.001]
  • [Cites] Cancer Cell. 2013 Jul 8;24(1):120-9 [23845444.001]
  • [Cites] Cell Growth Differ. 1993 Jul;4(7):563-9 [8398896.001]
  • [Cites] Cancer Res. 2013 Dec 15;73(24):7290-300 [24142344.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):809-13 [19812674.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Nature. 2012 Apr 04;486(7403):395-9 [22495314.001]
  • [Cites] Am J Pathol. 1977 Nov;89(2):413-30 [200144.001]
  • [Cites] Trends Immunol. 2016 Jul;37(7):462-76 [27216414.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):99-109 [27680982.001]
  • [Cites] Cancer Res. 2012 Jun 1;72(11):2705-13 [22467173.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):584-90 [3967234.001]
  • [Cites] Int J Cancer. 1988 May 15;41(5):713-9 [3366492.001]
  • [Cites] J Immunol. 1993 May 1;150(9):3817-24 [8473734.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Immunol Lett. 2012 Aug 30;146(1-2):1-7 [22507217.001]
  • [Cites] Nat Rev Drug Discov. 2010 Apr;9(4):253-4 [20369394.001]
  • [Cites] Cell Immunol. 1996 Aug 1;171(2):186-99 [8806787.001]
  • [Cites] Clin Cancer Res. 2015 Apr 1;21(7):1688-98 [25208879.001]
  • [Cites] Cell. 2012 Mar 2;148(5):873-85 [22385957.001]
  • [Cites] Nature. 2014 Oct 2;514(7520):54-8 [25079331.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):71-8 [17049443.001]
  • [Cites] Cancer Cell. 2016 Mar 14;29(3):407-22 [26947176.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;119(1):35-40 [1400563.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):118-30 [17259968.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] J Cancer. 2014 Jan 23;5(2):156-65 [24563670.001]
  • [Cites] Breast Cancer Res. 2014 Apr 07;16(2):R36 [24708766.001]
  • [Cites] Nature. 1983 Feb 10;301(5900):527-30 [6823332.001]
  • [Cites] Genome Res. 2014 Nov;24(11):1881-93 [25060187.001]
  • [Cites] Cancer Cell. 2008 May;13(5):394-406 [18455123.001]
  • [Cites] Prostate. 2015 May;75(6):585-92 [25585936.001]
  • [Cites] Cancer. 1978 Jan;41(1):239-44 [626933.001]
  • [Cites] Nature. 2012 Apr 18;486(7403):346-52 [22522925.001]
  • [Cites] Lancet Oncol. 2007 Dec;8(12):1071-8 [18024211.001]
  • [Cites] Nature. 2012 Oct 4;490(7418):61-70 [23000897.001]
  • [Cites] J Endocrinol. 2006 Mar;188(3):589-601 [16522738.001]
  • [Cites] Nature. 2012 May 16;486(7403):400-4 [22722201.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jun;134(6):907-22 [20524868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18708-13 [22068913.001]
  • [Cites] Cancer Discov. 2011 Nov;1(6):508-23 [22586653.001]
  • [Cites] Breast Dis. 2006-2007;26:139-47 [17473372.001]
  • [Cites] Nat Commun. 2016 May 10;7:11479 [27161491.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):23-35 [18167337.001]
  • [Cites] Breast Cancer Res. 2010;12(5):R68 [20813035.001]
  • [Cites] Nature. 1988 Sep 15;335(6187):256-9 [2970594.001]
  • [Cites] Genome Res. 2009 Feb;19(2):167-77 [19056696.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):370-8 [18223211.001]
  • [Cites] Clin Chem. 2014 Jan;60(1):122-33 [24298072.001]
  • [Cites] Nat Med. 2015 Nov;21(11):1318-25 [26479923.001]
  • [Cites] J Cell Physiol. 1995 Apr;163(1):51-60 [7896900.001]
  • [Cites] Nature. 2012 Jun 20;486(7403):405-9 [22722202.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Adv Immunol. 2006;90:1-50 [16730260.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1059-65 [9230888.001]
  • [Cites] J Clin Oncol. 2014 Jul 20;32(21):2255-69 [24868023.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32 [8411256.001]
  • [Cites] Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23 [23456611.001]
  • [Cites] Cancer Cell. 2010 Nov 16;18(5):485-98 [21035406.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3731-40 [8916937.001]
  • [Cites] Cell. 1992 Mar 6;68(5):869-77 [1547488.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res Treat. 2012 Oct;135(3):913-22 [22941572.001]
  • [Cites] Cancer. 1980 Apr 15;45(8):2160-5 [7370957.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] BMC Cancer. 2003 Apr 24;3:13 [12713671.001]
  • [Cites] Clin Cancer Res. 2016 Aug 1;22(15):3764-73 [26957554.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] J Clin Oncol. 2014 Jul 1;32(19):2100-8 [24799487.001]
  • [Cites] Breast Cancer Res. 2004;6(1):22-30 [14680482.001]
  • [Cites] Nat Methods. 2014 Apr;11(4):396-8 [24633410.001]
  • [Cites] Cancer Metastasis Rev. 2010 Jun;29(2):309-16 [20405169.001]
  • [Cites] Int J Cancer. 2011 Nov 1;129(9):2194-206 [21544806.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] J Clin Oncol. 2015 Jun 10;33(17 ):1974-82 [25605845.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1299-311 [9588898.001]
  • [Cites] Breast Cancer Res. 2016 Jan 27;18(1):13 [26818199.001]
  • [Cites] Curr Drug Targets. 2010 Sep;11(9):1041-2 [20545615.001]
  • [Cites] Breast Cancer Res Treat. 2012 Jun;133(2):595-606 [22002565.001]
  • [Cites] Breast Cancer Res. 2016 Jun 28;18(1):68 [27349894.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):966-80 [16795075.001]
  • [Cites] Cancer Res. 2011 Jan 15;71(2):614-24 [21224357.001]
  • [Cites] J Natl Cancer Inst. 1975 Dec;55(6):1461-6 [1206764.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):69-86 [8738607.001]
  • [Cites] BioDrugs. 2009;23(5):277-87 [19754218.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 28025748.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112305; United States / NCI NIH HHS / CA / R01 CA172764; United States / NCI NIH HHS / CA / R01 CA173903; United States / NCI NIH HHS / CA / R01 CA129765; United States / NCI NIH HHS / CA / K08 CA164048; United States / NCI NIH HHS / CA / R01 CA140985; United States / NCI NIH HHS / CA / P30 CA034196; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / R01 CA166422; United States / NCI NIH HHS / CA / R21 CA185460; United States / NCI NIH HHS / CA / R01 CA101860; United States / NCI NIH HHS / CA / P50 CA058183; United States / NCATS NIH HHS / TR / UL1 TR000448; United States / NCI NIH HHS / CA / U01 CA214172; United States / NCI NIH HHS / CA / U54 CA149196; United States / NCI NIH HHS / CA / R21 CA187890; United States / NCI NIH HHS / CA / P50 CA186784
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Breast cancer / Immunocompromised/immunodeficient mice / PDX consortium / Patient-derived xenograft / Translational research
  •  go-up   go-down


65. Ji L, Bonnet F, Charbonnel B, Gomes MB, Kosiborod M, Khunti K, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Shimomura I, Watada H, Fenici P, Hammar N, Hashigami K, Macaraeg G, Surmont F, Medina J: Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. J Diabetes Complications; 2017 Jul;31(7):1188-1196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The global DISCOVER study program aims to describe the disease management patterns and a broad range of associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice.
  • METHODS: The DISCOVER program comprises two longitudinal observational studies involving more than 15,000 patients in 38 countries across six continents.
  • RESULTS: The DISCOVER program will record patient, healthcare provider, and healthcare system characteristics, treatment patterns, and factors influencing changes in therapy.
  • Microvascular and macrovascular complications, incidence of hypoglycemic events, and patient-reported outcomes will also be captured.
  • CONCLUSIONS: The DISCOVER program will provide insights into the current management of patients with type 2 diabetes worldwide, which will contribute to informing future clinical guidelines and improving patient care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28499961.001).
  • [ISSN] 1873-460X
  • [Journal-full-title] Journal of diabetes and its complications
  • [ISO-abbreviation] J. Diabetes Complicat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Longitudinal observational study / Outcomes / Real-world evidence / Second-line therapy / Treatment patterns / Type 2 diabetes
  •  go-up   go-down


66. Wheeler C, Halter M, Drennan VM, de Lusignan S, Grant R, Gabe J, Gage H, Begg P, Ennis J, Parle J: Physician associates working in secondary care teams in England: Interprofessional implications from a national survey. J Interprof Care; 2017 Nov;31(6):774-776

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician associates working in secondary care teams in England: Interprofessional implications from a national survey.
  • This study investigated the deployment of PAs within secondary care teams in England, through the use of a cross-sectional electronic, self-report survey.
  • Both direct and non-direct patient care activities were reported, with the type of work undertaken varying at times, depending on the presence or absence of other healthcare professionals.
  • PAs reported working within a variety of secondary care team staffing permutations, with the majority of these being interprofessional.
  • Further research is required to understand the nature of PAs' contribution to collaborative care within secondary care teams in England.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876145.001).
  • [ISSN] 1469-9567
  • [Journal-full-title] Journal of interprofessional care
  • [ISO-abbreviation] J Interprof Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Interprofessional collaboration / physician assistants / physician associates / secondary care / secondary care teams
  •  go-up   go-down


67. Erek E, Aydın S, Suzan D, Yıldız O, Altın F, Kırat B, Demir IH, Ödemiş E: Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest in children after cardiac surgery. Anatol J Cardiol; 2017 Apr;17(4):328-333

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medical records of all the patients who experienced cardiac arrest and ECPR in an early postoperative period (n=25; 4%) were analyzed.
  • Sixteen patients had palliative procedures.
  • In 88% of the patients, cardiac arrest episodes occurred in the first 24 h after operation.
  • RESULTS: The CPR duration until commencing mechanical support was <20 min in two patients, 20-40 min in 11 patients, and >40 min in 12 patients.
  • Eleven patients (44%) were weaned successfully from ECMO and survived more than 7 days.
  • While four patients were observed to have normal neuromotor development, one patient died of cerebral bleeding 6 months after discharge.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2014 Feb;45(2):276-7 [23828848.001]
  • [Cites] Resuscitation. 2009 Oct;80(10):1124-9 [19695762.001]
  • [Cites] Ann Thorac Surg. 2013 Jun;95(6):2140-6; discussion 2146-7 [23506632.001]
  • [Cites] World J Pediatr Congenit Heart Surg. 2012 Apr 1;3(2):229-35 [23804779.001]
  • [Cites] Ann Thorac Surg. 2012 Sep;94(3):874-9; discussion 879-80 [22698774.001]
  • [Cites] Circulation. 1994 Nov;90(5 Pt 2):II280-4 [7955266.001]
  • [Cites] Circulation. 2010 Sep 14;122(11 Suppl):S241-8 [20837920.001]
  • [Cites] Resuscitation. 2012 Jun;83(6):710-4 [22306256.001]
  • [Cites] Circulation. 1999 Nov 9;100(19 Suppl):II194-9 [10567303.001]
  • [Cites] ARYA Atheroscler. 2013 Mar;9(2):145-9 [23690815.001]
  • [Cites] Circulation. 1992 Nov;86(5 Suppl):II300-4 [1424017.001]
  • [Cites] J Intensive Care. 2014 Dec 31;2(1):68 [25705425.001]
  • [Cites] Resuscitation. 2013 Mar;84(3):326-30 [22800860.001]
  • [Cites] Circulation. 2010 Nov 2;122(18 Suppl 3):S876-908 [20956230.001]
  • [Cites] Artif Organs. 2013 Jan;37(1):E29-34 [23305584.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Mar;33(3):409-17 [18206379.001]
  • [Cites] Pediatr Crit Care Med. 2009 Jul;10(4):445-51 [19451851.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):2095-101; discussion 2101-2 [11789800.001]
  • [Cites] Crit Care Med. 1997 Dec;25(12):1951-5 [9403741.001]
  • [Cites] Eur J Cardiothorac Surg. 2009 Jul;36(1):3-28 [19297185.001]
  • [Cites] Circulation. 2007 Oct 9;116(15):1693-700 [17893278.001]
  • [Cites] Eur J Cardiothorac Surg. 2014 Feb;45(2):268-75 [23818569.001]
  • (PMID = 28045013.001).
  • [ISSN] 2149-2271
  • [Journal-full-title] Anatolian journal of cardiology
  • [ISO-abbreviation] Anatol J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


68. Yarmolenko PS, Eranki A, Partanen A, Celik H, Kim A, Oetgen M, Beskin V, Santos D, Patel J, Kim PCW, Sharma K: Technical aspects of osteoid osteoma ablation in children using MR-guided high intensity focussed ultrasound. Int J Hyperthermia; 2017 Apr 24;:1-10
figshare. supplemental materials - Supporting Data and Materials for the article .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging-guided high intensity focussed ultrasound (MR-HIFU) allows non-invasive treatment without ionising radiation exposure, in contrast to the current standard of care treatment with radiofrequency ablation (RFA).
  • This report describes technical aspects of MR-HIFU ablation in the first 8 paediatric OO patients treated in a safety and feasibility clinical trial (total enrolment of up to 12 patients).
  • Detailed treatment workflow, patient positioning and coupling strategies, as well as temperature and tissue perfusion changes were summarised and correlated.
  • Ultrasound standoff pads were shaped to conform to extremity contours providing acoustic coupling and aided patient positioning.
  • Complete pain relief with no medication occurred in 7/8 patients within 28 days following treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28540807.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinical trials-thermal ablation / children / high intensity focused ultrasound / osteoid osteoma / thermal ablation
  •  go-up   go-down


69. Gratz I, Deal E, Spitz F, Baruch M, Allen IE, Seaman JE, Pukenas E, Jean S: Continuous Non-invasive finger cuff CareTaker® comparable to invasive intra-arterial pressure in patients undergoing major intra-abdominal surgery. BMC Anesthesiol; 2017 03 21;17(1):48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous Non-invasive finger cuff CareTaker® comparable to invasive intra-arterial pressure in patients undergoing major intra-abdominal surgery.
  • METHODS: A convenience sample of 24 patients scheduled for major abdominal surgery were consented to participate in this IRB approved pilot study.
  • Each patient was monitored with a radial arterial catheter and CT using a finger cuff applied to the contralateral thumb.
  • Most patients exhibited very good agreement between methods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anesthesiology. 2012 May;116(5):1092-103 [22415387.001]
  • [Cites] Anesth Analg. 2010 Nov;111(5):1180-92 [20736431.001]
  • [Cites] Biomed Eng Online. 2014 Jul 08;13:96 [25005686.001]
  • [Cites] Nonlinear Biomed Phys. 2008 Feb 22;2(1):1 [18294366.001]
  • [Cites] Anesth Analg. 2015 Aug;121(2):514-24 [26039419.001]
  • [Cites] Med Biol Eng Comput. 1986 May;24(3):248-54 [3747623.001]
  • [Cites] Crit Care. 2014 Nov 30;18(6):644 [25433536.001]
  • [Cites] Anesthesiology. 2014 May;120(5):1080-97 [24637618.001]
  • [Cites] J Clin Monit Comput. 2015 Oct;29(5):659-69 [25516162.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2011 Jun;25(3):536-46 [21419654.001]
  • [Cites] Nonlinear Biomed Phys. 2011 Jan 12;5(1):1 [21226911.001]
  • [Cites] Circulation. 1985 Dec;72(6):1257-69 [4064270.001]
  • [Cites] Anesthesiology. 2015 Jan;122(1):208-9 [25611656.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H222-34 [25888513.001]
  • (PMID = 28327093.001).
  • [ISSN] 1471-2253
  • [Journal-full-title] BMC anesthesiology
  • [ISO-abbreviation] BMC Anesthesiol
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM007175
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Keywords] NOTNLM ; CareTaker (major topic) / Central blood pressure (major topic) / Finger cuff (major topic) / Intra-Arterial pressure (major topic) / Non-Invasive (major topic)
  •  go-up   go-down


70. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE: Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst); 2017;8:111-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus guidelines for lumbar puncture in patients with neurological diseases.
  • RESULTS: Our consensus guidelines address contraindications, as well as patient-related and procedure-related risk factors that can influence the development of post-LP complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Scand. 1998 Dec;98(6):445-51 [9875625.001]
  • [Cites] Br J Anaesth. 2012 Feb;108(2):308-15 [22157954.001]
  • [Cites] Acad Emerg Med. 2014 Feb;21(2):130-6 [24673668.001]
  • [Cites] Ann Emerg Med. 1993 Dec;22(12):1863-70 [8239110.001]
  • [Cites] Eur J Neurol. 2014 Feb;21(2):305-11 [24320927.001]
  • [Cites] Neurology. 1959 Apr;9(4):290-7 [13644562.001]
  • [Cites] J Neurol. 1998 Sep;245(9):589-92 [9758296.001]
  • [Cites] Anaesthesia. 1999 Jul;54(7):647-50 [10417455.001]
  • [Cites] Neurology. 2000 Oct 10;55(7):909-14 [11061243.001]
  • [Cites] J Neurol Sci. 2011 Jul 15;306(1-2):24-8 [21549395.001]
  • [Cites] Ann Chir Gynaecol. 1981;70(3):107-11 [7325577.001]
  • [Cites] Can J Anaesth. 1995 Aug;42(8):706-10 [7586110.001]
  • [Cites] Neurology. 2002 Oct 8;59(7):1120; author reply 1120-1 [12370487.001]
  • [Cites] Pediatrics. 1992 May;89(5 Pt 1):895-7 [1579400.001]
  • [Cites] BMJ. 2001 Apr 21;322(7292):993-4 [11312243.001]
  • [Cites] Cephalalgia. 2016 Feb;36(2):131-8 [25908221.001]
  • [Cites] Neurologist. 2009 Jan;15(1):17-20 [19131853.001]
  • [Cites] Spine J. 2015 Jul 1;15(7):1571-6 [25794941.001]
  • [Cites] Acta Neurol Scand. 2001 Jun;103(6):396-8 [11421853.001]
  • [Cites] Haematologica. 2007 Jul;92(7):1007-8 [17606461.001]
  • [Cites] Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):632-4 [23834161.001]
  • [Cites] Neurology. 2006 Oct 24;67(8):1492-4 [17060584.001]
  • [Cites] BMJ. 1999 Mar 13;318(7185):728-30 [10074024.001]
  • [Cites] S Afr Med J. 1978 Apr 29;53(17):666-8 [675447.001]
  • [Cites] Anesth Analg. 1995 Feb;80(2):303-9 [7818117.001]
  • [Cites] Ulster Med J. 2014 May;83(2):93-102 [25075138.001]
  • [Cites] Reg Anesth. 1997 Jan-Feb;22(1):66-72 [9010949.001]
  • [Cites] Reg Anesth Pain Med. 2000 Mar-Apr;25(2):163-9 [10746529.001]
  • [Cites] Acad Radiol. 2014 May;21(5):612-6 [24703473.001]
  • [Cites] Lancet Neurol. 2014 Jun;13(6):614-29 [24849862.001]
  • [Cites] Anesth Analg. 1989 Oct;69(4):457-60 [2782645.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):2008-9 [12499507.001]
  • [Cites] Headache. 1972 Jul;12(2):73-8 [4262477.001]
  • [Cites] Neurology. 2001 Dec 26;57(12):2310-2 [11756618.001]
  • [Cites] Br J Anaesth. 2003 Nov;91(5):718-29 [14570796.001]
  • [Cites] Neurology. 1993 Mar;43(3 Pt 1):625-7 [8451016.001]
  • [Cites] AJNR Am J Neuroradiol. 2014 Aug;35(8):1475-80 [24722309.001]
  • [Cites] Cephalalgia. 2004;24 Suppl 1:9-160 [14979299.001]
  • [Cites] Clin Anat. 2004 Oct;17(7):544-53 [15376294.001]
  • [Cites] J Alzheimers Dis. 2014;39(4):719-26 [24254700.001]
  • [Cites] Ann Clin Biochem. 1995 Mar;32 ( Pt 2):210-2 [7785952.001]
  • [Cites] BMJ. 2001 Apr 21;322(7292):994 [11312245.001]
  • [Cites] Alzheimers Dement. 2011 May;7(3):263-9 [21514250.001]
  • [Cites] Clin Radiol. 1991 Nov;44(5):338-41 [1836989.001]
  • [Cites] Neurology. 1996 Jul;47(1):33-7 [8710120.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):220-5 [16327349.001]
  • [Cites] JRSM Short Rep. 2012 Dec;3(12):82 [23476725.001]
  • [Cites] CMAJ. 1993 Mar 15;148(6):961-5 [8448711.001]
  • [Cites] Paediatr Anaesth. 1999;9(5):429-34 [10447907.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jun;190(6):1686-9 [18492925.001]
  • [Cites] Eur Radiol. 2002 Mar;12 (3):686-91 [11870488.001]
  • [Cites] Eur Radiol. 1996;6(2):184-7 [8797976.001]
  • [Cites] BMJ. 1998 Mar 28;316(7136):1018 [9550978.001]
  • [Cites] J Neurol. 1994 May;241(6):376-80 [7931432.001]
  • [Cites] Eur J Neurol. 2013 Mar;20(3):410-9 [23323801.001]
  • [Cites] Neurology. 2014 Feb 25;82(8):734-5 [24566228.001]
  • [Cites] Dan Med J. 2012 Jul;59(7):A4483 [22759849.001]
  • [Cites] J Headache Pain. 2005 Oct;6(5):400-4 [16362713.001]
  • [Cites] Biol Psychiatry. 1996 Jun 15;39(12):1058-60 [8780844.001]
  • [Cites] Alzheimers Dement. 2016 Feb;12(2):154-63 [26368321.001]
  • [Cites] Int J Nurs Stud. 2011 Nov;48(11):1315-22 [21561619.001]
  • [Cites] Neurol Clin. 1998 Feb;16(1):83-105 [9421542.001]
  • [Cites] J Clin Neurosci. 2014 Mar;21(3):536-7 [24156907.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001791 [20091522.001]
  • [Cites] Cephalalgia. 2012 Sep;32(12):916-23 [22843225.001]
  • [Cites] Dan Med J. 2013 Sep;60(9):A4684 [24001459.001]
  • [Cites] Br J Haematol. 2011 Aug;154(3):311-24 [21671894.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):E24 [15824326.001]
  • [Cites] Neurology. 2005 Aug 23;65(4):510-2 [16116106.001]
  • [Cites] N Engl J Med. 2001 Dec 13;345(24):1727-33 [11742046.001]
  • [Cites] Neurol Sci. 2014 Dec;35(12):1997-9 [25139108.001]
  • [Cites] Eur Heart J. 2013 Jul;34(27):2094-106 [23625209.001]
  • [Cites] Neurology. 2012 Jan 10;78(2):109-13 [22205758.001]
  • [Cites] JAMA. 2006 Oct 25;296(16):2012-22 [17062865.001]
  • [Cites] Headache. 2001 Apr;41(4):385-90 [11318885.001]
  • [Cites] Alzheimers Dement. 2011 May;7(3):270-9 [21514249.001]
  • [Cites] Headache. 1986 May;26(5):224-6 [3721858.001]
  • [Cites] J Neurol. 2012 Aug;259(8):1530-45 [22278331.001]
  • [Cites] BMJ. 2001 Apr 21;322(7292):993; author reply 994 [11312241.001]
  • [Cites] Paediatr Anaesth. 2008 Mar;18(3):230-4 [18230066.001]
  • [Cites] Arch Dis Child. 2014 Mar;99(3):203-7 [24233069.001]
  • [Cites] Cochrane Database Syst Rev. 2015 Jul 15;(7):CD007887 [26176166.001]
  • [Cites] Cephalalgia. 2001 Sep;21(7):738-43 [11595002.001]
  • [Cites] JAMA Neurol. 2015 Mar;72(3):325-32 [25622095.001]
  • [Cites] J Emerg Med. 2014 Jul;47(1):59-64 [24775990.001]
  • [Cites] BMJ. 2000 Oct 21;321(7267):986-90 [11039963.001]
  • [Cites] Anaesthesia. 1989 Feb;44(2):147-9 [2929939.001]
  • [Cites] AJR Am J Roentgenol. 2016 Jan;206(1):20-5 [26700333.001]
  • [Cites] Anesthesiology. 2001 Aug;95(2):334-9 [11506102.001]
  • [Cites] Anesth Analg. 2004 Jul;99(1):303; author reply 303-4 [15281552.001]
  • [Cites] Clin Neurol Neurosurg. 2015 Mar;130:74-9 [25590665.001]
  • [Cites] Acta Neurol Scand. 1992 Jul;86(1):50-4 [1519474.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1987 Aug;50(8):1071-4 [3655817.001]
  • [Cites] Cephalalgia. 1989 Jun;9(2):99-106 [2743417.001]
  • [Cites] Neurology. 2013 Apr 23;80(17):e180-2 [23610152.001]
  • [Cites] Cephalalgia. 1993 Aug;13(4):296-7 [8374947.001]
  • [Cites] Psychosom Med. 1967 Jun-Aug;29(4):376-9 [4862603.001]
  • [Cites] Neurology. 2011 Jul 5;77(1):71-4 [21593442.001]
  • [Cites] J Neurointerv Surg. 2014 May;6(4):324-8 [23729498.001]
  • [Cites] Cephalalgia. 1998 Nov;18(9):635-7; discussion 591 [9876888.001]
  • [Cites] Cephalalgia. 1992 Aug;12(4):259 [1525802.001]
  • [Cites] Acta Anaesthesiol Scand. 2000 Feb;44(2):210-3 [10695916.001]
  • (PMID = 28603768.001).
  • [ISSN] 2352-8729
  • [Journal-full-title] Alzheimer's & dementia (Amsterdam, Netherlands)
  • [ISO-abbreviation] Alzheimers Dement (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Back pain / Cerebrospinal fluid / Consensus guidelines / Evidence-based guidelines / Headache / Lumbar puncture / Post-LP complications
  •  go-up   go-down


71. Weimar C, Bilbilis K, Rekowski J, Holst T, Beyersdorf F, Breuer M, Dahm M, Diegeler A, Kowalski A, Martens S, Mohr FW, Ondrášek J, Reiter B, Roth P, Seipelt R, Siggelkow M, Steinhoff G, Moritz A, Wilhelmi M, Wimmer-Greinecker G, Diener HC, Jakob H, Ose C, Scherag A, Knipp SC, CABACS Trial Investigators: Safety of Simultaneous Coronary Artery Bypass Grafting and Carotid Endarterectomy Versus Isolated Coronary Artery Bypass Grafting: A Randomized Clinical Trial. Stroke; 2017 Oct;48(10):2769-2775
MedlinePlus Health Information. consumer health - Patient Safety.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The optimal operative strategy in patients with severe carotid artery disease undergoing coronary artery bypass grafting (CABG) is unknown.
  • METHODS: Patients with asymptomatic high-grade carotid artery stenosis ≥80% according to ECST (European Carotid Surgery Trial) ultrasound criteria (corresponding to ≥70% NASCET [North American Symptomatic Carotid Endarterectomy Trial]) who required CABG surgery were randomly assigned to synchronous carotid endarterectomy+CABG or isolated CABG.
  • RESULTS: From 2010 to 2014, a total of 129 patients were enrolled at 17 centers in Germany and the Czech Republic.
  • At 30 days, the rate of any stroke or death in the intention-to-treat population was 12/65 (18.5%) in patients receiving synchronous carotid endarterectomy+CABG as compared with 6/62 (9.7%) in patients receiving isolated CABG (absolute risk reduction, 8.8%; 95% confidence interval, -3.2% to 20.8%; <i>P</i><sub>WALD</sub>=0.12).
  • Also for all secondary end points at 30 days and 1 year, there was no evidence for a significant treatment-group effect although patients undergoing isolated CABG tended to have better outcomes.
  • Five-year follow-up of patients is still ongoing.
  • [MeSH-major] Carotid Stenosis / diagnosis. Carotid Stenosis / surgery. Coronary Artery Bypass / standards. Endarterectomy, Carotid / standards. Patient Safety / standards

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s).
  • [Cites] Int J Stroke. 2012 Jun;7(4):354-60 [22103798.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2003 May;25(5):380-9 [12713775.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):395-402 [11172175.001]
  • [Cites] World J Surg. 2010 Oct;34(10):2292-8 [20645099.001]
  • [Cites] J Am Coll Cardiol. 2013 Nov 19;62(21):1948-56 [23876675.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Apr;37(4):379-87 [19201215.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2005 Sep;30(3):275-84 [16130207.001]
  • [Cites] J Neurol Sci. 2015 Oct 15;357(1-2):1-7 [26208801.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Sep;134(3):690-6 [17723819.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1379-87 [9593407.001]
  • [Cites] Lancet. 2010 Sep 25;376(9746):1062-73 [20832852.001]
  • [Cites] JACC Cardiovasc Interv. 2017 Feb 13;10 (3):286-298 [28183469.001]
  • [Cites] J Vasc Surg. 1989 Mar;9(3):455-63 [2784172.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2011 May;41(5):607-24 [21396854.001]
  • [Cites] Nat Rev Cardiol. 2011 Oct 11;9(2):116-24 [21989048.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):107-16 [12531577.001]
  • [Cites] JACC Cardiovasc Interv. 2009 May;2(5):393-401 [19463460.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2003 Sep;26(3):230-41 [14509884.001]
  • [Cites] J Vasc Surg. 2011 Oct;54(4):993-9; discussion 998-9 [21703806.001]
  • [Cites] Stroke. 2011 Oct;42(10):2801-5 [21817149.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2016 Jun;51(6):761-5 [27085660.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):11-23 [20505173.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2002 Apr;23(4):283-94 [11991687.001]
  • [Cites] Int J Geriatr Psychiatry. 2004 Feb;19(2):136-43 [14758579.001]
  • [Cites] N Engl J Med. 2016 Mar 17;374(11):1011-20 [26886419.001]
  • [Cites] Fortschr Neurol Psychiatr. 2010 Sep;78(9):532-5 [20563965.001]
  • (PMID = 28916664.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Keywords] NOTNLM ; carotid stenosis / coronary artery bypass / endarterectomy, carotid / randomized controlled trial / stroke
  •  go-up   go-down


72. Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S: Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology; 2017 Nov 14;89(20):2092-2100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Investigators at 6 US centers retrospectively identified patients with CNS sarcoidosis treated with infliximab, including only patients with definite or probable neurosarcoidosis following rigorous exclusion of other causes.
  • RESULTS: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 years, the mean age was 47.5 years at infliximab initiation (SD 11.7, range 24-71 years); 56.1% were female; 62.1% were white, 37.0% African American, and 3% Hispanic.
  • Using infliximab doses ranging from 3 to 7 mg/kg every 4-8 weeks, MRI evidence of a favorable treatment response was observed in 82.1% of patients with imaging follow-up (n = 56), with complete remission of active disease in 51.8% and partial MRI improvement in 30.1%; MRI worsened in 1 patient (1.8%).
  • There was clinical improvement in 77.3% of patients, with complete neurologic recovery in 28.8%, partial improvement in 48.5%, clinical stability in 18.2%, worsening in 3%, and 1 lost to follow-up.
  • In 16 patients in remission when infliximab was discontinued, the disease recurred in 9 (56%), typically in the same neuroanatomic location.
  • CONCLUSIONS: Most patients with CNS sarcoidosis treated with infliximab exhibit favorable imaging and clinical treatment responses, including some previously refractory to other immunosuppressive treatments.
  • CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with CNS sarcoidosis infliximab is associated with favorable imaging and clinical responses.
  • [MeSH-major] Central Nervous System Diseases / drug therapy. Immunosuppressive Agents / pharmacology. Infliximab / pharmacology. Outcome Assessment (Health Care). Sarcoidosis / drug therapy. Tumor Necrosis Factor-alpha / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • [Cites] Neurology. 2010 Aug 10;75(6):568-70 [20697110.001]
  • [Cites] Eur Respir J. 2008 Jun;31(6):1189-96 [18256069.001]
  • [Cites] Clin Mol Allergy. 2015 Sep 01;13(1):19 [26330764.001]
  • [Cites] Semin Respir Crit Care Med. 2007 Feb;28(1):22-35 [17330190.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802 [16840744.001]
  • [Cites] Expert Opin Drug Saf. 2016 Jan;15(1):43-52 [26559805.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2153-65 [18032765.001]
  • [Cites] Sarcoidosis Vasc Diffuse Lung Dis. 2006 Oct;23(3):201-8 [18038919.001]
  • [Cites] Chest. 2005 Aug;128(2):1062-47 [16100213.001]
  • [Cites] Spinal Cord. 2007 Dec;45(12):802-3 [17710103.001]
  • [Cites] Neurol Clin. 2010 Feb;28(1):185-98 [19932381.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):763-9 [10717011.001]
  • [Cites] J Lab Clin Med. 1990 Jan;115(1):36-42 [2299255.001]
  • [Cites] Rheumatology (Oxford). 2010 Jul;49(7):1215-28 [20194223.001]
  • [Cites] Neurology. 2002 Nov 26;59(10):1660-1 [12451224.001]
  • [Cites] J Rheumatol. 2003 Aug;30(8):1864-7 [12913948.001]
  • [Cites] Chest. 2003 Nov;124(5):2023-6 [14605084.001]
  • [Cites] J Neurol. 2009 Jan;256(1):139-40 [19219574.001]
  • [Cites] Ann Clin Transl Neurol. 2015 Oct;2(10):947-8 [26478894.001]
  • [Cites] Arch Neurol. 1998 Sep;55(9):1248-54 [9740120.001]
  • [Cites] Arch Intern Med. 1997 Sep 8;157(16):1864-8 [9290546.001]
  • [Cites] Clin Chest Med. 2015 Dec;36(4):569-84 [26593134.001]
  • [Cites] QJM. 1999 Feb;92(2):103-17 [10209662.001]
  • [Cites] Rheumatol Int. 2012 Aug;32(8):2367-70 [21644042.001]
  • [Cites] Chest. 2003 Jul;124(1):177-85 [12853521.001]
  • [Cites] Clin Rev Allergy Immunol. 2015 Aug;49(1):36-44 [25762348.001]
  • [Cites] Intern Med J. 2012 Jan;42(1):89-94 [22389903.001]
  • [Cites] Eur Respir J. 2014 Nov;44(5):1296-307 [25034562.001]
  • [Cites] J Neurol. 2017 May;264(5):891-897 [28260120.001]
  • [Cites] Arch Neurol. 2007 May;64(5):691-6 [17502468.001]
  • [Cites] Arch Neurol. 1995 Sep;52(9):875-9 [7661724.001]
  • [Cites] Am J Respir Crit Care Med. 1997 May;155(5):1665-9 [9154873.001]
  • [Cites] Clin Neuropharmacol. 2014 Sep-Oct;37(5):142-8 [25229171.001]
  • [Cites] JAMA. 2011 Jan 26;305(4):391-9 [21266686.001]
  • [Cites] Ann Rheum Dis. 2017 Mar;76(3):543-546 [27474764.001]
  • [Cites] Cell. 1989 Mar 10;56(5):731-40 [2647299.001]
  • [Cites] QJM. 2009 Jul;102(7):449-60 [19383611.001]
  • [Cites] Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):19-27 [24751450.001]
  • [Cites] Neurology. 2016 Dec 13;87(24):2517-2521 [27856779.001]
  • [Cites] Eur Respir J. 2013 Jan;41(1):115-22 [22903958.001]
  • (PMID = 29030454.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; Neurosarcoidosis
  •  go-up   go-down


73. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, Best B, Jones J, Schanberg LE, CARRA Registry Investigators: The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J; 2017 Apr 17;15(1):30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.
  • BACKGROUND: Herein we describe the history, design, and rationale of the new Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry and present the characteristics of patients with juvenile idiopathic arthritis (JIA) enrolled in the first 12 months of operation.
  • Data are collected every 6 months and include clinical assessments, detailed medication use, patient-reported outcomes, and safety events.
  • RESULTS: As of July 2016, 1192 patients with JIA were enrolled in the CARRA Registry at 49 clinical sites.
  • Owing to preferential enrollment, patients with systemic JIA (13%) and with a polyarticular course (75%) were over-represented compared to patients in typical clinical practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):919-28 [18383377.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10 [23983017.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53 [22076847.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):658-66 [19405003.001]
  • [Cites] J Rheumatol. 2012 Dec;39(12):2341-51 [23070991.001]
  • [Cites] Arthritis Care Res (Hoboken). 2014 Jul;66(7):1063-72 [24339215.001]
  • [Cites] Am J Epidemiol. 2003 Nov 1;158(9):915-20 [14585769.001]
  • [Cites] J Am Med Inform Assoc. 2013 Jan 1;20(1):172-9 [22733975.001]
  • [Cites] Arthritis Care Res (Hoboken). 2013 May;65(5):745-52 [23139240.001]
  • [Cites] Pediatrics. 2013 Nov;132(5):e1384-94 [24144710.001]
  • [Cites] J Rheumatol. 2013 Dec;40(12):2088-96 [24187099.001]
  • [Cites] Pediatr Rheumatol Online J. 2016 Mar 10;14 (1):14 [26965173.001]
  • [Cites] J Rheumatol. 2016 Sep;43(9):1755-62 [27307527.001]
  • [Cites] J Rheumatol. 2016 Apr;43(4):799-803 [26879356.001]
  • [Cites] J Rheumatol. 2013 Jun;40(6):936-42 [23588937.001]
  • [Cites] Lupus. 2016 Jun;25(7):749-53 [26980741.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175-85 [22505322.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83 [22162255.001]
  • [Cites] Pediatr Rheumatol Online J. 2016 Feb 16;14 (1):9 [26879972.001]
  • [Cites] Am Heart J. 2011 Nov;162(5):844-51 [22093200.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Lupus. 2014 Aug;23(9):898-904 [24729278.001]
  • [Cites] Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10 [22290637.001]
  • [Cites] J Rheumatol. 2012 Sep;39(9):1867-74 [22859354.001]
  • [Cites] J Rheumatol. 2002 May;29(5):1058-64 [12022323.001]
  • [Cites] Ann Rheum Dis. 2013 Dec;72(12):1983-8 [23256951.001]
  • [Cites] Pediatr Clin North Am. 2012 Apr;59(2):301-27 [22560572.001]
  • [Cites] J Am Heart Assoc. 2014 Feb 07;3(1):e000523 [24510115.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36 [21717596.001]
  • (PMID = 28416023.001).
  • [ISSN] 1546-0096
  • [Journal-full-title] Pediatric rheumatology online journal
  • [ISO-abbreviation] Pediatr Rheumatol Online J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Abramson L; Akoghlanian S; Anderson E; Andrew M; Baszis K; Becker M; Bell-Brunson H; Benham H; Birmingham J; Blier P; Brunner H; Chalom E; Chang J; Charpentier P; Chowdhury N; Dean J; Dedeoglu F; Dionizovik-Dimanovski M; Feldman B; Ferguson P; Fox M; Francis K; Franco L; Gervasini M; Goh I; Goldsmith D; Graham TB; Griffin T; Helfrich D; Hickey K; Hoeltzel M; Holtschlag S; Hsu J; Huber A; Huttenlocher A; Imundo L; Inman C; Jaquith J; Jerath R; Jones S; Kahn P; Kingsbury D; Klein K; Klein-Gitelman M; Kramer S; Kunkel A; Lapidus S; Latham D; Lehman T; Lindsley C; Linehan S; Lorenzo J; Malla B; Martyniuk A; Mason T; McConnell K; McCurdy D; McKibben K; McMullen-Jackson C; Milojevic D; Mims K; Moniz C; Morgan S; Murray E; Nicely K; O'Neil K; Onel K; Orange J; Ponder L; Prahalad S; Punaro M; Rabinovich CE; Rakestraw A; Rauch S; Reichley L; Rhea A; Ringold S; Riordan ME; Roberson S; Robinson A; Rosenkranz M; Ross K; Rothman D; Ruas Y; Ruth N; Sanders R; Schikler K; Singer N; Smith C; Stapp H; Swann S; Syed R; Tangarone A; Thatayatikom A; Trejo D; Tress J; Vehe R; von Scheven E; Watts A; Weiss J; Weiss P; Woo J; Yalcindag A; Zeft A; Zemel L; Zhu A
  •  go-up   go-down


74. Holt TA, Dalton A, Marshall T, Fay M, Qureshi N, Kirkpatrick S, Hislop J, Lasserson D, Kearley K, Mollison J, Yu LM, Hobbs FD, Fitzmaurice D: Automated Software System to Promote Anticoagulation and Reduce Stroke Risk: Cluster-Randomized Controlled Trial. Stroke; 2017 Mar;48(3):787-790
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effectiveness of a software tool (AURAS-AF [Automated Risk Assessment for Stroke in Atrial Fibrillation]) designed to identify such individuals during routine care through a cluster-randomized trial.
  • METHODS: Screen reminders appeared each time the electronic health records of an eligible patient was accessed until a decision had been taken over OAC treatment.
  • Control practices continued usual care.
  • Incidence of recorded transient ischemic attack was higher in the intervention practices (median 10.0 versus 2.3 per 1000 patients with atrial fibrillation; <i>P</i>=0.027), but at 12 months, we found a lower incidence of both all cause stroke (<i>P</i>=0.06) and hemorrhage (<i>P</i>=0.054).

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] Trials. 2013 Nov 13;14:385 [24220602.001]
  • [Cites] Br J Gen Pract. 2012 Oct;62(603):e710-7 [23265231.001]
  • [Cites] Lancet. 2014 Mar 15;383(9921):955-62 [24315724.001]
  • [Cites] Am J Med. 2010 Jul;123(7):638-645.e4 [20609686.001]
  • [Cites] Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001096 [19588323.001]
  • [Cites] Stroke. 1991 Aug;22(8):983-8 [1866765.001]
  • [Cites] Thromb Res. 2006;118(3):321-33 [16198396.001]
  • (PMID = 28119433.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / WMCLAHRC-2014-1
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants
  • [Keywords] NOTNLM ; anticoagulants (major topic) / atrial fibrillation (major topic) / electronic health records (major topic) / reminder systems (major topic) / stroke (major topic)
  •  go-up   go-down


75. Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME: Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. J Clin Oncol; 2017 Jul 10;35(20):2329-2337
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discuss a conceptual framework for identifying and genetically testing previously diagnosed but unreferred patients with ovarian cancer and other unrecognized BRCA1 or BRCA2 mutation carriers to improve the detection of families at risk for breast or ovarian cancer.
  • To achieve an interdisciplinary perspective, the workshop assembled international experts in genetics, medical and gynecologic oncology, clinical psychology, epidemiology, genomics, cost-effectiveness modeling, pathology, bioethics, and patient advocacy to identify factors to consider when undertaking a Traceback program.
  • [MeSH-minor] Family. Female. Germ-Line Mutation. Humans. Patient Acceptance of Health Care. Pedigree. Privacy. Registries

  • MedlinePlus Health Information. consumer health - Genetic Counseling.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2012 Jul 20;30(21):2654-63 [22711857.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4 [11097234.001]
  • [Cites] Front Oncol. 2016 May 11;6:119 [27242959.001]
  • [Cites] J Med Genet. 2017 Apr;54(4):254-259 [28330940.001]
  • [Cites] J Natl Cancer Inst. 2015 Apr 08;107(5):null [25855707.001]
  • [Cites] J Law Med Ethics. 2015 Fall;43(3):464-75 [26479556.001]
  • [Cites] J Natl Cancer Inst. 2013 Jun 5;105(11):812-22 [23628597.001]
  • [Cites] JAMA Oncol. 2016 Apr;2(4):482-90 [26720728.001]
  • [Cites] JAMA. 2010 Sep 1;304(9):967-75 [20810374.001]
  • [Cites] Adv Ther. 2016 Feb;33(2):129-50 [26809252.001]
  • [Cites] Gynecol Oncol. 2013 Aug;130(2):329-33 [23707676.001]
  • [Cites] J Law Med Ethics. 2015 Fall;43(3):476-85 [26479557.001]
  • [Cites] JAMA Oncol. 2016 Jun 1;2(6):730-6 [26867710.001]
  • [Cites] Curr Opin Obstet Gynecol. 2015 Feb;27(1):23-33 [25502425.001]
  • [Cites] Methods Mol Biol. 2009;471:487-500 [19109796.001]
  • [Cites] J Clin Oncol. 2016 May 1;34(13):1433-5 [26976416.001]
  • [Cites] Oncologist. 2013;18(5):518-24 [23615697.001]
  • [Cites] Am J Clin Oncol. 2016 Aug;39(4):363-7 [24710121.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] J Clin Oncol. 2016 Aug 1;34(22):2610-8 [27161971.001]
  • [Cites] J Health Dispar Res Pract. 2015 Fall;8(4):124-135 [26855846.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2012;13:433-54 [22607273.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):68-72 [19019415.001]
  • [Cites] Gigascience. 2015 Nov 04;4:50 [26543556.001]
  • [Cites] N Engl J Med. 2015 Jan 29;372(5):397-9 [25629736.001]
  • [Cites] J Law Med Ethics. 2015 Fall;43(3):440-63 [26479555.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Med J Aust. 2007 Jan 15;186(2):88-90 [17223771.001]
  • [Cites] J Natl Med Assoc. 2013 Spring;105(1):17-22 [23862292.001]
  • [Cites] Eur J Hum Genet. 2016 Aug;24(8):1104-11 [26733283.001]
  • [Cites] Cancer. 2009 May 15;115(10):2222-33 [19241424.001]
  • [Cites] Ann Surg Oncol. 2012 Jun;19(6):1732-7 [22427173.001]
  • [Cites] Int J Gynecol Cancer. 2013 Mar;23(3):431-6 [23354368.001]
  • [Cites] Gynecol Oncol. 2015 Jul;138(1):109-14 [25933682.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1329-33 [17416853.001]
  • [Cites] Nat Rev Clin Oncol. 2016 Sep;13(9):581-8 [27296296.001]
  • [Cites] Oncotarget. 2016 Jan 12;7(2):1076-83 [26745875.001]
  • [Cites] Fam Cancer. 2016 Jul;15(3):423-7 [26969309.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1003-7 [15824179.001]
  • [Cites] J Pathol. 2010 Feb;220(3):392-400 [19967725.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1876-85 [11920551.001]
  • [Cites] Breast J. 2009 Sep-Oct;15 Suppl 1:S56-62 [19775331.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] J Genet Couns. 2013 Oct;22(5):662-73 [23677535.001]
  • [Cites] Am J Pathol. 2016 Apr;186(4):733-47 [27012190.001]
  • [Cites] Genet Med. 2015 May;17(5):405-24 [25741868.001]
  • [Cites] J Clin Oncol. 2015 Sep 10;33(26):2901-7 [26261251.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1616-22 [12023993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10 [25192939.001]
  • [Cites] J Law Med Ethics. 2015 Fall;43(3):502-13 [26479559.001]
  • [Cites] Genet Med. 2011 Apr;13(4):349-55 [21358336.001]
  • [Cites] Psychooncology. 2008 Aug;17(8):774-82 [18646245.001]
  • [Cites] J Hum Genet. 2016 Apr;61(4):275-82 [26740237.001]
  • [Cites] J Genet Couns. 2015 Jun;24(3):388-99 [25577298.001]
  • [Cites] J Natl Cancer Inst. 2015 Aug 27;107(11): [26315354.001]
  • [Cites] J Clin Oncol. 2016 Dec;34(34):4071-4078 [27621404.001]
  • [Cites] J Natl Compr Canc Netw. 2010 May;8(5):562-94 [20495085.001]
  • [Cites] JAMA. 2005 Apr 13;293(14):1729-36 [15827311.001]
  • [Cites] Ann Oncol. 2015 Oct;26(10 ):2057-65 [26153499.001]
  • [Cites] JAMA Oncol. 2015 Oct;1(7):943-51 [26270727.001]
  • [Cites] Am J Public Health. 2013 Dec;103(12):2220-5 [24134351.001]
  • [Cites] J Natl Cancer Inst. 2009 Jan 21;101(2):80-7 [19141781.001]
  • [Cites] Obstet Gynecol. 2010 May;115(5):945-52 [20410767.001]
  • [Cites] Curr Treat Options Oncol. 2016 Aug;17(8):39 [27315065.001]
  • [Cites] JAMA. 2014 Sep 17;312(11):1091-2 [25198398.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1117-30 [12677558.001]
  • (PMID = 28398847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


76. Kashiura M, Hamabe Y, Akashi A, Sakurai A, Tahara Y, Yonemoto N, Nagao K, Yaguchi A, Morimura N, SOS-KANTO 2012 Study Group: Association between cardiopulmonary resuscitation duration and one-month neurological outcomes for out-of-hospital cardiac arrest: a prospective cohort study. BMC Anesthesiol; 2017 04 21;17(1):59
MedlinePlus Health Information. consumer health - CPR.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data were utilized from a prospective multi-center cohort study of out-of-hospital cardiac arrest patients transported to 67 emergency hospitals between January 2012 and March 2013 in the Kanto area of Japan.
  • A total of 3,353 patients with out-of-hospital cardiac arrest (age ≥18 years) who underwent CPR by emergency medical service personnel and achieved the return of spontaneous circulation in a pre- or in-hospital setting were analyzed.
  • The CPR duration required to achieve return of spontaneous circulation in >99% of out-of-hospital cardiac arrest patients with a 1-month favorable neurological outcome was 45 min, considering both pre- and in-hospital settings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S465-82 [26472996.001]
  • [Cites] Crit Care. 2014 Sep 26;18(5):535 [25255842.001]
  • [Cites] Crit Care Med. 1985 Nov;13(11):930-1 [4053643.001]
  • [Cites] Circulation. 1991 Aug;84(2):960-75 [1860248.001]
  • [Cites] Circulation. 2015 Nov 3;132(18 Suppl 2):S383-96 [26472991.001]
  • [Cites] Crit Care. 2015 Sep 10;19:322 [26353809.001]
  • [Cites] Resuscitation. 2007 Jun;73(3):394-9 [17289244.001]
  • [Cites] Resuscitation. 2014 Dec;85(12):1779-89 [25438253.001]
  • [Cites] Resuscitation. 2013 Jan;84(1):54-9 [22705831.001]
  • [Cites] Am J Emerg Med. 2015 May;33(5):677-81 [25753293.001]
  • [Cites] Resuscitation. 2015 Nov;96:323-7 [25986336.001]
  • [Cites] J Am Heart Assoc. 2016 Mar 18;5(3):e002819 [26994129.001]
  • [Cites] Circulation. 2013 Dec 3;128(23):2488-94 [24243885.001]
  • [Cites] Resuscitation. 2010 Nov;81(11):1479-87 [20828914.001]
  • [Cites] Resuscitation. 2015 Oct;95:302-11 [26477419.001]
  • [Cites] Resuscitation. 2008 Sep;78(3):355-8 [18573588.001]
  • [Cites] Emerg Med J. 2014 Jul;31(7):549-555 [23639589.001]
  • [Cites] Resuscitation. 2016 Apr;101:50-6 [26851705.001]
  • [Cites] N Engl J Med. 2010 Mar 18;362(11):994-1004 [20237345.001]
  • [Cites] Circulation. 2010 Nov 2;122(18 Suppl 3):S665-75 [20956219.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):63-81 [20123673.001]
  • [Cites] Resuscitation. 2007 Mar;72(3):394-403 [17161519.001]
  • [Cites] Resuscitation. 2015 Nov;96:328-40 [25438254.001]
  • [Cites] Crit Care. 2016 Mar 01;20:49 [26926006.001]
  • [Cites] Circulation. 2013 Dec 3;128(23):2465-7 [24135072.001]
  • [Cites] Perfusion. 2016 Apr;31(3):200-6 [26081930.001]
  • [Cites] J Thorac Dis. 2016 Oct;8(10 ):E1435-E1437 [27867652.001]
  • [Cites] Resuscitation. 2016 Mar;100:25-31 [26774172.001]
  • [Cites] Lancet. 2008 Aug 16;372(9638):554-61 [18603291.001]
  • (PMID = 28431508.001).
  • [ISSN] 1471-2253
  • [Journal-full-title] BMC anesthesiology
  • [ISO-abbreviation] BMC Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiopulmonary resuscitation (major topic) / Emergency medical services (major topic) / Out-of-hospital cardiac arrest (major topic) / Patient outcome assessment (major topic)
  • [Investigator] Inokuchi S; Masui Y; Miura K; Tsutsumi H; Takuma K; Atsushi I; Nakano M; Tanaka H; Ikegami K; Arai T; Yaguchi A; Kitamura N; Oda S; Kobayashi K; Suda T; Ono K; Morimura N; Furuya R; Koido Y; Iwase F; Nagao K; Kanesaka S; Okada Y; Unemoto K; Sadahiro T; Iyanaga M; Muraoka A; Hayashi M; Ishimatsu S; Miyake Y; Yokokawa H; Koyama Y; Tsuchiya A; Kashiyama T; Hayashi M; Oshima K; Kiyota K; Hamabe Y; Yokota H; Hori S; Inaba S; Sakamoto T; Harada N; Kimura A; Kanai M; Otomo Y; Sugita M; Kinoshita K; Sakurai T; Kitano M; Matsuda K; Tanaka K; Yoshihara K; Yoh K; Suzuki J; Toyoda H; Mashiko K; Shimizu N; Muguruma T; Shimada T; Kobe Y; Nakanishi K; Shiga T; Yamamoto T; Sekine K; Izuka S
  •  go-up   go-down


77. Tokimatsu I, Shigemura K, Kotaki T, Yoshikawa H, Yamamichi F, Tomo T, Arakawa S, Fujisawa M, Kadota JI: A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. Intern Med; 2017;56(11):1315-1319
MedlinePlus Health Information. consumer health - Pneumonia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.
  • Objectives To investigate the efficacy of oral moxifloxacin (MFLX) as a treatment for pneumonia in hemodialysis (HD) patients and the pharmacokinetic (PK) profile of MFLX after oral administration.
  • Methods Thirteen adult patients who required HD due to chronic renal failure were enrolled in the present study, which was performed to investigate the treatment of community-acquired pneumonia in HD patients.
  • Results In total, 13 HD patients with pneumonia (male, n=7; female, n=6) were enrolled in the present study.
  • The evaluation on the 3rd day showed that treatment was successful in 11 patients (84.6%) and that 10 patients were cured (76.9%).
  • In the one case in which MFLX treatment failed, the patient was cured by switching to ceftriaxone (CTRX) (2 g, intravenously) plus levofloxacin (LVFX) (250 mg, orally).
  • The causative bacterium in this male patient was P. aeruginosa.
  • One patient had liver dysfunction due to MFLX.
  • The PK parameters of MFLX among the patients in whom adverse events occurred or in whom a cure was not achieved did not differ from those of the other patients to a statistically significant extent.
  • Conclusion MFLX showed good efficacy and safety in HD patients with community-acquired pneumonia and the results of the PK analysis were favorable.
  • Further prospective studies with larger numbers of patients will be needed to draw definitive conclusions.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 2004 Mar;48(3):1012-6 [14982797.001]
  • [Cites] Br J Clin Pharmacol. 2007 Dec;64(6):745-9 [17555469.001]
  • [Cites] J Antimicrob Chemother. 2011 Oct;66(10):2330-5 [21729931.001]
  • [Cites] J Infect Chemother. 2014 Jul;20(7):417-22 [24787737.001]
  • [Cites] J Infect Chemother. 2011 Oct;17(5):640-5 [21369775.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416 [15699079.001]
  • [Cites] Drugs R D. 2012 Jun 1;12(2):71-100 [22715866.001]
  • [Cites] Am J Med. 2005 Jul;118 Suppl 7A:29S-38S [15993675.001]
  • [Cites] Respir Investig. 2013 Jun;51(2):103-26 [23790739.001]
  • [Cites] Perit Dial Int. 2009 Sep-Oct;29(5):575-9 [19776053.001]
  • [Cites] Hemodial Int. 2007 Jan;11(1):62-71 [17257358.001]
  • [Cites] J Antimicrob Chemother. 2004 Oct;54(4):780-4 [15347636.001]
  • [Cites] Int J Clin Pract. 2010 Feb;64(3):378-88 [20456176.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5 [9687407.001]
  • [Cites] Drugs. 2000 Jan;59(1):115-39 [10718103.001]
  • [Cites] Nephrol Dial Transplant. 2011 Sep;26(9):2899-906 [21273232.001]
  • [Cites] Int J Antimicrob Agents. 2012 Jun;39(6):455-7 [22483562.001]
  • [Cites] J Infect Chemother. 2011 Oct;17(5):678-85 [21847518.001]
  • (PMID = 28566592.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Fluoroquinolones
  • [Keywords] NOTNLM ; hemodialysis / moxifloxacin / pharmacokinetics / pneumonia
  •  go-up   go-down


78. Schober A, Sterz F, Herkner H, Wallmueller C, Weiser C, Hubner P, Testori C: Emergency extracorporeal life support and ongoing resuscitation: a retrospective comparison for refractory out-of-hospital cardiac arrest. Emerg Med J; 2017 May;34(5):277-281

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracorporeal cardiopulmonary resuscitation (ECPR) is an option for certain patients with cardiac arrest.
  • The aim of this study was to evaluate characteristics of patients selected for ECPR.
  • METHODS: Anonymised data of adult patients suffering refractory cardiac arrest, transported with ongoing CPR to an ED of a tertiary care centre between 2002 and 2012 were analysed.
  • RESULTS: Overall, 239 patients fulfilled the inclusion criteria.
  • ECPR was initiated in seven patients.
  • Patients treated with ECPR were younger (46 vs 60 years; p=0.04), had shorter intervals before CPR was started (0 vs 1 min; p=0.013), faster admissions at the ED (38 vs 56 min; p=0.31) and lower blood glucose levels on admission (14 vs 21 mmol/L; p=0.018).
  • Survival to discharge in good neurological condition was achieved in 14 (6%) of all patients.
  • One patient in the ECPR group survived in excellent neurological condition.
  • CONCLUSIONS: Emergency extracorporeal life support was used for a highly selected group of patients in refractory cardiac arrest.
  • The patient selection resulting in a survival of one patient out of seven treated seems reasonable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
  • (PMID = 28213587.001).
  • [ISSN] 1472-0213
  • [Journal-full-title] Emergency medicine journal : EMJ
  • [ISO-abbreviation] Emerg Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrest / ECLS / ECPR / Extracorporeal life support / Resuscitation / Ventricular fibrillation
  •  go-up   go-down


79. Probyn K, Bowers H, Caldwell F, Mistry D, Underwood M, Matharu M, Pincus T, CHESS Team: Prognostic factors for chronic headache: A systematic review. Neurology; 2017 Jul 18;89(3):291-301
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for chronic headache: A systematic review.
  • OBJECTIVE: To identify predictors of prognosis and trial outcomes in prospective studies of people with chronic headache.
  • METHODS: This was a systematic review of published literature in peer-reviewed journals<b>.
  • </b> We included (1) randomized controlled trials (RCTs) of interventions for chronic headache that reported subgroup analyses and (2) prospective cohort studies, published in English, since 1980.
  • Participants included adults with chronic headache (including chronic headache, chronic migraine, and chronic tension-type headache with or without medication overuse headache).
  • We searched key databases using free text and MeSH terms.
  • Two reviewers independently extracted data and assessed the methodologic quality of studies and overall quality of evidence identified using appropriate published checklists.
  • RESULTS: We identified 16,556 titles, removed 663 duplicates, and reviewed 199 articles, of which 27 were included in the review-17 prospective cohorts and 10 RCTs with subgroup analyses reported.
  • There was moderate-quality evidence indicating that depression, anxiety, poor sleep and stress, medication overuse, and poor self-efficacy for managing headaches are potential prognostic factors for poor prognosis and unfavorable outcomes from preventive treatment in chronic headache.
  • There was inconclusive evidence about treatment expectations, age, age at onset, body mass index, employment, and several headache features.
  • CONCLUSIONS: This review identified several potential predictors of poor prognosis and worse outcome postinterventions in people with chronic headache.
  • The majority of these are modifiable.
  • The findings also highlight the need for more longitudinal high-quality research of prognostic factors in chronic headache.
  • [MeSH-major] Headache Disorders / diagnosis
  • [MeSH-minor] Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  • [Cites] Cephalalgia. 2011 Nov;31(15):1510-21 [22019576.001]
  • [Cites] J Epidemiol Community Health. 2007 Mar;61(3):254-61 [17325405.001]
  • [Cites] Pain. 2012 Dec;153(12):2432-40 [23073072.001]
  • [Cites] Neurology. 2003 Jul 22;61(2):160-4 [12874392.001]
  • [Cites] Cephalalgia. 2001 Dec;21(10):980-6 [11843870.001]
  • [Cites] Cephalalgia. 2001 Jul;21(6):691-6 [11531902.001]
  • [Cites] Arch Gen Psychiatry. 2002 Oct;59(10):877-83 [12365874.001]
  • [Cites] Pain. 2012 Mar;153(3):682-6 [22281099.001]
  • [Cites] Cephalalgia. 2006 Apr;26(4):445-50 [16556246.001]
  • [Cites] Cephalalgia. 2011 Jan;31(2):133-43 [20647241.001]
  • [Cites] Syst Rev. 2013 Sep 05;2:71 [24007720.001]
  • [Cites] Headache. 2005 May;45(5):513-9 [15953268.001]
  • [Cites] Cephalalgia. 2007 Nov;27(11):1219-25 [17888081.001]
  • [Cites] Neurology. 2007 Jul 3;69(1):26-31 [17475943.001]
  • [Cites] Headache. 2008 Feb;48(2):194-200 [17868356.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):427-37 [16549855.001]
  • [Cites] Headache. 2010 Jun;50(6):981-8 [20236336.001]
  • [Cites] Headache. 2006 Jul-Aug;46(7):1186-90 [16866723.001]
  • [Cites] Headache. 2012 Nov-Dec;52(10):1456-70 [22830411.001]
  • [Cites] Pain. 2004 May;109(1-2):110-4 [15082132.001]
  • [Cites] Neurology. 2003 May 27;60(10):1682-3 [12771266.001]
  • [Cites] Headache. 2005 Apr;45(4):308-14 [15836566.001]
  • [Cites] Eur J Pain. 2011 Sep;15(8):775.e1-11 [21354838.001]
  • [Cites] Cephalalgia. 2005 Jan;25(1):12-5 [15606564.001]
  • [Cites] Headache. 2012 Feb;52(2):244-61 [22413151.001]
  • [Cites] Pain. 2009 Jun;143(3):213-22 [19342174.001]
  • [Cites] Brain. 2013 Nov;136(Pt 11):3489-96 [24080152.001]
  • [Cites] Arthritis Rheum. 2003 Dec;48(12):3359-70 [14673987.001]
  • [Cites] JAMA. 1998 Feb 4;279(5):381-3 [9459472.001]
  • [Cites] Cephalalgia. 2013 Jul;33(9):629-808 [23771276.001]
  • [Cites] BMJ. 2004 Mar 27;328(7442):744 [15023828.001]
  • [Cites] Clin J Pain. 2013 Nov;29(11):982-7 [23370087.001]
  • [Cites] BMC Med Res Methodol. 2011 Jan 31;11:14 [21281501.001]
  • [Cites] Biochem Med (Zagreb). 2014;24(2):199-210 [24969913.001]
  • [Cites] BMC Neurol. 2011 Oct 10;11:124 [21985562.001]
  • [Cites] Arthritis Care Res. 1996 Apr;9(2):97-104 [8970267.001]
  • [Cites] Clin J Pain. 2005 Jan-Feb;21(1):44-55; discussion 69-72 [15599131.001]
  • [Cites] Eur J Neurol. 2009 Jun;16(6):705-12 [19236455.001]
  • [Cites] Headache. 2007 Sep;47(8):1118-24 [17883516.001]
  • [Cites] Headache. 2013 Mar;53(3):427-36 [23470015.001]
  • [Cites] Headache. 2012 Jan;52(1):3-17 [22106869.001]
  • [Cites] Headache. 2015 Sep;55(8):1102-11 [26247313.001]
  • [Cites] Cephalalgia. 2010 May;30(5):599-609 [19614702.001]
  • [Cites] Eur J Pain. 2011 Feb;15(2):213-9 [20655254.001]
  • [Cites] Patient Educ Couns. 2004 Nov;55(2):177-84 [15530752.001]
  • [Cites] J Headache Pain. 2008 Feb;9(1):37-41 [18231713.001]
  • (PMID = 28615422.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


80. Dreyer RP, Dharmarajan K, Hsieh AF, Welsh J, Qin L, Krumholz HM: Sex Differences in Trajectories of Risk After Rehospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. Circ Cardiovasc Qual Outcomes; 2017 May;10(5)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: We identified >3 000 000 hospitalizations of patients with a principal discharge diagnosis of heart failure, acute myocardial infarction, or pneumonia and estimated sex differences in the daily risk of rehospitalization/death 1 year after discharge from a population of Medicare fee-for-service beneficiaries aged 65 years and older.
  • We calculated the (1) time required for adjusted rehospitalization/mortality risks to decline 50% from maximum values after discharge, (2) time required for the adjusted readmission risk to approach plateau periods of minimal day-to-day change, and (3) extent to which adjusted risks are greater among recently hospitalized patients versus Medicare patients.
  • [MeSH-major] Heart Failure / therapy. Myocardial Infarction / therapy. Patient Readmission / trends. Pneumonia / therapy. Risk Assessment / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • [Cites] JAMA. 2009 Aug 26;302(8):874-82 [19706861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):869-74 [24367114.001]
  • [Cites] Circulation. 2015 Jul 21;132(3):158-66 [26085455.001]
  • [Cites] Heart. 2009 Jan;95(1):20-6 [18463200.001]
  • [Cites] Heart. 2015 Mar;101(5):349-55 [25510395.001]
  • [Cites] Crit Care Med. 2014 May;42(5):1110-20 [24365862.001]
  • [Cites] JAMA. 2011 Oct 19;306(15):1669-78 [22009099.001]
  • [Cites] Arch Intern Med. 1998 Oct 12;158(18):2054-62 [9778206.001]
  • [Cites] Am Heart J. 2008 Feb;155(2):375-81 [18215611.001]
  • [Cites] Chest. 1994 Sep;106(3):827-34 [8082366.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):243-52 [21406673.001]
  • [Cites] Circulation. 2014 Aug 26;130(9):757-67 [25052403.001]
  • [Cites] J Hosp Med. 2011 Mar;6(3):142-50 [21387551.001]
  • [Cites] J Mix Methods Res. 2007 Jul;1(3):242-266 [23785307.001]
  • [Cites] Circulation. 1995 Mar 15;91(6):1861-71 [7882498.001]
  • [Cites] PLoS Med. 2014 Sep 30;11(9):e1001737 [25268126.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):33-40 [20031810.001]
  • [Cites] Intensive Care Med. 1996 Nov;22(11):1155-61 [9120106.001]
  • [Cites] Intern Med J. 2013 Nov;43(11):1210-5 [23941077.001]
  • [Cites] J Health Soc Behav. 2009 Mar;50(1):31-48 [19413133.001]
  • [Cites] Shock. 2004 May;21(5):410-4 [15087816.001]
  • [Cites] Health Serv Res. 2008 Aug;43(4):1424-41 [18756617.001]
  • [Cites] Circulation. 1993 Jun;87(6):1947-53 [8504508.001]
  • [Cites] JAMA. 2001 Jun 20;285(23):2987-94 [11410097.001]
  • [Cites] J Am Heart Assoc. 2014 Sep 30;3(5):e001252 [25271209.001]
  • [Cites] Health Qual Life Outcomes. 2010 Nov 25;8:140 [21108810.001]
  • [Cites] J Am Coll Cardiol. 2005 Nov 15;46(10):1845-51 [16286169.001]
  • [Cites] J Intern Med. 1989 Jul;226(1):25-32 [2787829.001]
  • [Cites] JAMA. 2004 Jul 21;292(3):344-50 [15265849.001]
  • [Cites] N Engl J Med. 1999 Jul 22;341(4):217-25 [10413733.001]
  • [Cites] J Womens Health (Larchmt). 2007 Jan-Feb;16(1):93-101 [17324100.001]
  • [Cites] Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):29-37 [20031785.001]
  • [Cites] Circulation. 2015 Jun 2;131(22):1971-80 [25862743.001]
  • [Cites] PLoS One. 2011 Apr 12;6(4):e17401 [21532758.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2002 Nov;57(11):M741-6 [12403803.001]
  • [Cites] Circulation. 2006 Apr 4;113(13):1693-701 [16549636.001]
  • [Cites] JAMA. 1999 Dec 8;282(22):2143-8 [10591336.001]
  • [Cites] J Am Coll Cardiol. 2009 Aug 4;54(6):491-8 [19643307.001]
  • [Cites] Med Care. 2005 May;43(5):480-5 [15838413.001]
  • [Cites] Eur Respir J Suppl. 2003 May;40:10s-14s [12762568.001]
  • [Cites] Circulation. 2017 Feb 7;135(6):521-531 [28153989.001]
  • [Cites] JAMA. 2011 Oct 26;306(16):1794-5 [22028355.001]
  • [Cites] Respir Med. 2007 Sep;101(9):1845-63 [17544265.001]
  • [Cites] J Am Heart Assoc. 2015 Apr 02;4(4):null [25836055.001]
  • [Cites] BMJ. 2015 Feb 05;350:h411 [25656852.001]
  • (PMID = 28506980.001).
  • [ISSN] 1941-7705
  • [Journal-full-title] Circulation. Cardiovascular quality and outcomes
  • [ISO-abbreviation] Circ Cardiovasc Qual Outcomes
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K23 AG048331; United States / NIA NIH HHS / AG / P30 AG021342
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Keywords] NOTNLM ; heart failure / hospitalization / myocardial infarction / pneumonia / women
  •  go-up   go-down


81. Tammes P, Morris RW, Brangan E, Checkland K, England H, Huntley A, Lasserson D, MacKichan F, Salisbury C, Wye L, Purdy S: Exploring the relationship between general practice characteristics and attendance at Walk-in Centres, Minor Injuries Units and Emergency Departments in England 2009/10-2012/2013: a longitudinal study. BMC Health Serv Res; 2017 Aug 08;17(1):546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigated associations of general practice and practice population characteristics with emergency care service attendance rates.
  • METHODS: A longitudinal design with practice-level measures of access and continuity of care, patient population demographics and use of emergency care for the financial years 2009/10 to 2012/13.
  • The main outcome measures were self-referred discharged ED attendance rate, and combined self-referred discharged ED, self-referred Walk-in Centre (WiC) and self-referred Minor Injuries Unit (MIU) attendance rate per 1000 patients.
  • Multilevel models estimated adjusted regression coefficients for relationships between patients' emergency attendance rates and patients' reported satisfaction with opening hours and waiting time at the practice, proportion of patients having a preferred GP, and use of WiC and MIU, both between practices, and within practices over time.
  • RESULTS: Practice characteristics associated with higher ED attendance rates included lower percentage of patients satisfied with waiting time (0.22 per 1% decrease, 95%CI 0.02 to 0.43) and lower percentage having a preferred GP (0.12 per 1% decrease, 95%CI 0.02 to 0.21).
  • Population influences on higher attendance included more elderly, more female and more unemployed patients, and lower male life-expectancy and urban conurbation location.
  • Combined emergency care attendance fell over time if more patients within a practice were satisfied with opening hours (-0.26 per 1% increase, 95%CI -0.45 to -0.08).
  • CONCLUSION: Practices with more patients satisfied with waiting time, having a preferred GP, and using MIU and WIC services, had lower ED attendance.
  • Increases over time in attendance at MIUs, and patient satisfaction with opening hours was associated with reductions in service use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Gen Pract. 2011 Dec;61(593):e787-93 [22137415.001]
  • [Cites] Emerg Med J. 2012 Jun;29(6):487-91 [21561984.001]
  • [Cites] Emerg Med J. 2011 May;28(5):373-7 [20961936.001]
  • [Cites] Br J Gen Pract. 2014 Jul;64(624):e434-9 [24982496.001]
  • [Cites] BMJ Open. 2013 Aug 19;3(8):e003320 [23959757.001]
  • [Cites] PLoS One. 2013 Jun 12;8(6):e66699 [23776694.001]
  • [Cites] Emerg Med J. 2007 Apr;24(4):265-9 [17384380.001]
  • [Cites] J Health Serv Res Policy. 2006 Oct;11(4):196-201 [17018192.001]
  • [Cites] BMJ. 2003 Mar 8;326(7388):532 [12623914.001]
  • [Cites] Emerg Med J. 2010 Jan;27(1):22-5 [20029001.001]
  • [Cites] BMJ Qual Saf. 2011 Nov;20(11):953-8 [21685185.001]
  • [Cites] Emerg Med J. 2016 Oct;33(10 ):702-8 [27317586.001]
  • [Cites] BMJ. 2014 Nov 11;349:g6423 [25389120.001]
  • [Cites] Br J Gen Pract. 2015 Oct;65(639):e649-54 [26412841.001]
  • [Cites] BMJ Open. 2013 Dec 06;3(12):e003612 [24319279.001]
  • [Cites] Emerg Med J. 2015 Apr;32(4):295-300 [24406328.001]
  • [Cites] Arch Intern Med. 2010 Oct 11;170(18):1671-7 [20937927.001]
  • [Cites] BMJ Open. 2014 May 23;4(5):e004746 [24860000.001]
  • [Cites] BMJ Open. 2013 Aug 19;3(8):e003482 [23959760.001]
  • [Cites] Br J Hosp Med (Lond). 2014 Nov;75(11):627-30 [25383432.001]
  • [Cites] Pediatrics. 2001 Mar;107(3):524-9 [11230593.001]
  • (PMID = 28789652.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative health care service / Continuity of care / Longitudinal study / Multilevel modelling / Population characteristics / Primary health care / hospital’ / ‘Emergency service
  •  go-up   go-down


82. Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation: 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol; 2017 May;69(5):898-910
Genetic Alliance. consumer health - Polymyositis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial.
  • RESULTS: Consensus was reached for a conjoint analysis-based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels).
  • Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively.
  • [MeSH-minor] Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Creatine Kinase / metabolism. Europe. Fructose-Bisphosphate Aldolase / metabolism. Humans. L-Lactate Dehydrogenase / metabolism. Logistic Models. Muscle Strength. Outcome Assessment (Health Care). Patient Reported Outcome Measures. Polymyositis / drug therapy. Polymyositis / metabolism. Polymyositis / physiopathology. Rheumatology. Societies, Medical. Surveys and Questionnaires. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Myositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017, American College of Rheumatology.
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):658-66 [19405003.001]
  • [Cites] Lancet. 2016 Feb 13;387(10019):671-8 [26645190.001]
  • [Cites] Rheumatology (Oxford). 2001 Nov;40(11):1262-73 [11709610.001]
  • [Cites] Arch Dis Child. 2011 Jun;96(6):596-601 [21317432.001]
  • [Cites] Arthritis Care Res (Hoboken). 2016 May;68(5):667-72 [26414176.001]
  • [Cites] Ann Rheum Dis. 2014 Dec;73(12):2168-73 [24026675.001]
  • [Cites] Eur J Clin Pharmacol. 2011 May;67 Suppl 1:125-31 [21103985.001]
  • [Cites] Health Econ. 2012 Feb;21(2):145-72 [22223558.001]
  • [Cites] Curr Rheumatol Rep. 2008 Apr;10(2):142-6 [18460270.001]
  • [Cites] Can J Psychiatry. 2002 Apr;47(3):262-6 [11987478.001]
  • [Cites] Arthritis Rheum. 2013 Feb;65(2):314-24 [23124935.001]
  • [Cites] Open Rheumatol J. 2012;6:54-63 [22723809.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57 [22588740.001]
  • [Cites] Arthritis Rheum. 2008 Jan 15;59(1):4-13 [18163404.001]
  • [Cites] Ann Rheum Dis. 2010 May;69(5):790-7 [20388738.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2281-90 [15248228.001]
  • [Cites] J Rheumatol. 2003 Mar;30(3):603-17 [12610824.001]
  • [Cites] Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41 [20583105.001]
  • [Cites] Arthritis Rheum. 2011 Oct;63(10):3142-52 [21647864.001]
  • [Cites] Rheumatology (Oxford). 2003 Dec;42(12):1452-9 [12832713.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] J Rheumatol. 2007 May;34(5):1184-7 [17477484.001]
  • [Cites] Arthritis Rheum. 1995 Jun;38(6):727-35 [7779114.001]
  • [Cites] Ther Adv Neurol Disord. 2014 Nov;7(6):263-75 [25371708.001]
  • [Cites] Arthritis Rheumatol. 2015 Oct;67(10):2557-68 [26352873.001]
  • [Cites] Arthritis Rheumatol. 2017 May;69(5):898-910 [28382787.001]
  • [Cites] Arthritis Rheum. 2007 Mar 15;57(2):193-202 [17330293.001]
  • [Cites] Arthritis Rheumatol. 2017 May;69(5):911-923 [28382778.001]
  • (PMID = 28382787.001).
  • [ISSN] 2326-5205
  • [Journal-full-title] Arthritis & rheumatology (Hoboken, N.J.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA ES101081-15; United States / Intramural NIH HHS / / ZIA ES101081-14; United States / Intramural NIH HHS / / ZIA ES101081-13; United States / Intramural NIH HHS / / ZID ES102465-05; United States / Intramural NIH HHS / / ZIA ES101081-12; United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 2.7.3.2 / Creatine Kinase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  • [Investigator] Rider LG; Ruperto N; Aggarwal R; Miller FW; Vencovsky J; Aggarwal R; Erman B; Bayat N; Pistorio A; Huber AM; Feldman BM; Hansen P; Rockette H; Lachenbruch PA; Ruperto N; Rider LG; Amato AA; Chinoy H; Christopher-Stine L; Chung L; Cooper RG; Criscione-Schreiber L; Crofford L; Cronin ME; Dankó K; Fiorentino D; García-De la Torre I; Gordon P; Hengstman G; Katz JD; Mammen A; Marder G; McHugh N; Oddis CV; Schiopu E; Selva-O'Callaghan A; Wook Song Y; Vencovsky J; Wolfe G; Wortmann R; Amato AA; Chinoy H; Chung L; Cooper RG; Dankó K; Fiorentino D; García-De la Torre I; Gourley M; Lundberg I; Miller FW; Oddis CV; Plotz P; Rider LG; Wook Song Y; Vencovsky J; Aggarwal R; Amato AA; Ascherman D; Barohn R; Benveniste O; De Bleecker J; Callen J; Charles-Schoeman C; Chinoy H; Christopher-Stine L; Chung L; Cooper RG; Crofford L; Cronin ME; Dankó K; Danoff S; Dastmalchi M; de Visser M; Dimachkie M; DiMartino S; Dourmishev L; Ernste F; Fiorentino D; García-De la Torre I; Gono T; Gordon P; Gourley M; Isenberg D; Katsumata Y; Katz JD; Kissel J; Leff RL; Levine T; Lundberg I; Mammen A; Mann H; Marder G; Marie I; McHugh N; Merola J; Miller FW; Oddis CV; Olesinska M; Olsen N; Pipitone N; Ramchandren S; Rutkove S; Saketkoo LA; Schiffenbauer A; Selva-O'Callaghan A; Katsuyuki Shinjo S; Shupak R; Wook Song Y; Swierkocka K; Vencovsky J; Wanschitz J; Werth V; Whitt I; Wortmann R; Ytterberg SR; Aggarwal R; Amato AA; Chinoy H; Christopher-Stine L; Chung L; Cooper RG; Cronin ME; Dankó K; Dimachkie M; DiMartino S; Fiorentino D; García-De la Torre I; Gordon P; Lundberg I; Mann H; Miller FW; Oddis CV; Selva-O'Callaghan A; Vencovsky J; Werth V; Wortmann R; Ytterberg SR; Amato AA; Chinoy H; Cooper RG; Dastmalchi M; de Visser M; Fiorentino D; Isenberg D; Katz JD; Mammen A; Oddis CV; Vencovsky J; Ytterberg SR; Cimaz R; Cuttica R; Feitosa de Oliveira SK; Feldman BM; Huber AM; Lindsley CB; Pilkington C; Punaro M; Ravelli A; Reed A; Rouster-Stevens K; van Royen-Kerkhof A
  •  go-up   go-down


83. Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE: There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scand J Rheumatol; 2017 Oct 09;:1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty experts from 13 countries were included; 67% were male, 63% were from Europe and 37% from North America; median experience of 22.5 years, with a median of 55 new SSc patients annually.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28990485.001).
  • [ISSN] 1502-7732
  • [Journal-full-title] Scandinavian journal of rheumatology
  • [ISO-abbreviation] Scand. J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Mayanja BN, Kasamba I, Levin J, Namakoola I, Kazooba P, Were J, Kaleebu P, Munderi P, CoLTART study team: COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther; 2017;14:26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no differences in renal dysfunction between patients on Tenofovir and Non-Tenofovir containing ART regimens.
  • Patients on PI regimens had higher total cholesterol, lower high density lipoprotein, higher low density lipoprotein, higher triglycerides, and a high atherogenic index for plasma than the non-PI regimen, p = 0.001 or < 0.001.
  • Patients on Non-PI regimens had higher mean diastolic hypertension than patients on PI regimens, p < 0.001.
  • CONCLUSIONS: Our finding of no differences in renal dysfunction between patients on Tenofovir and those on Non-Tenofovir containing ART regimens means that Tenofovir based first line ART can safely be initiated even in settings without routine renal function monitoring.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):283-90 [16355343.001]
  • [Cites] AIDS. 2007 Jun 19;21(10):1273-81 [17545703.001]
  • [Cites] PLoS One. 2015 Aug 24;10(8):e0135188 [26301416.001]
  • [Cites] Biomed Pharmacother. 2008 Jan;62(1):6-11 [17574807.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] Lancet. 2010 Jan 9;375(9709):123-31 [20004464.001]
  • [Cites] HIV Med. 2011 Oct;12(9):553-61 [21535347.001]
  • [Cites] Bioinformatics. 2009 May 1;25(9):1197-8 [19304876.001]
  • [Cites] AIDS. 2011 Mar 13;25(5):671-8 [21252634.001]
  • [Cites] AIDS Patient Care STDS. 2008 Feb;22(2):99-103 [18260800.001]
  • [Cites] J Hypertens. 2011 Jun;29(6):1061-8 [21505357.001]
  • [Cites] AIDS. 2009 Mar 27;23(6):689-96 [19262355.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):429-45 [16863444.001]
  • [Cites] Int J Epidemiol. 2013 Feb;42(1):129-41 [23364209.001]
  • [Cites] Curr Med Chem. 2006;13(26):3121-32 [17168701.001]
  • [Cites] Diabetes Obes Metab. 2008 Jun;10(6):441-50 [17825081.001]
  • [Cites] J Trop Med. 2011;2011:598341 [21845196.001]
  • [Cites] J Infect Dis. 2013 May 1;207(9):1359-69 [23382571.001]
  • [Cites] AIDS. 2004 Apr 30;18(7):1074-6 [15096814.001]
  • [Cites] Afr Health Sci. 2009 Sep;9(3):143-6 [20589141.001]
  • [Cites] J Infect Dis. 2008 Jun 1;197(11):1490-2 [18422454.001]
  • [Cites] Popul Health Metr. 2011 Aug 04;9:36 [21816100.001]
  • [Cites] CMAJ. 2004 Jan 20;170(2):229-38 [14734438.001]
  • [Cites] Trop Med Int Health. 2010 Jun;15(6):697-705 [20406428.001]
  • [Cites] Clin Infect Dis. 2013 Feb;56(4):567-75 [23143096.001]
  • [Cites] Afr Health Sci. 2006 Sep;6(3):139-44 [17140334.001]
  • [Cites] AIDS. 1997 Apr;11(5):633-40 [9108945.001]
  • [Cites] Clin Infect Dis. 2006 May 15;42(10):1488-95 [16619164.001]
  • [Cites] PLoS One. 2015 May 14;10(5):e0126166 [25974077.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):43-8 [19106702.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2155-63 [18832879.001]
  • [Cites] Lancet. 2000 Jun 17;355(9221):2106-11 [10902624.001]
  • [Cites] AIDS. 2005 Aug 12;19(12):1332-3 [16052093.001]
  • [Cites] Int J STD AIDS. 2001 Sep;12(9):555-62; quiz 563-4 [11516363.001]
  • [Cites] J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):388-95 [23254151.001]
  • (PMID = 28484508.001).
  • [ISSN] 1742-6405
  • [Journal-full-title] AIDS research and therapy
  • [ISO-abbreviation] AIDS Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antiretroviral therapy / Cohort profile / HIV / Metabolic abnormalities / Renal complications / Uganda
  • [Investigator] Mayanja BN; Nalwadda J; Nakibuuka G; Namugenyi H; Kazooba P; Lubega R; Mugisha A; Tereka A; Kalyebara A; Namara A; Nakitto D; Wangi D; Nume F; Ssemwanga G; Nabulime G; Nassuna G; Lubega G; Namakoola I; Lutaakome J; Generous L; Matama L; Massa R; Tino S; Nakahima W; Kapaata AA; Magambo B; Parry C; Lyagoba F; Nazziwa J; Nannyonjo M; Muhigirwa E; Wamalugu F; Kabajuma F; Nakazibwe HG; Were J; Bwandinga J; Bukenya J; Kamushaaga MZ; Hughes P; Nkurunziza P; Balungi PA; Mukasa S; Nassimbwa S; Vudriko T; Senyonga W; Ochola W; Nakimbugwe A; Nampewo C; Nambuba D; Naphtali E; Barigye G; Nakamanya I; Kasamba I; Levin J; Kahwa J; Matovu JN; Namayirira L; Lubega RN; Nabalayo S; Kaddu S; Munderi P
  •  go-up   go-down


85. Subbe CP, Kellett J, Barach P, Chaloner C, Cleaver H, Cooksley T, Korsten E, Croke E, Davis E, De Bie AJ, Durham L, Hancock C, Hartin J, Savijn T, Welch J, Crisis Checklist Collaborative: Crisis checklists for in-hospital emergencies: expert consensus, simulation testing and recommendations for a template determined by a multi-institutional and multi-disciplinary learning collaborative. BMC Health Serv Res; 2017 May 08;17(1):334
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: 'Failure to rescue' of hospitalized patients with deteriorating physiology on general wards is caused by a complex array of organisational, technical and cultural failures including a lack of standardized team and individual expected responses and actions.
  • The aim of this study using a learning collaborative method was to develop consensus recomendations on the utility and effectiveness of checklists as training and operational tools to assist in improving the skills of general ward staff on the effective rescue of patients with abnormal physiology.
  • We sought to achieve a consensus on procedures and clinical simulation technology to determine the requirements, develop and test a safe using a checklist template that is rapidly accessible to assist in emergency management of common events for general ward use.
  • RESULTS: Safety considerations about deteriorating patients were agreed upon and summarized.
  • 'Stop & Think'), and, a list of items required for the safe "handover" of patients that remain on the general ward (i.e. 'Check Out').
  • Simulation usability assessment of the template demonstrated feasibility for clinical management of deteriorating patients.
  • CONCLUSIONS: Emergency checklists custom-designed for general ward patients have the potential to guide the treatment speed and reliability of responses for emergency management of patients with abnormal physiology while minimizing the risk of adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acute Med. 2014;13(2):56-60 [24940567.001]
  • [Cites] N Engl J Med. 2010 Nov 11;363(20):1928-37 [21067384.001]
  • [Cites] Emerg Med J. 2011 Jun;28(6):507-12 [21036796.001]
  • [Cites] Surg Neurol Int. 2012;3:2 [22347672.001]
  • [Cites] BMJ Qual Saf. 2013 Jun;22(6):507-14 [23457361.001]
  • [Cites] BMJ Qual Saf. 2015 Jul;24(7):428-31 [25969512.001]
  • [Cites] J Nurs Care Qual. 2012 Jan-Mar;27(1):43-50 [21849908.001]
  • [Cites] Med Care. 1992 Jul;30(7):615-29 [1614231.001]
  • [Cites] Clin Med (Lond). 2012 Dec;12 (6):501-3 [23342400.001]
  • [Cites] Implement Sci. 2011 Apr 16;6:39 [21496276.001]
  • [Cites] Qual Saf Health Care. 2005 Oct;14(5):326-31 [16195564.001]
  • [Cites] Ann Surg. 2014 Apr;259(4):807-13 [24096751.001]
  • [Cites] Qual Saf Health Care. 2010 Oct;19(5):e44 [20538629.001]
  • [Cites] J Am Coll Surg. 2011 Aug;213(2):212-217.e10 [21658974.001]
  • [Cites] Crit Care Med. 2004 Oct;32(10):2014-20 [15483409.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2015 May;41(5):212-20 [25977248.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):844-51; discussion 851-2 [12796581.001]
  • [Cites] N Engl J Med. 2014 Mar 13;370(11):1029-38 [24620866.001]
  • [Cites] Lancet. 2009 Aug 8;374(9688):444-5 [19681190.001]
  • [Cites] Ann Surg. 2012 Dec;256(6):925-33 [22968074.001]
  • [Cites] Crit Care Med. 2011 Nov;39(11):2401-6 [21705896.001]
  • [Cites] Crit Care. 2006 Feb;10(1):R30 [16507153.001]
  • [Cites] Intensive Care Med. 2010 Jan;36(1):100-6 [19760206.001]
  • [Cites] Ann Intern Med. 2005 May 3;142(9):756-64 [15867408.001]
  • [Cites] Crit Care. 2005;9(6):R808-15 [16356230.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2005 May;31(5):243-8 [15960014.001]
  • [Cites] Resuscitation. 2011 Jul;82(7):810-4 [21497982.001]
  • [Cites] BMJ Qual Saf. 2015 Sep;24(9):545-9 [26089207.001]
  • [Cites] Resuscitation. 2010 Nov;81(11):1509-15 [20673606.001]
  • [Cites] QJM. 2001 Oct;94(10 ):521-6 [11588210.001]
  • [Cites] BMJ Qual Saf. 2012 Sep;21(9):737-45 [22927487.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):491-9 [19144931.001]
  • [Cites] N Engl J Med. 2013 Jan 17;368(3):246-53 [23323901.001]
  • [Cites] Anaesth Intensive Care. 1995 Apr;23(2):183-6 [7793590.001]
  • [Cites] Implement Sci. 2013 Jun 20;8:70 [23786847.001]
  • [Cites] BMJ Qual Saf. 2011 Jan;20(1):102-7 [21228082.001]
  • [Cites] Hum Factors. 2008 Jun;50(3):442-8 [18689051.001]
  • (PMID = 28482890.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Crisis / Learning Collaborative / Patient safety / Rapid response teams / Reliability / Simulation
  • [Investigator] Barach P; Beaugrand H; Breen D; Byrne D; Chalmers C; Cleaver H; Cooksley T; Croke E; Davis E; De Bie A; Donnelly P; Dunne E; Durham L; Ellis B; Goel R; Hancock C; Hartin J; Hinge D; Holland M; Hueske-Kraus D; Kellett J; Kennelly S; Korsten E; Lighthall G; Lunn R; Müller M; O'Dwyer C; O'Mahony K; Paice N; Roberts L; Savijn T; Subbe CP; Thomas D; Walsh R; Weber F; Welch J; Woodworth S
  •  go-up   go-down


86. Koami H, Sakamoto Y, Sakurai R, Ohta M, Imahase H, Yahata M, Umeka M, Miike T, Nagashima F, Iwamura T, Yamada KC, Inoue S: Thromboelastometric analysis of the risk factors for return of spontaneous circulation in adult patients with out-of-hospital cardiac arrest. PLoS One; 2017;12(4):e0175257

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboelastometric analysis of the risk factors for return of spontaneous circulation in adult patients with out-of-hospital cardiac arrest.
  • It is well known that coagulopathy is observed in patients with out-of-hospital cardiac arrest (OHCA).
  • Thrombolytic therapy for those patients has been controversial until now.
  • The purpose of this study was to identify a significant predictor for return of spontaneous circulation (ROSC) of OHCA patients in the emergency department (ED) using whole blood viscoelastic testing.
  • Adult non-trauma OHCA patients transported to our hospital that underwent thromboelastometry (ROTEM) during cardiopulmonary resuscitation between January 2013 and December 2015 were enrolled in this study.
  • We divided patients into two groups based on the presence or absence of ROSC, and performed statistical analysis utilizing patient characteristics, prehospital data, laboratory data, and ROTEM data.
  • Seventy-five patients were enrolled.
  • The ROSC group and non-ROSC group included 23 and 52 patients, respectively.
  • We defined a positive prediction for ROSC if the patient presented lower lactate level (<12.0 mmol/L) and higher A30 of EXTEM (≥48.0 mm) with high specificity (94.7%) and accuracy (75.0%).
  • The present study showed that lactate level and ROTEM parameter of clot firmness were reliable predictors of ROSC in the ED for adult patients with OHCA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Anaesth. 2015 Jan;114(1):91-102 [25303988.001]
  • [Cites] Resuscitation. 2006 Jul;70(1):31-6 [16762481.001]
  • [Cites] N Engl J Med. 2002 May 16;346(20):1522-8 [12015391.001]
  • [Cites] Resuscitation. 2007 May;73(2):189-201 [17239516.001]
  • [Cites] Transplant Proc. 2013;45(10):3637-9 [24314981.001]
  • [Cites] Crit Care. 2010;14(2):R55 [20374650.001]
  • [Cites] Resuscitation. 2001 Jul;50(1):71-6 [11719132.001]
  • [Cites] Arch Intern Med. 2000 May 22;160(10):1529-35 [10826469.001]
  • [Cites] J Intern Med. 1991 Apr;229(4):331-5 [2026986.001]
  • [Cites] Resuscitation. 2006 Jun;69(3):399-406 [16563599.001]
  • [Cites] Medicine (Baltimore). 2016 Aug;95(31):e4514 [27495106.001]
  • [Cites] Circulation. 1995 Nov 1;92(9):2572-8 [7586359.001]
  • [Cites] Resuscitation. 2013 Apr;84(4):454-9 [22922072.001]
  • [Cites] Thromb Res. 1999 Oct 15;96(2):107-13 [10574588.001]
  • [Cites] Crit Care Med. 2011 Dec;39(12):2652-8 [21765358.001]
  • [Cites] Resuscitation. 2003 Apr;57(1):49-55 [12668299.001]
  • [Cites] J Cardiothorac Vasc Anesth. 2014 Apr;28(2):210-6 [24630470.001]
  • [Cites] N Engl J Med. 2008 Dec 18;359(25):2651-62 [19092151.001]
  • [Cites] Resuscitation. 2012 Dec;83(12):1451-5 [22634432.001]
  • (PMID = 28380019.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lactates
  •  go-up   go-down


87. Miyauchi R, Itoh Y, Kawamura M, Hirakawa A, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S: Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. Nagoya J Med Sci; 2017 Feb;79(2):211-220

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this retrospective study was to analyze data in patients with stage IB-IIB uterine cervical cancer who were treated with concurrent chemoradiotherapy (CCRT) with high dose cisplatin and fluorouracil as postoperative adjuvant therapy.
  • Between February 2003 and November 2011, 76 patients with FIGO stage IB-IIB cervical cancer were analyzed.
  • Seventy patients were treated with postoperative CCRT and 6 patients were treated with radiation therapy alone.
  • The median patient age was 45 years (range, 20-80 years).
  • Fifty-eight patients (76.3%) had a squamous cell histologic type, 55 patients (72.4%) had lymphovascular invasion, 31 patients (40.8%) had parametrial invasion, and 28 patients (36.8%) had lymph node metastases.
  • Five-year DFS in stage IB1 patients was significantly higher than in stage IB2-IIB patients (p = 0.022).
  • Nineteen patients (25%) had grade 3 or 4 neutropenia, 13 patients (17.1%) had grade 3 anemia, and 2 patients (2.6%) had grade 3 thrombocytopenia, but none of these patients died from the disease.
  • Three patients experienced chronic toxicity: one had bladder perforation, one had hydronephrosis, and one experienced ileus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81 [21840137.001]
  • [Cites] Int J Clin Oncol. 2015 Apr;20(2):240-8 [25800808.001]
  • [Cites] Eur J Cancer Care (Engl). 2008 Mar;17(2):174-81 [18302655.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):288-93 [16182347.001]
  • [Cites] Gynecol Oncol. 2012 Jan;124(1):63-7 [22004904.001]
  • [Cites] J Obstet Gynaecol Res. 2015 Oct;41(10 ):1638-43 [26177790.001]
  • [Cites] Int J Gynecol Cancer. 2013 Mar;23(3):567-75 [23385284.001]
  • [Cites] J Obstet Gynaecol Res. 2010 Oct;36(5):1009-14 [20722988.001]
  • [Cites] Radiat Oncol. 2015 Jan 13;10:18 [25582425.001]
  • [Cites] Radiat Oncol. 2015 Aug 25;10:180 [26300325.001]
  • [Cites] Obstet Gynecol Sci. 2013 Jan;56(1):15-21 [24327975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):118-25 [17869451.001]
  • [Cites] JAMA. 1995 Aug 2;274(5):387-93 [7616634.001]
  • [Cites] Radiat Oncol. 2012 Nov 23;7:197 [23176540.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):727-32 [15943983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):34-9 [2703164.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jul-Aug;17(4):833-42 [17367320.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):177-83 [10329031.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):721-8 [15721417.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):463-7 [9062151.001]
  • [Cites] J Gynecol Oncol. 2009 Dec;20(4):227-31 [20041099.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76 [16427212.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):352-7 [2227547.001]
  • (PMID = 28626256.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; 5-FU. / Cisplatin / Concurrent chemoradiotherapy / Hysterectomy / Uterine cervical cancer
  •  go-up   go-down


88. Foldager CB, Bendtsen M, Berg LC, Brinchmann JE, Brittberg M, Bunger C, Canseco J, Chen L, Christensen BB, Colombier P, Deleuran BW, Edwards J, Elmengaard B, Farr J, Gatenholm B, Gomoll AH, Hui JH, Jakobsen RB, Joergensen NL, Kassem M, Koch T, Kold S, Krogsgaard MR, Lauridsen H, Le D, Le Visage C, Lind M, Nygaard JV, Olesen ML, Pedersen M, Rathcke M, Richardson JB, Roberts S, Rölfing JH, Sakai D, Toh WS, Urban J, Spector M: Aarhus Regenerative Orthopaedics Symposium (AROS). Acta Orthop; 2016 Dec;87(sup363):1-5
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this position paper, we review our contemporary understanding of societal, patient-related, and basic science-related challenges in order to provide a reasoned roadmap for the future to deal with this compelling and urgent healthcare problem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Technol Assess. 2005 Dec;9(47):iii-iv, ix-x, 1-82 [16336842.001]
  • [Cites] Biomed Mater. 2016 Feb 02;11(1):014110 [26836246.001]
  • [Cites] Eur J Trauma Emerg Surg. 2017 Feb;43(1):113-119 [26260068.001]
  • [Cites] Science. 1965 Nov 12;150(3698):893-9 [5319761.001]
  • [Cites] China Economic J. 2012;5(2-3):131-149 [24443653.001]
  • [Cites] Tissue Eng Part B Rev. 2008 Jun;14(2):179-86 [18544015.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):35-44 [11134178.001]
  • [Cites] Circulation. 1999 Jan 19;99(2):237-42 [9892589.001]
  • [Cites] Am J Sports Med. 2010 Jun;38(6):1110-6 [20392971.001]
  • [Cites] Stem Cell Rev. 2014 Oct;10(5):686-96 [24869958.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):889-95 [8078550.001]
  • [Cites] Clin Orthop Relat Res. 2004 Aug;(425):2-3 [15292781.001]
  • [Cites] Arthroscopy. 2013 Dec;29(12):2020-8 [24286801.001]
  • [Cites] Neurobiol Aging. 1999 Mar-Apr;20(2):105-10 [10537019.001]
  • [Cites] Science. 1988 Dec 16;242(4885):1528-34 [3201241.001]
  • [Cites] Biomed Res Int. 2014;2014:921905 [25143954.001]
  • [Cites] Spine (Phila Pa 1976). 2011 Mar 15;36(6):E373-9 [21372649.001]
  • [Cites] Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51 [18179993.001]
  • [Cites] Nat Neurosci. 2006 Jun;9(6):715-7 [16732197.001]
  • [Cites] Am J Public Health. 2008 Jul;98(7):1198-200 [18511722.001]
  • [Cites] Med Care. 1992 Jul;30(7):646-58 [1614233.001]
  • [Cites] Cartilage. 2015 Jul;6(3):166-73 [26175862.001]
  • [Cites] Cartilage. 2010 Oct;1(4):312-9 [26069562.001]
  • [Cites] Am J Sports Med. 2009 Nov;37 Suppl 1:167S-76S [19861696.001]
  • [Cites] J Orthop Sci. 2006 May;11(3):318-25 [16721538.001]
  • [Cites] Arthritis Rheum. 1988 Apr;31(4):561-5 [3358814.001]
  • [Cites] J Biol Chem. 1989 Aug 15;264(23):13377-80 [2547759.001]
  • [Cites] Soc Sci Med. 2005 Feb;60(4):833-43 [15571900.001]
  • [Cites] Osteoarthritis Cartilage. 2007 Sep;15(9):1061-9 [17470400.001]
  • [Cites] Cartilage. 2016 Apr;7(2):140-8 [27047636.001]
  • (PMID = 28271925.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Grant] United Kingdom / Arthritis Research UK / / 20631
  • [Publication-type] Congresses
  • [Publication-country] England
  •  go-up   go-down


89. Joseph B, Orouji Jokar T, Hassan A, Azim A, Mohler MJ, Kulvatunyou N, Siddiqi S, Phelan H, Fain M, Rhee P: Redefining the association between old age and poor outcomes after trauma: The impact of frailty syndrome. J Trauma Acute Care Surg; 2017 Mar;82(3):575-581
MedlinePlus Health Information. consumer health - Wounds and Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Frailty syndrome (FS) is a well-established predictor of outcomes in geriatric patients.
  • The aim of this study was to quantify the prevalence of FS in geriatric trauma patients and to determine its association with trauma readmissions, repeat falls, and mortality at 6 months.
  • METHODS: we performed a 2-year (2012-2013) prospective cohort analysis of all consecutive geriatric (age, ≥ 65 years) trauma patients.
  • Patients were stratified into: nonfrail, TSFI ≤ 0.12; prefrail, TSFI = 0.1 to 0.27; and frail, TSFI > 0.27.
  • Patient follow-up occurred at 6 months to assess outcomes.
  • RESULTS: Three hundred fifty patients were enrolled.
  • Frail patients were more likely to develop in-hospital complications (nonfrail, 12%; prefrail, 17.4%; and frail, 33.4%; p = 0.02) and an adverse discharge disposition compared with nonfrail and prefrail (nonfrail, 8%; prefrail,18%; and frail, 47%; p = 0.001).
  • Six-month follow-up was recorded in 80% of the patients.
  • Compared with nonfrail patients, frail patients were more likely to have had a trauma-related readmission (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.2-3.6) and/or repeated falls (OR, 1.6; 95%CI, 1.1-2.5) over the 6-month period.
  • Overall 6-month mortality was 2.8% (n = 10), and frail elderly patients were more likely to have died (OR, 1.1; 95% CI, 1.04-4.7) compared with nonfrail patients.
  • CONCLUSION: Over a third of geriatric trauma patients had FS.
  • TSFI provides a practical and accurate assessment tool for identifying elderly trauma patients who are at increased risk of both short-term and long-term outcomes.
  • Early focused intervention in frail geriatric patients is warranted to improve long-term outcomes.
  • [MeSH-minor] Accidental Falls / statistics & numerical data. Aged. Aged, 80 and over. Female. Hospital Mortality. Humans. Male. Patient Readmission / statistics & numerical data. Prevalence. Prognosis. Prospective Studies. Recurrence. Risk Factors. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28225741.001).
  • [ISSN] 2163-0763
  • [Journal-full-title] The journal of trauma and acute care surgery
  • [ISO-abbreviation] J Trauma Acute Care Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. James ML, Langefeld CD, Sekar P, Moomaw CJ, Elkind MSV, Worrall BB, Sheth KN, Martini SR, Osborne J, Woo D, ERICH Investigators: Assessment of the interaction of age and sex on 90-day outcome after intracerebral hemorrhage. Neurology; 2017 Sep 05;89(10):1011-1019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Unlike in ischemic stroke, there was no evidence that patient sex modified the effect of age on 90-day outcomes after ICH in a large multiracial/ethnic population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  • [Cites] Stroke. 2015 Mar;46(3):886-92 [25657181.001]
  • [Cites] Acta Neurochir Suppl. 2010;106:159-62 [19812941.001]
  • [Cites] Br J Neurosurg. 2006 Apr;20(2):73-8 [16753620.001]
  • [Cites] Stroke. 2009 Nov;40(11):3567-73 [19729603.001]
  • [Cites] Acta Neurochir Suppl. 2011;111:113-7 [21725740.001]
  • [Cites] J Neurotrauma. 2007 Mar;24(3):473-80 [17402853.001]
  • [Cites] Neuroendocrinology. 2016;103(6):665-77 [26562172.001]
  • [Cites] Behav Brain Res. 1993 Oct 21;57(1):47-51 [8292254.001]
  • [Cites] Stroke. 2007 Mar;38(3):1085-7 [17255545.001]
  • [Cites] Stroke. 2002 May;33(5):1197-201 [11988590.001]
  • [Cites] Lancet Neurol. 2008 Oct;7(10):915-26 [18722812.001]
  • [Cites] Acta Neurochir Suppl. 2011;111:289-93 [21725770.001]
  • [Cites] Neurology. 2009 Oct 6;73(14):1088-94 [19726752.001]
  • [Cites] PLoS One. 2013 Nov 27;8(11):e81664 [24312335.001]
  • [Cites] Ann N Y Acad Sci. 2010 Oct;1207:58-70 [20955427.001]
  • [Cites] Stroke. 2009 Apr;40(4):1082-90 [19211488.001]
  • [Cites] CNS Neurosci Ther. 2012 Sep;18(9):773-80 [22943144.001]
  • [Cites] Neurology. 2011 Oct 25;77(17 ):1599-604 [21998314.001]
  • [Cites] Stroke. 2004 Feb;35(2):426-31 [14757893.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):531-6 [12296635.001]
  • [Cites] Stroke. 2003 May;34(5):1114-9 [12690218.001]
  • [Cites] Stroke. 2002 May;33(5):1190-5 [11988589.001]
  • [Cites] Stroke. 2010 Apr;41(4):739-44 [20150543.001]
  • [Cites] Stroke. 2001 Apr;32(4):891-7 [11283388.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):144-9 [20667864.001]
  • [Cites] Transl Stroke Res. 2012 Mar;3(1):94-101 [23935764.001]
  • [Cites] Stroke. 2013 Oct;44(10 ):e120-5 [24021679.001]
  • [Cites] Neuroepidemiology. 2009;32(1):11-8 [18997472.001]
  • [Cites] Transl Stroke Res. 2012 Jul;3(Suppl 1):132-46 [22707991.001]
  • [Cites] Eur Neuropsychopharmacol. 2012 Aug;22(8):562-8 [22225860.001]
  • [Cites] Neurology. 2007 Mar 20;68(12 ):889-94 [17372123.001]
  • [Cites] Neurol Res Int. 2013;2013:219097 [24083025.001]
  • [Cites] Neurology. 2004 Sep 28;63(6):1059-64 [15452298.001]
  • [Cites] Cell Physiol Biochem. 2011;27(3-4):201-6 [21471708.001]
  • [Cites] Crit Care Med. 2009 Apr;37(4):1442-7 [19242340.001]
  • [Cites] Cerebrovasc Dis. 2009;28(6):564-71 [19844096.001]
  • [Cites] Circulation. 2001 Feb 6;103(5):638-42 [11156873.001]
  • [Cites] Stroke. 2005 Sep;36(9):1881-5 [16081867.001]
  • [Cites] Acta Neurochir Suppl. 2006;96:218-21 [16671458.001]
  • [Cites] Neuroendocrinology. 2016;103(5):518-30 [26356626.001]
  • (PMID = 28710330.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Investigator] Luke James ML; Worrall BB; Warwick T; Chong JY; Birnbaum L; Gonzales N; Hall C; Sung G; Koch S; Tran H; Kittner S; Testai F; Coull B; Rosand J; Elkind MSV; Langefeld C; McCauley J; Hussman JP; Kidwell C; Woo D
  •  go-up   go-down


91. Kiriyama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, Hata J, Liau KH, Miura F, Horiguchi A, Liu KH, Su CH, Wada K, Jagannath P, Itoi T, Gouma DJ, Mori Y, Mukai S, Giménez ME, Huang WS, Kim MH, Okamoto K, Belli G, Dervenis C, Chan ACW, Lau WY, Endo I, Gomi H, Yoshida M, Mayumi T, Baron TH, de Santibañes E, Teoh AYB, Hwang TL, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Higuchi R, Kitano S, Inomata M, Deziel DJ, Jonas E, Hirata K, Sumiyama Y, Inui K, Yamamoto M: Diagnostic and severity grading criteria for acute cholangitis in the Tokyo Guidelines 2018. J Hepatobiliary Pancreat Sci; 2017 Oct 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analyzing big data from this study confirmed that the diagnostic rate of acute cholangitis based on the TG13 diagnostic criteria was higher than that based on the TG07 criteria, and that 30-day mortality in patients with a higher severity based on the TG13 severity grading criteria was significantly higher.
  • Furthermore, a comparison of patients treated with early or urgent biliary drainage versus patients not treated this way showed no difference in 30-day mortality among patients with Grade I or Grade III AC, but significantly lower 30-day mortality in patients with Grade II AC who were treated with early or urgent biliary drainage.
  • This suggests that the TG13 severity grading criteria can be used to identify Grade II patients whose prognoses may be improved through biliary drainage.
  • The TG13 severity grading criteria may therefore be useful as an indicator for biliary drainage as well as a predictive factor when assessing the patient's prognosis.
  • The TG13 diagnostic and severity grading criteria for AC can provide results quickly, are minimally invasive for the patients, and are inexpensive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 29032610.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Diagnostic criteria / Diagnostic imaging / Guidelines / Severity grading / acute cholangitis
  •  go-up   go-down


92. Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y: Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. Eur Urol; 2017 Sep 18;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, AND PARTICIPANTS: The study sequenced whole-genome and transcriptome of tumor-benign paired tissues from 65 treatment-naive Chinese PCa patients.
  • RESULTS AND LIMITATIONS: We demonstrated an association of high frequency of CHD1 deletion with a low rate of TMPRSS2-ERG fusion a